

Literature Review

Psoriasis (Disease State)

Medication Name	Title	Pubmed Link
6-THIOGUANINE	Treatment of psoriasis with 6-thioguanine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3272126
6-THIOGUANINE	6-Thioguanine treatment of psoriasis: experience in 81 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8113459
6-THIOGUANINE	6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8496447
6-THIOGUANINE	Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10606055
6-THIOGUANINE	6-thioguanine in the treatment of psoriasis: a case report and literature review. [Review] [18 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=12001005
6-THIOGUANINE	Treatment of psoriasis with 6-thioguanine and hepatic venoocclusive disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12451396
ABATACEPT	Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21036648
ABATACEPT	Therapeutic hotline. Abatacept: our experience of use in two patients with refractory psoriasis and psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21410619
ABATACEPT	Abatacept-induced psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22017062
ABATACEPT, ETANERCEPT	Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21696691
ACITRETIN	Oral acitretin in psoriasis: drug and vitamin A concentrations in plasma, skin and adipose tissue.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1350412
ACITRETIN	Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1827799
ACITRETIN	A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1827800
ACITRETIN	Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1838750
ACITRETIN	Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2138875
ACITRETIN	Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2459874
ACITRETIN	Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2522405
ACITRETIN	Side-effect profile of acitretin therapy in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2526824

Medication Name	Title	Pubmed Link
ACITRETIN	A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=252705 4
ACITRETIN	A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=253025 1
ACITRETIN	Acitretin treatment of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=253284 0
ACITRETIN	Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=253284 6
ACITRETIN	Acitretin versus etretinate in severe psoriasis. A double-blind randomized Nordic multicenter study in 168 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=253284 7
ACITRETIN	A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=256360 6
ACITRETIN	Acitretin improves psoriasis in a dose-dependent fashion.	https://www.ncbi.nlm.nih.gov/pubmed/?term=296731 0
ACITRETIN	Fish oil supplementation results in decreased hypertriglyceridemia in patients with psoriasis undergoing etretinate or acitretin therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=296992 4
ACITRETIN	Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=297169 2
ACITRETIN	Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=297600 0
ACITRETIN	Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A randomized double-blind parallel study comparing acitretin and etretinate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=297640 6
ACITRETIN	Pharmacokinetics of etretinate and acitretin with special reference to treatment of psoriasis. [Review] [257 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=790049 7
ACITRETIN	Acitretin does not prevent psoriasis relapse related to cyclosporin A tapering.	https://www.ncbi.nlm.nih.gov/pubmed/?term=812358 2
ACITRETIN	Pseudoallergic hepatitis after a single intake of 10 mg acitretin (Neotigason) for treatment of psoriasis pustulosa.	https://www.ncbi.nlm.nih.gov/pubmed/?term=857897 0
ACITRETIN	Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis. [Review] [11 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=903180 5
ACITRETIN	Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection.	https://www.ncbi.nlm.nih.gov/pubmed/?term=919782 4

Medication Name	Title	Pubmed Link
ACITRETIN	The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=939033 6
ACITRETIN	The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=953622 7
ACITRETIN	The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=998853 7
ACITRETIN	Acitretin in psoriasis: an overview of adverse effects. [Review] [28 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=104591 40
ACITRETIN	Coexistence of morphea and psoriasis responding to acitretin treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=105684 90
ACITRETIN	Psoriasis associated with HCV and exacerbated by interferon alpha: complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=110539 30
ACITRETIN	Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. [Review] [75 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=115687 45
ACITRETIN	Efficacy of acitretin and commercial tanning bed therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=127070 89
ACITRETIN	The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=128143 39
ACITRETIN	Efficacy of acitretin in severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=128582 31
ACITRETIN	Single-center retrospective study of long-term use of low-dose acitretin (Soriatane) for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=147546 43
ACITRETIN	An impressive therapeutic result of nail psoriasis to acitretin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=150093 17
ACITRETIN	A review of acitretin, a systemic retinoid for the treatment of psoriasis. [Review] [74 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=160866 58
ACITRETIN	Punctate palmoplantar keratoderma (Buschke-Fischer-Brauer disease) with psoriasis: a rare association showing excellent response to acitretin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=161674 22
ACITRETIN	Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164338 08
ACITRETIN	Occupational trachyonychia due to psoriasis: report of a case successfully treated with oral acitretin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164872 89
ACITRETIN	Increased suicidal tendency in a case of psoriasis vulgaris under acitretin treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=166431 52

Medication Name	Title	Pubmed Link
ACITRETIN	Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=167663 32
ACITRETIN	Combination therapy with acitretin for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=167663 35
ACITRETIN	A woman with sudden bilateral sensorineural hearing loss after treatment psoriasis with acitretin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=168589 38
ACITRETIN	Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=169240 49
ACITRETIN	Acitretin induces capillary leak syndrome in a patient with pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=170973 61
ACITRETIN	The efficacy of combination treatment with narrowband UVB (TL-01) and acitretin vs narrowband UVB alone in plaque-type psoriasis: a retrospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=177182 65
ACITRETIN	Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=177216 63
ACITRETIN	Combination of efalizumab and acitretin in chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=182114 28
ACITRETIN	Comparative study of histopathological and immunohistochemical findings in skin biopsies from patients with psoriasis before and after treatment with acitretin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=182517 45
ACITRETIN	Erythroderma in a patient taking acitretin for plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=184595 22
ACITRETIN	Acitretin is a safe treatment option for infantile pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=186087 13
ACITRETIN	An updated review of acitretin--a systemic retinoid for the treatment of psoriasis. [Review] [85 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=186246 82
ACITRETIN	Evaluation of the efficacy of acitretin therapy for nail psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192897 55
ACITRETIN	Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=193806 60
ACITRETIN	Effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome type.	https://www.ncbi.nlm.nih.gov/pubmed/?term=194079 53

Medication Name	Title	Pubmed Link
ACITRETIN	Severe nail psoriasis with a rapid response to acitretin.[Erratum appears in Clin Exp Dermatol. 2009 Dec;34(8):944 Note: Lopez Castillo, V [corrected to Lopez, V]; Molina Gallardo, I [corrected to Molina, I]; Marti Fajardo, N [corrected to Marti, N]; Mart	https://www.ncbi.nlm.nih.gov/pubmed/?term=19456766
ACITRETIN	A review of acitretin for the treatment of psoriasis. [Review] [83 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=19998529
ACITRETIN	Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20858539
ACITRETIN	Efficacy of low-dose acitretin in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21787207
ACITRETIN	Acitretin for the treatment of psoriasis: an assessment of national trends.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21818508
ACITRETIN	NAPSI utilization as an evaluation method of nail psoriasis in patients using acitretin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22570030
ACITRETIN	Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22816881
ACITRETIN	Acitretin exerted a greater influence on T-helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22913391
ACITRETIN	Treatment of severe nail psoriasis with acitretin: an impressive therapeutic result.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23384024
ACITRETIN	Liraglutide in combination with acitretin for severe recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23834125
ACITRETIN	Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23891453
ACITRETIN	The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24021889
ACITRETIN	Complete and rapid regression of primary cutaneous follicular lymphoma with repeated oral administration of acitretin for palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24034386
ACITRETIN	Acitretin in psoriasis: an evolving scenario. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=24601982
ACITRETIN	Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24978351
ACITRETIN	Acquired ichthyosis during acitretin therapy for psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25175920

Medication Name	Title	Pubmed Link
ACITRETIN	Efficacy and safety of Tripterygium wilfordii hook F versus acitretin in moderate to severe psoriasis vulgaris: a randomized clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25673443
ACITRETIN	Drug fever as an adverse effect of acitretin in complicated psoriasis patient.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26133643
ACITRETIN	Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26919330
ACITRETIN	Effectiveness and Safety of Acitretin in Children with Plaque Psoriasis: A Multicenter Retrospective Analysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27443789
ACITRETIN	Optimizing acitretin use in patients with plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27998019
ACITRETIN	Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference.[Erratum appears in Int J Mol Sci. 2017 Sep 04;18(9):: PMID: 28869550]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28146080
ACITRETIN	Cushing's Syndrome Induced by High-Potency Topical Corticosteroids in Two Children with Palmoplantar Psoriasis Taking Acitretin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28297143
ACITRETIN	Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28400341
ACITRETIN	Management of pediatric psoriasis with acitretin: A review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=29094450
ACITRETIN	Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=29098909
ACITRETIN	Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29503541
ACITRETIN	Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29619998
ACITRETIN, PHOTOTHERAPY, METHOTREXATE	A comparative study of histopathological findings in skin biopsies from patients with psoriasis before and after treatment with acitretin, methotrexate and phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25265261
ACITRETIN, TAZAROTENE	Pharmacokinetics of tazarotene and acitretin in psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=30134735

Medication Name	Title	Pubmed Link
ACITRETIN, ETANERCEPT	Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18410408
ACITRETIN, ETANERCEPT	Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18763027
ACITRETIN, ETANERCEPT, PHOTOTHERAPY	Acitretin narrow-band TL-01 phototherapy but not etanercept treatment improves a localized inflammatory linear verrucous epidermal naevus with concomitant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19470068
ACITRETIN, INFILIXIMAB	Rapid downregulation of innate immune cells, interleukin-12 and interleukin-23 in generalized pustular psoriasis with infliximab in combination with acitretin. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=23343611
ACITRETIN, PHOTOTHERAPY	Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18619709
ACITRETIN, PHOTOTHERAPY	A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19002344
ACITRETIN, ADALI MUMAB	Refractory generalized pustular psoriasis responsive to a combination of adalimumab and acitretin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22834488
ACITRETIN, CYCLO SPORINE	Sequential therapy using cyclosporine and acitretin for treatment of total body psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15499760
ACITRETIN, CYCLO SPORINE	Serum concentrations of interleukin-2 and tumour necrosis factor-alpha under cyclosporine versus acitretin treatment in plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25143337
ACITRETIN, METHO TREXATE	Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23066720
ACITRETIN, METHO TREXATE	The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28414177
ACITRETIN, PHOTO THERAPY	Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2527051
ACITRETIN, PHOTO THERAPY	Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15491438
ACITRETIN, PHOTO THERAPY	Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16780493

Medication Name	Title	Pubmed Link
ACITRETIN, PHOTO THERAPY	Home narrowband UV-B phototherapy in combination with low-dose acitretin in patients with moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=187944 74
ACITRETIN, PHOTO THERAPY	Narrow band ultraviolet-B versus Goeckerman therapy for psoriasis with and without acitretin: A retrospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=265158 36
ADALIMUMAB	Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=153275 61
ADALIMUMAB	Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. [Review] [14 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=153797 77
ADALIMUMAB	Extensive plaque psoriasis successfully treated with adalimumab (Humira).	https://www.ncbi.nlm.nih.gov/pubmed/?term=158881 91
ADALIMUMAB	Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164281 60
ADALIMUMAB	Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=170107 38
ADALIMUMAB	Treatment of psoriasis with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=173059 04
ADALIMUMAB	Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=173652 64
ADALIMUMAB	Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.	https://www.ncbi.nlm.nih.gov/pubmed/?term=175742 99
ADALIMUMAB	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=179364 11
ADALIMUMAB	Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=180475 21
ADALIMUMAB	Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=180584 94
ADALIMUMAB	Adalimumab: a new alternative biologic agent for chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=182755 21
ADALIMUMAB	Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. [Review] [77 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=182941 06

Medication Name	Title	Pubmed Link
ADALIMUMAB	Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18559778
ADALIMUMAB	Long-term efficacy of adalimumab in generalized pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18569276
ADALIMUMAB	Palmoplantar psoriasis: a paradoxical adverse reaction induced by adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18624839
ADALIMUMAB	Successful response to narrow-band UVB in a patient undergoing concomitant treatment with adalimumab for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18638229
ADALIMUMAB	Adalimumab: safe and successful in severe pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18761550
ADALIMUMAB	Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18831744
ADALIMUMAB	Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18837728
ADALIMUMAB	Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18936418
ADALIMUMAB	Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19036225
ADALIMUMAB	Efficacy of adalimumab in plaque psoriasis: experience on 28 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19112756
ADALIMUMAB	Adalimumab therapy of psoriasis and psoriatic arthritis in a patient with cirrhosis of the liver.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19119119
ADALIMUMAB	Treatment of severe facial psoriasis with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19137771
ADALIMUMAB	Adalimumab: in plaque psoriasis. [Review] [35 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=19170412
ADALIMUMAB	First case report of adalimumab-induced psoriasis in Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19262532
ADALIMUMAB	A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19309570
ADALIMUMAB	Proteinuria in a patient using adalimumab for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19348667

Medication Name	Title	Pubmed Link
ADALIMUMAB	Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=194385 35
ADALIMUMAB	Development of bullous pemphigoid during treatment of psoriasis with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=194385 55
ADALIMUMAB	Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers.	https://www.ncbi.nlm.nih.gov/pubmed/?term=194624 33
ADALIMUMAB	Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=197018 44
ADALIMUMAB	Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies. [Review] [8 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=197998 28
ADALIMUMAB	Adalimumab for the treatment of psoriasis. [Review] [4 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=198046 89
ADALIMUMAB	Treatment of nail psoriasis with adalimumab: an open label unblinded study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=198078 25
ADALIMUMAB	Marked improvement in nail psoriasis during treatment with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=198510 59
ADALIMUMAB	Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=198916 86
ADALIMUMAB	Adalimumab in the management of palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199034 43
ADALIMUMAB	Adalimumab treatment of a patient with psoriasis suppurativa Hallopeau associated osteoarthropathy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199171 79
ADALIMUMAB	Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199404 37
ADALIMUMAB	Adalimumab in the management of palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=200279 43
ADALIMUMAB	Rapid remission of psoriasis with reversible leucopenia after two injections with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=200558 18
ADALIMUMAB	Psoriasis and its treatment with adalimumab. [Review] [57 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=200782 31
ADALIMUMAB	Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=201570 22

Medication Name	Title	Pubmed Link
ADALIMUMAB	The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219265
ADALIMUMAB	Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20448079
ADALIMUMAB	Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20507398
ADALIMUMAB	Pregnancy during adalimumab use for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20569288
ADALIMUMAB	Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20605254
ADALIMUMAB	Superimposed linear psoriasis unmasked by therapy with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20621851
ADALIMUMAB	Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20716225
ADALIMUMAB	Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20932070
ADALIMUMAB	Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21083543
ADALIMUMAB	Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21110526
ADALIMUMAB	Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21173304
ADALIMUMAB	Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21214631
ADALIMUMAB	Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21290129
ADALIMUMAB	Papillary thyroid carcinoma in a patient with severe psoriasis receiving adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21496712

Medication Name	Title	Pubmed Link
ADALIMUMAB	Recalcitrant pustular psoriasis successfully treated with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21504452
ADALIMUMAB	The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21616560
ADALIMUMAB	Interaction between adalimumab with concurrent pregabalin and duloxetine administration in a psoriasis patient with diabetic peripheral neuropathy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21699129
ADALIMUMAB	Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21752491
ADALIMUMAB	Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21764467
ADALIMUMAB	Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21787203
ADALIMUMAB	Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF- α blockers.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21818515
ADALIMUMAB	The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21834597
ADALIMUMAB	Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21834808
ADALIMUMAB	Generalized pustular psoriasis-like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21957978
ADALIMUMAB	New-onset psoriasis associated with adalimumab: a report of two cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21971280
ADALIMUMAB	Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIb study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22023702
ADALIMUMAB	High-field MRI and powerdoppler sonography: supplementary imaging, techniques in assessing disease activity in patients with psoriasis arthritis (PsA) and rheumatoid arthritis (RA) receiving adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22138673

Medication Name	Title	Pubmed Link
ADALIMUMAB	Alopecia areata during treatment of psoriasis with adalimumab and leflunomide: a case and review of the literature. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22301842
ADALIMUMAB	Topical treatment habits in psoriasis patients receiving adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22414626
ADALIMUMAB	Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22416818
ADALIMUMAB	Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22429586
ADALIMUMAB	Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22506677
ADALIMUMAB	Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22555836
ADALIMUMAB	Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22562972
ADALIMUMAB	Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22564148
ADALIMUMAB	TNF-alpha inhibitor (adalimumab) induced psoriasis: a case report.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22571571
ADALIMUMAB	An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22702802
ADALIMUMAB	Multiple eruptive squamous cell carcinoma in a patient with chronic plaque psoriasis on adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22758905
ADALIMUMAB	Effect of adalimumab on sleep parameters in patients with psoriasis and obstructive sleep apnea: a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22834968
ADALIMUMAB	An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22880843

Medication Name	Title	Pubmed Link
ADALIMUMAB	Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22897348
ADALIMUMAB	Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22928715
ADALIMUMAB	An inflammatory verrucous epidermal nevus concomitant with psoriasis: treatment with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23122018
ADALIMUMAB	Adalimumab-induced psoriasis in a patient with Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23151897
ADALIMUMAB	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23178916
ADALIMUMAB	Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23204039
ADALIMUMAB	Palmoplantar pustulosis with fulminant dystrophic 20-nail psoriasis in a patient receiving adalimumab therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23377322
ADALIMUMAB	Successful treatment of psoriasis with interrupted adalimumab use: a case report.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23488871
ADALIMUMAB	Central retinal vein occlusion and subsequent neovascular glaucoma after adalimumab treatment for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23692635
ADALIMUMAB	Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23790018
ADALIMUMAB	Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23909993
ADALIMUMAB	Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23930916
ADALIMUMAB	Adherence to adalimumab in patients with moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24011280
ADALIMUMAB	Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24033358

Medication Name	Title	Pubmed Link
ADALIMUMAB	Possible drug-drug interaction between adalimumab and duloxetine and/or pregabalin in a psoriasis patient.	https://www.ncbi.nlm.nih.gov/pubmed/?term=240850 41
ADALIMUMAB	Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.	https://www.ncbi.nlm.nih.gov/pubmed/?term=243523 54
ADALIMUMAB	Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=245525 91
ADALIMUMAB	Woronoff ring associated with adalimumab therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=246053 51
ADALIMUMAB	A case of inverse psoriasis successfully treated with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=246388 68
ADALIMUMAB	The effect of adalimumab on key drivers in the pathogenesis of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=246409 89
ADALIMUMAB	Infective endocarditis complicating adalimumab therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=247081 55
ADALIMUMAB	Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=247212 90
ADALIMUMAB	A case of nail psoriasis-associated psoriatic arthritis successfully treated with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=248138 47
ADALIMUMAB	Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=248465 18
ADALIMUMAB	Suicide and depression in a patient with psoriasis receiving adalimumab: the role of the dermatologist.	https://www.ncbi.nlm.nih.gov/pubmed/?term=249349 16
ADALIMUMAB	Occurrence of psoriatic plaques on previous adalimumab injection sites during disease relapse in a patient with pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=249477 09
ADALIMUMAB	A case of acute generalized pustular psoriasis of von Zumbusch treated with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=249811 61
ADALIMUMAB	Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=249847 57
ADALIMUMAB	Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient.	https://www.ncbi.nlm.nih.gov/pubmed/?term=250073 73
ADALIMUMAB	Complete primary treatment failure of adalimumab in a patient with photoaggravated psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=250557 51
ADALIMUMAB	Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry.	https://www.ncbi.nlm.nih.gov/pubmed/?term=250884 51

Medication Name	Title	Pubmed Link
ADALIMUMAB	Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25284275
ADALIMUMAB	Pulmonary sarcoidosis and latent tuberculosis in a patient with psoriasis treated with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25612132
ADALIMUMAB	Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25665143
ADALIMUMAB	Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=25916786
ADALIMUMAB	Autoimmune hemolytic anemia during adalimumab treatment for plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25948357
ADALIMUMAB	Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26088404
ADALIMUMAB	Case of psoriasis vulgaris developing ulcerative colitis during adalimumab treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26111055
ADALIMUMAB	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26190240
ADALIMUMAB	Palmoplantar pustular psoriasis induced by adalimumab: a case report and literature review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26250408
ADALIMUMAB	Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26547918
ADALIMUMAB	Cerebral tuberculoma with pulmonary tuberculosis in a patient with psoriasis treated with adalimumab, an anti-tumor necrosis factor-alpha agent.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26566776
ADALIMUMAB	Adalimumab: A Review in Chronic Plaque Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26586242
ADALIMUMAB	Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26702800
ADALIMUMAB	Persistence and failure rates of adalimumab monotherapy in biologic-naïve patients with psoriasis: A retrospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26892660

Medication Name	Title	Pubmed Link
ADALIMUMAB	The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27086491
ADALIMUMAB	Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27168265
ADALIMUMAB	Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27324646
ADALIMUMAB	Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27450634
ADALIMUMAB	Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27545848
ADALIMUMAB	Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27774694
ADALIMUMAB	Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27783534
ADALIMUMAB	Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27815915
ADALIMUMAB	Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete Clearance.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27868145
ADALIMUMAB	Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27940624
ADALIMUMAB	Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-alpha.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28005985
ADALIMUMAB	Value of ultrasonography findings for nail psoriasis before and after adalimumab administration.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28044350
ADALIMUMAB	Relapsing polychondritis associated with psoriasis vulgaris successfully treated with adalimumab: A case report with published work review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28266051
ADALIMUMAB	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28291552
ADALIMUMAB	Resolution of psoriatic lesions on the gingiva and hard palate following administration of adalimumab for cutaneous psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28319621

Medication Name	Title	Pubmed Link
ADALIMUMAB	Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=283529 29
ADALIMUMAB	Adalimumab in paediatric psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=284789 69
ADALIMUMAB	First Case Report of Aseptic Meningitis Induced by Adalimumab Administered for Treatment of Chronic Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=285702 23
ADALIMUMAB	Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=286041 27
ADALIMUMAB	Importance of immunogenicity testing for cost-effective management of psoriasis patients treated with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=286328 83
ADALIMUMAB	Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287379 94
ADALIMUMAB	Adalimumab in Chronic Plaque Psoriasis: A Clinical Guide. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=288099 93
ADALIMUMAB	Adalimumab for treating childhood plaque psoriasis: a clinical trial evaluation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=288292 04
ADALIMUMAB	Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=289930 05
ADALIMUMAB	Guillain-Barre syndrome in a patient on adalimumab for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=292674 56
ADALIMUMAB	Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=293802 51
ADALIMUMAB	Adalimumab-related alopecia in a patient affected by psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=294696 96
ADALIMUMAB	Mycobacterium marinum infection contracted from seaweed wrap in a psoriasis patient undergoing treatment with adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=294697 48
ADALIMUMAB	Anti-TNF therapy-induced lupus erythematosus-like syndrome in a patient treated with adalimumab for cutaneous psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=296541 01
ADALIMUMAB, APREMILAST	Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=261583 70
ADALIMUMAB, ETANERCEPT	Adalimumab vs. etanercept in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=176920 64
ADALIMUMAB, ETANERCEPT	Adalimumab treats psoriasis in patients previously treated with etanercept: a case series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=195398 61

Medication Name	Title	Pubmed Link
ADALIMUMAB, ETANERCEPT	Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=195730 <u>24</u>
ADALIMUMAB, ETANERCEPT	Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=204944 <u>79</u>
ADALIMUMAB, ETANERCEPT	Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=205248 <u>74</u>
ADALIMUMAB, ETANERCEPT	Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=206497 <u>98</u>
ADALIMUMAB, ETANERCEPT	Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=208313 <u>02</u>
ADALIMUMAB, ETANERCEPT	Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=208544 <u>08</u>
ADALIMUMAB, ETANERCEPT	An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=214555 <u>50</u>
ADALIMUMAB, ETANERCEPT	Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population.	https://www.ncbi.nlm.nih.gov/pubmed/?term=226683 <u>21</u>
ADALIMUMAB, ETANERCEPT	Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=232953 <u>83</u>
ADALIMUMAB, ETANERCEPT	Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=235509 <u>25</u>
ADALIMUMAB, ETANERCEPT	Comment on 'Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study'.	https://www.ncbi.nlm.nih.gov/pubmed/?term=238555 <u>84</u>
ADALIMUMAB, ETANERCEPT	Comment on 'Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study': reply from authors.	https://www.ncbi.nlm.nih.gov/pubmed/?term=238556 <u>19</u>
ADALIMUMAB, ETANERCEPT	'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network.	https://www.ncbi.nlm.nih.gov/pubmed/?term=248074 <u>71</u>

Medication Name	Title	Pubmed Link
ADALIMUMAB, ETANERCEPT	Disease control for patients with psoriasis receiving continuous versus interrupted therapy with adalimumab or etanercept: a clinical practice study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=252172 34
ADALIMUMAB, ETANERCEPT	Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=253062 95
ADALIMUMAB, ETANERCEPT	Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=257260 29
ADALIMUMAB, ETANERCEPT	Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=261839 82
ADALIMUMAB, ETANERCEPT	Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=265589 24
ADALIMUMAB, ETANERCEPT	Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t	https://www.ncbi.nlm.nih.gov/pubmed/?term=269898 52
ADALIMUMAB, ETANERCEPT	Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.	https://www.ncbi.nlm.nih.gov/pubmed/?term=275798 64
ADALIMUMAB, ETANERCEPT	Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=279433 84
ADALIMUMAB, ETANERCEPT	Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=281962 70
ADALIMUMAB, ETANERCEPT	Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=284487 78
ADALIMUMAB, ETANERCEPT	Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=291056 21
ADALIMUMAB, ETANERCEPT	Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review".	https://www.ncbi.nlm.nih.gov/pubmed/?term=291328 66

Medication Name	Title	Pubmed Link
ADALIMUMAB, ETANERCEPT	Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29304933
ADALIMUMAB, ETANERCEPT, INFILXIMAB	Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. [Review] [39 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=16167412
ADALIMUMAB, ETANERCEPT, INFILXIMAB	Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab. [Review] [112 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=19710553
ADALIMUMAB, ETANERCEPT, INFILXIMAB	Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22126264
ADALIMUMAB, ETANERCEPT, INFILXIMAB	Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23527597
ADALIMUMAB, ETANERCEPT, INFILXIMAB	Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25600828
ADALIMUMAB, ETANERCEPT, INFILXIMAB, PIMECROLIMUS, TAZAROTENE	Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. [Review] [61 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=15638763
ADALIMUMAB, ETANERCEPT, PHOTOTHERAPY, METHOTREXATE	Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21414495
ADALIMUMAB, ETANERCEPT, PHOTOTHERAPY, METHOTREXATE	Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24422992
ADALIMUMAB, ETANERCEPT, USTEKINUMAB	Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28224166
ADALIMUMAB, GUSELKUMAB	A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26154787

Medication Name	Title	Pubmed Link
ADALIMUMAB, GUSELKUMAB	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-	https://www.ncbi.nlm.nih.gov/pubmed/?term=280573 <u>60</u>
ADALIMUMAB, GUSELKUMAB	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, p	https://www.ncbi.nlm.nih.gov/pubmed/?term=280573 <u>61</u>
ADALIMUMAB, INFLIXIMAB	Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=189746 <u>29</u>
ADALIMUMAB, INFLIXIMAB	Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.	https://www.ncbi.nlm.nih.gov/pubmed/?term=214538 <u>86</u>
ADALIMUMAB, INFLIXIMAB	Cutaneous pseudolymphoma induced by adalimumab and reproduced by infliximab in a patient with arthropathic psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=219107 <u>04</u>
ADALIMUMAB, INFLIXIMAB	Severe infliximab-induced psoriasis treated with adalimumab switching.	https://www.ncbi.nlm.nih.gov/pubmed/?term=229983 <u>30</u>
ADALIMUMAB, INFLIXIMAB	Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=230391 <u>79</u>
ADALIMUMAB, INFLIXIMAB	Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=234142 <u>25</u>
ADALIMUMAB, INFLIXIMAB	Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life.	https://www.ncbi.nlm.nih.gov/pubmed/?term=237829 <u>78</u>
ADALIMUMAB, INFLIXIMAB	Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=243297 <u>64</u>
ADALIMUMAB, INFLIXIMAB	Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=259193 <u>24</u>
ADALIMUMAB, INFLIXIMAB	Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=277433 <u>97</u>
ADALIMUMAB, INFLIXIMAB, METHOTREXATE	Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development.	https://www.ncbi.nlm.nih.gov/pubmed/?term=254254 <u>79</u>

Medication Name	Title	Pubmed Link
ADALIMUMAB, METHOTREXATE	Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).	https://www.ncbi.nlm.nih.gov/pubmed/?term=180475 <u>23</u>
ADALIMUMAB, METHOTREXATE	Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=184895 <u>93</u>
ADALIMUMAB, METHOTREXATE	Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=209333 <u>01</u>
ADALIMUMAB, METHOTREXATE	Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=231943 <u>89</u>
ADALIMUMAB, METHOTREXATE	Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=248098 <u>78</u>
ADALIMUMAB, METHOTREXATE	CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=259465 <u>54</u>
ADALIMUMAB, METHOTREXATE	Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=262677 <u>31</u>
ADALIMUMAB, METHOTREXATE	Adalimumab-Induced Pityriasis Lichenoides Chronica That Responded Well to Methotrexate in a Patient With Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=265222 <u>35</u>
ADALIMUMAB, METHOTREXATE	Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=284789 <u>75</u>
ADALIMUMAB, PHOTOTHERAPY	Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=214555 <u>46</u>
ADALIMUMAB, ETAN ERCEPT	Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=214289 <u>75</u>
ADALIMUMAB, ETAN ERCEPT	Reply to: Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review".	https://www.ncbi.nlm.nih.gov/pubmed/?term=291328 <u>67</u>
ADALIMUMAB, INFIL XIMAB	Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=291925 <u>52</u>
ANTHRALIN	Development of anthralin short-contact therapy in psoriasis: survey of published clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=153279 <u>0</u>

Medication Name	Title	Pubmed Link
ANTHRALIN	The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2142172
ANTHRALIN	"Ditrawash"--a novel remover of dithranol (anthralin) for short contact therapy of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2609870
ANTHRALIN	Anthralin-corticosteroid combination therapy in the treatment of chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3355198
ANTHRALIN	A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9522242
ANTHRALIN	Topical anthralin therapy for refractory nail psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9609979
ANTHRALIN	Topical anthralin for psoriasis vulgaris: evaluation of 70 Japanese patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10935350
ANTHRALIN	Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12566829
ANTHRALIN, COAL TAR, PHOTOTHERAPY	UVABA therapy for psoriasis. Efficacy with shortened treatment times with the combined use of coal tar, anthralin, and metal halide ultraviolet machines.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2033137
ANTHRALIN, CYCLOSPORINE	Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=7545705
APREMILAST	An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18419879
APREMILAST	Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20050849
APREMILAST	Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22257911
APREMILAST	Apremilast as a treatment for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22712800
APREMILAST	Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22748702
APREMILAST	Apremilast: a step forward in the treatment of psoriasis?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22748703
APREMILAST	Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23030767

Medication Name	Title	Pubmed Link
APREMILAST	New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=235693 59
APREMILAST	Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=236637 52
APREMILAST	Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4.	https://www.ncbi.nlm.nih.gov/pubmed/?term=236801 97
APREMILAST	Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=239861 62
APREMILAST	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).	https://www.ncbi.nlm.nih.gov/pubmed/?term=260890 47
APREMILAST	Apremilast: A Review in Psoriasis and Psoriatic Arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=262209 11
APREMILAST	Apremilast for the treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=262437 35
APREMILAST	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).	https://www.ncbi.nlm.nih.gov/pubmed/?term=263579 44
APREMILAST	Apremilast for psoriasis and psoriatic arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=263583 17
APREMILAST	Apremilast in the treatment of psoriasis and psoriatic arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=263829 06
APREMILAST	Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=264819 41
APREMILAST	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).	https://www.ncbi.nlm.nih.gov/pubmed/?term=265492 49
APREMILAST	A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.	https://www.ncbi.nlm.nih.gov/pubmed/?term=266921 25
APREMILAST	Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=267833 50
APREMILAST	Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=268201 48

Medication Name	Title	Pubmed Link
APREMILAST	Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=268370 52
APREMILAST	Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=268481 45
APREMILAST	Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.	https://www.ncbi.nlm.nih.gov/pubmed/?term=269543 11
APREMILAST	Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical	https://www.ncbi.nlm.nih.gov/pubmed/?term=270212 39
APREMILAST	Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=273077 07
APREMILAST	Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=273767 29
APREMILAST	Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=274866 41
APREMILAST	Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=275382 41
APREMILAST	Real-World Experience With Apremilast in Treating Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=278466 17
APREMILAST	Appearance of lentigines in psoriasis patients treated with apremilast.	https://www.ncbi.nlm.nih.gov/pubmed/?term=278469 46
APREMILAST	Safety evaluation of apremilast for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=281325 78
APREMILAST	Apremilast: A Review in Psoriasis and Psoriatic Arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=282138 62
APREMILAST	Apremilast for the management of moderate to severe plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=282767 77
APREMILAST	Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.	https://www.ncbi.nlm.nih.gov/pubmed/?term=283008 57
APREMILAST	Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for >=156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).	https://www.ncbi.nlm.nih.gov/pubmed/?term=284163 42

Medication Name	Title	Pubmed Link
APREMILAST	A Novel Apremilast Nail Lacquer Formulation for the Treatment of Nail Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28455829
APREMILAST	Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28597182
APREMILAST	Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28621002
APREMILAST	Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28809995
APREMILAST	The Use of Apremilast to Treat Psoriasis During Deployment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28810954
APREMILAST	Apremilast in psoriasis - a prospective real-world study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28925560
APREMILAST	Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA x BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29132853
APREMILAST	Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29240859
APREMILAST	Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29462231
APREMILAST, PHOTOTHERAPY	Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29036248
APREMILAST, ETA NERCEPT	The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).	https://www.ncbi.nlm.nih.gov/pubmed/?term=27768242
APREMILAST, MET HOTREXATE	Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naive patients with psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27476973
APREMILAST, SEC UKINUMAB	Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27168275
APREMILAST, TOF ACITINIB	Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26267722

Medication Name	Title	Pubmed Link
AZATHIOPRINE	Azathioprine: a forgotten alternative for treatment of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1478769
AZATHIOPRINE	Psoriasis and bullous pemphigoid treated with azathioprine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9674409
AZATHIOPRINE	Improvement of anti-TNFalpha antibody-induced pustular psoriasis by azathioprine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22853939
AZATHIOPRINE	Azathioprine for the Rare Case of Nonspecific Interstitial Pneumonitis in a Patient with Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26317277
AZATHIOPRINE	Effectiveness of azathioprine pulse therapy in prolonging remission of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27087143
AZATHIOPRINE	Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27663145
AZATHIOPRINE	Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open-label study: reply to author.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28736843
AZATHIOPRINE, INFliximab, METHOTREXATE	Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19207642
BARICITINIB	A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26800231
BETAMETHASONE	Epidermal cytokeratin and immunocyte responses during treatment of psoriasis with calcipotriol and betamethasone valerate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1373949
BETAMETHASONE	Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris.[Erratum appears in Lancet 1991 Apr 20;337(8747):9881]	https://www.ncbi.nlm.nih.gov/pubmed/?term=1670840
BETAMETHASONE	Calcipotriol and betamethasone valerate for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1673003
BETAMETHASONE	Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1809589
BETAMETHASONE	Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2076716
BETAMETHASONE	Therapeutic response to a dermatologic patch and betamethasone valerate 0.1 percent cream in the management of chronic plaques in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2190758

Medication Name	Title	Pubmed Link
BETAMETHASONE	0.05 percent betamethasone dipropionate in optimized cream vehicle for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2649319
BETAMETHASONE	A controlled clinical trial of a new formulation of betamethasone dipropionate cream in once-daily treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2692821
BETAMETHASONE	Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=7585843
BETAMETHASONE	Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=7999600
BETAMETHASONE	Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8428041
BETAMETHASONE	Topical 0.05% betamethasone dipropionate: efficacy in psoriasis with once a day vs. twice a day application.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8547019
BETAMETHASONE	Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8646866
BETAMETHASONE	Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8646870
BETAMETHASONE	Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: a comparat	https://www.ncbi.nlm.nih.gov/pubmed/?term=8949429
BETAMETHASONE	Augmented betamethasone: efficacy in psoriasis with different dosing frequencies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8961896
BETAMETHASONE	Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9039301
BETAMETHASONE	Calcipotriol in psoriasis vulgaris: a controlled trial comparing betamethasone dipropionate + salicylic acid.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9268756
BETAMETHASONE	Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9602870

Medication Name	Title	Pubmed Link
BETAMETHASONE	Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid.	https://www.ncbi.nlm.nih.gov/pubmed/?term=989290 9
BETAMETHASONE	Double-blind clinical study reveals synergistic action between alpha-hydroxy acid and betamethasone lotions towards topical treatment of scalp psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=108772 45
BETAMETHASONE	Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion.	https://www.ncbi.nlm.nih.gov/pubmed/?term=113142 40
BETAMETHASONE	Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=115860 14
BETAMETHASONE	Betamethasone valerate foam for treatment of nonscalp psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=119078 40
BETAMETHASONE	Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=119078 47
BETAMETHASONE	A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=121259 43
BETAMETHASONE	Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=121741 05
BETAMETHASONE	Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a new formulation for the treatment of psoriasis. [Review] [21 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=122239 76
BETAMETHASONE	Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=125346 07
BETAMETHASONE	Once daily application of a combination of calcipotriol and betamethasone dipropionate (Dovobet, Daivobet) for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=149611 73
BETAMETHASONE	The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=150091 04
BETAMETHASONE	The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=153773 55

Medication Name	Title	Pubmed Link
BETAMETHASONE	Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15539894
BETAMETHASONE	Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15663344
BETAMETHASONE	Efficacy and local safety of a calcipotriol/ betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15701591
BETAMETHASONE	A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. [Review] [15 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=15942215
BETAMETHASONE	Treatment of guttate psoriasis with a new two-compound product containing calcipotriol and betamethasone dipropionate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16402632
BETAMETHASONE	Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16405606
BETAMETHASONE	Calcipotriol-betamethasone ointment versus calcipotriol ointment in the treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16425973
BETAMETHASONE	A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16441622
BETAMETHASONE	Calcipotriol/betamethasone dipropionate for the treatment of psoriasis. [Review] [94 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=16553575
BETAMETHASONE	A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Davobet/Taclonex) in the treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16704648
BETAMETHASONE	Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17135738
BETAMETHASONE	Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17163256
BETAMETHASONE	Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17225026

Medication Name	Title	Pubmed Link
BETAMETHASONE	Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17365265
BETAMETHASONE	Calcipotriol and betamethasone dipropionate for the treatment of psoriasis: a 52-week study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17551662
BETAMETHASONE	Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17934937
BETAMETHASONE	Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18463448
BETAMETHASONE	Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18480933
BETAMETHASONE	A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19067709
BETAMETHASONE	Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19212110
BETAMETHASONE	Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19416259
BETAMETHASONE	Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19453810
BETAMETHASONE	Generalized pustular psoriasis (von Zumbusch) following the use of calcipotriol and betamethasone dipropionate ointment: a report of two cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19508565
BETAMETHASONE	Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol).	https://www.ncbi.nlm.nih.gov/pubmed/?term=19585059
BETAMETHASONE	Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: an immunohistochemical study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20055694
BETAMETHASONE	Iatrogenic adrenal insufficiency associated with calcipotriol-betamethasone topical combination in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20089083

Medication Name	Title	Pubmed Link
BETAMETHASONE	The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20232758
BETAMETHASONE	Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142833
BETAMETHASONE	The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142834
BETAMETHASONE	The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142838
BETAMETHASONE	Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21284407
BETAMETHASONE	Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21293107
BETAMETHASONE	Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21504248
BETAMETHASONE	Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol-gel): results.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21564540
BETAMETHASONE	Use of a psoriasis plaque test in the development of a gel formulation of calcipotriol and betamethasone dipropionate for scalp psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22103604
BETAMETHASONE	Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23149707
BETAMETHASONE	Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol gel) in the treatment of scalp psoriasis: results from a study in 885 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23621170

Medication Name	Title	Pubmed Link
BETAMETHASONE	Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24256460
BETAMETHASONE	Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24533503
BETAMETHASONE	Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24593129
BETAMETHASONE	Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24684739
BETAMETHASONE	Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=24684740
BETAMETHASONE	Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24980277
BETAMETHASONE	Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCOP): study protocol for a randomized controlled trial.[Erratum appears in Trials. 2016;17:357; PMID: 27460232]	https://www.ncbi.nlm.nih.gov/pubmed/?term=25052161
BETAMETHASONE	Alternative treatment with calcipotriol plus betamethasone dipropionate gel in psoriasis vulgaris using a short-contact approach.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25109395
BETAMETHASONE	A randomized, double-blinded trial evaluating the efficacy and tolerability of vescalical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone dipropionate ointment (64 mg/g) in patients with nail psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25116967
BETAMETHASONE	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25346093

Medication Name	Title	Pubmed Link
BETAMETHASONE	Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25708531
BETAMETHASONE	A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26224733
BETAMETHASONE	Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26337069
BETAMETHASONE	Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26503824
BETAMETHASONE	Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26794805
BETAMETHASONE	DFD-01, a Novel Medium Potency Betamethasone Dipropionate 0.05% Emollient Spray, Demonstrates Similar Efficacy to Augmented Betamethasone Dipropionate 0.05% Lotion for the Treatment of Moderate Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26885782
BETAMETHASONE	Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26924402
BETAMETHASONE	Improvement in Extensive Moderate Plaque Psoriasis With a Novel Emollient Spray Formulation of Betamethasone Dipropionate 0.05.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26954319
BETAMETHASONE	Effective treatment of severe nail psoriasis using topical calcipotriol with betamethasone dipropionate gel.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27088952
BETAMETHASONE	Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27306589
BETAMETHASONE	Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27531752
BETAMETHASONE	Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27663245

Medication Name	Title	Pubmed Link
BETAMETHASONE	Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=279369 <u>72</u>
BETAMETHASONE	DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=279672 <u>62</u>
BETAMETHASONE	Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=279955 <u>21</u>
BETAMETHASONE	Treatment of nail psoriasis with Pulse Dye Laser plus calcipotriol betametasona gel vs. Nd:YAG plus calcipotriol betamethasone gel: An intrapatient left-to-right controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=281189 <u>26</u>
BETAMETHASONE	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.[Erratum appears in Am J Clin Dermatol. 2017 May 24::: PMID: 28540589]	https://www.ncbi.nlm.nih.gov/pubmed/?term=282362 <u>23</u>
BETAMETHASONE	A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP).	https://www.ncbi.nlm.nih.gov/pubmed/?term=283010 <u>43</u>
BETAMETHASONE	Atorvastatin as adjunctive therapy for chronic plaque type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=285408 <u>70</u>
BETAMETHASONE	Low systemic exposure and calcemic effect of calcipotriol/betamethasone ointment in rats with imiquimod-induced psoriasis-like dermatitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=294768 <u>78</u>
BETAMETHASONE, CALCIPOTRIENE	Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks.	https://www.ncbi.nlm.nih.gov/pubmed/?term=108632 <u>25</u>
BETAMETHASONE, CALCIPOTRIENE	Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=125223 <u>70</u>
BETAMETHASONE, CALCIPOTRIENE	Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=167345 <u>05</u>
BETAMETHASONE, CALCIPOTRIENE	A betamethasone-calcipotriene combination for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=168410 <u>23</u>

Medication Name	Title	Pubmed Link
BETAMETHASONE, CALCIPOTRIENE	A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18694678
BETAMETHASONE, CALCIPOTRIENE	Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19180896
BETAMETHASONE, CALCIPOTRIENE	Calcipotriene/betamethasone in the treatment of psoriasis: a review article. [Review] [51 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=19663634
BETAMETHASONE, CALCIPOTRIENE	Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Davobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20684147
BETAMETHASONE, CALCIPOTRIENE	A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20964660
BETAMETHASONE, CALCIPOTRIENE	Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21967117
BETAMETHASONE, CALCIPOTRIENE	Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23377334
BETAMETHASONE, CALCIPOTRIENE	Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23986161
BETAMETHASONE, CALCIPOTRIENE	Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24063352
BETAMETHASONE, CALCIPOTRIENE	Calcipotriene-betamethasone dipropionate topical suspension in the management of psoriasis: a status report on available data with an overview of practical clinical application.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25279474
BETAMETHASONE, CALCIPOTRIENE	Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25307472

Medication Name	Title	Pubmed Link
BETAMETHASONE, CALCIPOTRIENE	Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25412565
BETAMETHASONE, CALCIPOTRIENE	Calcipotriene 0.005%--betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25566573
BETAMETHASONE, CALCIPOTRIENE	Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25607705
BETAMETHASONE, CALCIPOTRIENE	Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26444907
BETAMETHASONE, CALCIPOTRIENE	Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).	https://www.ncbi.nlm.nih.gov/pubmed/?term=26659941
BETAMETHASONE, CALCIPOTRIENE	Calcipotriene/betamethasone foam (Enstilar) for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27049509
BETAMETHASONE, CALCIPOTRIENE	Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27089906
BETAMETHASONE, CALCIPOTRIENE	Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27537995
BETAMETHASONE, CALCIPOTRIENE	The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27537999
BETAMETHASONE, CALCIPOTRIENE	Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28581873
BETAMETHASONE, CALCIPOTRIENE	Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28659016
BETAMETHASONE, CALCIPOTRIENE	A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28809989

Medication Name	Title	Pubmed Link
BETAMETHASONE, CALCIPOTRIENE, ETANERCEPT	Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21818509
BETAMETHASONE, CYCLOSPORINE	Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21756153
BETAMETHASONE, METHOTREXATE	Methotrexate-betamethasone weekly oral pulse in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17852636
BETAMETHASONE, PHOTOTHERAPY	Comparison of betamethasone valerate solution with phototherapy (UVB comb) in scalp psoriasis treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9779265
BETAMETHASONE, PIMECROLIMUS	1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16983001
BETAMETHASONE, TACROLIMUS	Exclusive plaque psoriasis of the lips: efficacy of combination therapy of topical tacrolimus, calcipotriol, and betamethasone dipropionate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22779103
BETAMETHASONE, TAZAROTENE	Tazarotene cream (0.1%) in combination with betamethasone valerate foam (0.12%) for plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15776784
BRODALUMAB	Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22455412
BRODALUMAB	Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24079852
BRODALUMAB	Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24846347
BRODALUMAB	Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25313095
BRODALUMAB	Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25553889
BRODALUMAB	Use of brodalumab for the treatment of psoriasis and psoriatic arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=25917624
BRODALUMAB	Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=25985813
BRODALUMAB	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26422722

Medication Name	Title	Pubmed Link
BRODALUMAB	Brodalumab versus ustekinumab in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=266270 75
BRODALUMAB	Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=267731 08
BRODALUMAB	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=269144 06
BRODALUMAB	Rebound pustular psoriasis after brodalumab discontinuation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=270376 61
BRODALUMAB	Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=271065 10
BRODALUMAB	Brodalumab established as an effective interleukin-17 receptor antagonist in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=275355 97
BRODALUMAB	Brodalumab for the treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=277187 60
BRODALUMAB	A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=281220 92
BRODALUMAB	Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=281979 01
BRODALUMAB	Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=284605 49
BRODALUMAB	Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=285857 07
BRODALUMAB	Brodalumab: the first anti-IL-17 receptor agent for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=286500 01
BRODALUMAB	Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3).	https://www.ncbi.nlm.nih.gov/pubmed/?term=287110 89
BRODALUMAB	Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=287440 98
BRODALUMAB	A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=288797 89

Medication Name	Title	Pubmed Link
BRODALUMAB	Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=289859 56
BRODALUMAB	The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=293235 42
BRODALUMAB	The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.	https://www.ncbi.nlm.nih.gov/pubmed/?term=293577 13
BRODALUMAB	In response to Lebwohl et al, "Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials".	https://www.ncbi.nlm.nih.gov/pubmed/?term=294476 87
BRODALUMAB	Reply to: "Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials".	https://www.ncbi.nlm.nih.gov/pubmed/?term=294476 88
BRODALUMAB, GUSELKUMAB, IXEKIZUMAB, SECUKINUMAB, TILDRAKIZUMAB	Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. [Rev]	https://www.ncbi.nlm.nih.gov/pubmed/?term=248007 03
BRODALUMAB, GUSELKUMAB, IXEKIZUMAB, SECUKINUMAB, TILDRAKIZUMAB	A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. [R]	https://www.ncbi.nlm.nih.gov/pubmed/?term=295326 93
BRODALUMAB, SECUKINUMAB	Transitioning Between Brodalumab and Secukinumab in Moderate to Severe Psoriasis: An Early Look.	https://www.ncbi.nlm.nih.gov/pubmed/?term=275379 93
CALCIPOTRIENE	Treatment of psoriasis: role of calcipotriene. [Review] [13 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=760476 7
CALCIPOTRIENE	Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=782251 9
CALCIPOTRIENE	Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=792992 1
CALCIPOTRIENE	Calcipotriene for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=803575 4
CALCIPOTRIENE	Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=860925 4
CALCIPOTRIENE	A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=870803 5

Medication Name	Title	Pubmed Link
CALCIPOTRIENE	Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=890328 6
CALCIPOTRIENE	Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=896189 7
CALCIPOTRIENE	Topical calcipotriene ointment and etretinate: another combination therapy for psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=914655 5
CALCIPOTRIENE	Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists. [Review] [25 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=934418 8
CALCIPOTRIENE	The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. [Review] [21 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=934418 9
CALCIPOTRIENE	Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions.	https://www.ncbi.nlm.nih.gov/pubmed/?term=953622 6
CALCIPOTRIENE	Evaluating the safety of calcipotriene 30 g per day in patients with psoriasis: a parallel group, vehicle-controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=959046 5
CALCIPOTRIENE	Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.	https://www.ncbi.nlm.nih.gov/pubmed/?term=973878 1
CALCIPOTRIENE	Treatment of psoriasis with calcipotriene plus psoralen-UV-A-bath therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=104111 75
CALCIPOTRIENE	Per-gram cost of medication is by itself a poor indicator for comparing costs of different psoriasis treatments: a retrospective cohort study of the cost of psoriasis treatment with topical corticosteroids versus topical calcipotriene.	https://www.ncbi.nlm.nih.gov/pubmed/?term=110037 15
CALCIPOTRIENE	Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. [Review] [30 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=111151 67
CALCIPOTRIENE	Psoriasis in infancy: therapy with calcipotriene ointment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=117661 19
CALCIPOTRIENE	A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes.	https://www.ncbi.nlm.nih.gov/pubmed/?term=170107 44
CALCIPOTRIENE	An unusual bullous eruption in a patient with psoriasis: Calcipotriene phototoxicity.	https://www.ncbi.nlm.nih.gov/pubmed/?term=204661 93

Medication Name	Title	Pubmed Link
CALCIPOTRIENE	Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20599292
CALCIPOTRIENE	Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.[Erratum appears in Am J Clin Dermatol. 2012 Dec 1;13(6):422]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22587791
CALCIPOTRIENE	A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23545912
CALCIPOTRIENE	Clobetasol Emulsion Foam and Calcipotriene 0.005% Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29537452
CALCIPOTRIENE, COAL TAR	Comparison of calcipotriene (Dovonex) with a coal tar emulsion (Exorex) in treating psoriasis in adults: a pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10206065
CALCIPOTRIENE, COAL TAR	Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20513160
CALCIPOTRIENE, PHOTOTHERAPY	Combination phototherapy of psoriasis with calcipotriene and narrow-band (311 nm) UVB.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9091500
CALCIPOTRIENE, PHOTOTHERAPY	Topical calcipotriene in combination with UVB phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9169336
CALCIPOTRIENE, TACROLIMUS	Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23094314
CALCIPOTRIENE, TAZAROTENE	A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11110233
CALCIPOTRIENE, TAZAROTENE	An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11147086
CALCIPOTRIENE, TAZAROTENE	Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11147087
CALCIPOTRIENE, TAZAROTENE	Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12063489

Medication Name	Title	Pubmed Link
CERTOLIZUMAB	Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19888257
CERTOLIZUMAB	Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22413944
CERTOLIZUMAB	Certolizumab pegol for the treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28165828
COAL TAR	Re-examining crude coal tar treatment for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1610712
COAL TAR	Detection of DNA adducts in skin biopsies of coal tar-treated psoriasis patients: immunofluorescence and 32P postlabeling.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2127679
COAL TAR	Formation of DNA adducts in the skin of psoriasis patients, in human skin in organ culture, and in mouse skin and lung following topical application of coal-tar and juniper tar.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2299199
COAL TAR	Low concentration dithranol and coal tar (Psorin) in psoriasis: a comparison with alcoholic coal tar extract and allantoin (Alphosyl).	https://www.ncbi.nlm.nih.gov/pubmed/?term=2590619
COAL TAR	Effectiveness of a new coal tar preparation in the treatment of chronic plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2590625
COAL TAR	Effect of UVB therapy and a coal tar bath on short contact dithranol treatment for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3042009
COAL TAR	Lack of additive effect of coal tar combined with dithranol for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3214958
COAL TAR	Treatment of psoriasis with a combination of dithranol and coal tar.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3256465
COAL TAR	The importance of the coal tar bath in the Ingram treatment of psoriasis. Evaluation by evaporiometry and laser Doppler flowmetry.[Erratum appears in Br J Dermatol 1988 Jul;119(1):1401	https://www.ncbi.nlm.nih.gov/pubmed/?term=3281703
COAL TAR	Quantitation of polycyclic aromatic hydrocarbons, 1-hydroxypyrene, and mutagenicity in urine of coal tar-treated psoriasis patients and untreated volunteers.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8049634
COAL TAR	Comparative effects of calcipotriol ointment (50 micrograms/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9158266
COAL TAR	Coal tar therapy in palmoplantar psoriasis: old wine in an old bottle?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9169338

Medication Name	Title	Pubmed Link
COAL TAR	A double blind, randomized, controlled clinical trial to assess the efficacy of a new coal tar preparation (Exorex) in the treatment of chronic, plaque type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11167965
COAL TAR	Crude coal tar treatment every day versus every other day for plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11558890
COAL TAR	Comparison of calcipotriol and coal tar in conjunction with sun exposure in chronic plaque psoriasis: a pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560163
COAL TAR	The effects of topical corticosteroids and a coal tar preparation on dithranol-induced irritation in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12566824
COAL TAR	Observer-blind, randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex) and calcipotriol cream in the treatment of plaque type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12932242
COAL TAR	Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=14521705
COAL TAR	Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=14754644
COAL TAR	Dandruff, seborrheic dermatitis, and psoriasis drug products containing coal tar and menthol for over-the-counter human use; amendment to the monograph. Final rule.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17447341
COAL TAR	A novel LCD (coal tar) solution for psoriasis does not discolor naturally light or color-processed hair in an exaggerated exposure test model.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19735520
COAL TAR	No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20016499
COAL TAR	Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20486463
COAL TAR	An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=20941951
COAL TAR	Novel stain-free lecithinized coal tar formulation for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21671911
COAL TAR	DNA adducts in skin biopsies and 1-hydroxypyrene in urine of psoriasis patients and healthy volunteers following treatment with coal tar.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21810456
COAL TAR	Comparative evaluation of topical calcipotriol versus coal tar and salicylic acid ointment in chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23986159

Medication Name	Title	Pubmed Link
COAL TAR	Oxidative damage to nucleic acids and benzo(a)pyrene-7,8-diol-9,10-epoxide-DNA adducts and chromosomal aberration in children with psoriasis repeatedly exposed to crude coal tar ointment and UV radiation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=251974 <u>29</u>
COAL TAR	Review of the mechanism of action of coal tar in psoriasis. [Review][Erratum appears in J Dermatolog Treat. 2018 May;29(3):x; PMID: 29415583]	https://www.ncbi.nlm.nih.gov/pubmed/?term=288141 <u>17</u>
COAL TAR, METHOTREXATE	Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=246659 <u>10</u>
COAL TAR, METHOTREXATE	Methotrexate iontophoresis versus coal tar ointment in palmoplantar psoriasis: A pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287310 <u>17</u>
COAL TAR, PHOTOTHERAPY	Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=215070 <u>36</u>
COAL TAR, PHOTOTHERAPY	Crude Coal Tar and Ultraviolet (UV) A radiation (Modified Goeckerman Technique) in Treatment of Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=264768 <u>99</u>
COAL TAR, TAZAROTENE	Topical tazarotene vs. coal tar in stable plaque psoriasis.[Erratum appears in Clin Exp Dermatol. 2010 Aug;35(6):685]	https://www.ncbi.nlm.nih.gov/pubmed/?term=198743 <u>76</u>
CYCLOSPORINE	Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=137202 <u>7</u>
CYCLOSPORINE	Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=140128 <u>0</u>
CYCLOSPORINE	Hypertriglyceridemia in patients with psoriasis treated with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=140130 <u>0</u>
CYCLOSPORINE	Differential effects of cyclosporine and etretinate on serum cytokine levels in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=140130 <u>9</u>
CYCLOSPORINE	Cyclosporine therapy for psoriasis: a cell cycle-derived dosing schedule.	https://www.ncbi.nlm.nih.gov/pubmed/?term=140131 <u>1</u>
CYCLOSPORINE	Bullous pemphigoid and severe erythrodermic psoriasis: combined low-dose treatment with cyclosporine and systemic steroids.	https://www.ncbi.nlm.nih.gov/pubmed/?term=143038 <u>0</u>

Medication Name	Title	Pubmed Link
CYCLOSPORINE	Topical cyclosporine is ineffective in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1478774
CYCLOSPORINE	Can maintenance cyclosporine be used in psoriasis without decreasing renal function?. [Review] [69 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=1493094
CYCLOSPORINE	Psoriasis symposium. Cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1493100
CYCLOSPORINE	Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1552052
CYCLOSPORINE	Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1564147
CYCLOSPORINE	Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1599264
CYCLOSPORINE	The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1613146
CYCLOSPORINE	Cyclosporine in psoriasis treatment. Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor alpha/epidermal growth factor receptor pathways.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1677800
CYCLOSPORINE	Multiple eruptive benign keratoses associated with cyclosporine therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1732322
CYCLOSPORINE	Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1732342
CYCLOSPORINE	Hypertriglyceridemia in patients with psoriasis treated with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1791223
CYCLOSPORINE	Cyclosporine A in psoriasis. [Review] [62 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=1822409
CYCLOSPORINE	Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1986287
CYCLOSPORINE	Systemic treatment of severe psoriasis--the role of cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1986292
CYCLOSPORINE	Psoriasis, cyclosporine, and pregnancy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1998383
CYCLOSPORINE	Bullous pemphigoid and psoriasis: treatment with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1999519
CYCLOSPORINE	Cyclosporine for treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2041556

Medication Name	Title	Pubmed Link
CYCLOSPORINE	Worldwide experience with Sandimmune (cyclosporine) in autoimmune diseases: multiple sclerosis, rheumatoid arthritis, psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2096278
CYCLOSPORINE	Is cyclosporine blood concentration monitoring necessary in patients treated for severe chronic plaque form psoriasis?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2190392
CYCLOSPORINE	Acrodermatitis continua-type of pustular psoriasis responds to low-dose cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2212157
CYCLOSPORINE	Cyclosporine A in the treatment of psoriasis: a clinical and mechanistic perspective. [Review] [15 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=2230215
CYCLOSPORINE	Differential effects of cyclosporine A on Langerhans cells and regulatory T-cell populations in severe psoriasis: an immunohistochemical and flow cytometric analysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2252524
CYCLOSPORINE	Rapid response of von Zumbusch psoriasis to cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2254478
CYCLOSPORINE	Systemic and local administration of cyclosporine in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2277131
CYCLOSPORINE	Effects of cyclosporine on renal function in psoriasis patients. [Review] [42 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=2277137
CYCLOSPORINE	Effects of cyclosporine on immunologic mechanisms in psoriasis. [Review] [119 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=2277141
CYCLOSPORINE	Placebo-controlled study of psoriasis patients treated topically with a 10% cyclosporine gel.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2298950
CYCLOSPORINE	Intralesional cyclosporine in the treatment of psoriasis. A clinical, immunologic, and pharmacokinetic study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2298969
CYCLOSPORINE	Low predictive value of cyclosporine level for efficacy or renal dysfunction in psoriasis and idiopathic nephrotic syndrome.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2349691
CYCLOSPORINE	Two distinct squamous cell carcinomas in a psoriasis patient receiving low-dose cyclosporine maintenance treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2584466
CYCLOSPORINE	Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2778110
CYCLOSPORINE	Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2787338
CYCLOSPORINE	Effects of cyclosporine A treatment on psoriasis. I: Influence of low-dose cyclosporine on human monocyte function in vitro.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2837854
CYCLOSPORINE	The effects of cyclosporine A on T lymphocyte and dendritic cell subpopulations in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3260052

Medication Name	Title	Pubmed Link
CYCLOSPORINE	Cyclosporine A in psoriasis: an immunohistological study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=326005 3
CYCLOSPORINE	Low-dose cyclosporine effective in severe psoriasis: a double-blind study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=328921 1
CYCLOSPORINE	Topical cyclosporine in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=334642 2
CYCLOSPORINE	Long-term cyclosporine in the management of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=338127 6
CYCLOSPORINE	Cyclosporine for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=338127 9
CYCLOSPORINE	Cyclosporine maintenance therapy in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=338130 1
CYCLOSPORINE	Combination of cyclosporine A and topical corticosteroid in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=338130 2
CYCLOSPORINE	Resistant severe psoriasis controlled with systemic cyclosporine therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=338130 3
CYCLOSPORINE	Cyclosporine for psoriasis: beneficial effect in refractory skin and joint disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=338130 4
CYCLOSPORINE	Low-dose cyclosporine A in severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=338130 5
CYCLOSPORINE	Effects of cyclosporine on cytokines and cytokine receptors in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=749036 4
CYCLOSPORINE	Low-dose cyclosporine A improves severe disabling psoriasis in Latin America. Latin American Multicenter Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=759144 5
CYCLOSPORINE	Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=761179 4
CYCLOSPORINE	Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=765787 0
CYCLOSPORINE	Cyclosporine: a new therapeutic option for severe, recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=772719 6
CYCLOSPORINE	Renal structure and function effects after low dose cyclosporine in psoriasis patients: a preliminary report.	https://www.ncbi.nlm.nih.gov/pubmed/?term=777406 9
CYCLOSPORINE	Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=799461 6

Medication Name	Title	Pubmed Link
CYCLOSPORINE	A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8021375
CYCLOSPORINE	Development of human papillomavirus-associated Buschke-Lowenstein penile carcinoma during cyclosporine therapy for generalized pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8040428
CYCLOSPORINE	Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8188867
CYCLOSPORINE	Effect of cyclosporine on genital psoriasis and lichen planus.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8245246
CYCLOSPORINE	Development of human papillomavirus-associated Buschke-Lowenstein penile carcinoma during cyclosporine therapy for generalized pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8393464
CYCLOSPORINE	Long-term safety of cyclosporine in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8651712
CYCLOSPORINE	Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8786246
CYCLOSPORINE	Treatment of psoriasis by cyclosporine and grapefruit juice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8859044
CYCLOSPORINE	Adenocarcinoma of the mouth in a patient with psoriasis under short-term cyclosporine therapy. [Review] [9 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=8864632
CYCLOSPORINE	Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8912566
CYCLOSPORINE	Cyclosporine and angiogenesis in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=8959979
CYCLOSPORINE	Cyclosporine as maintenance therapy in patients with severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9091474
CYCLOSPORINE	Effects of cyclosporine on cytokines and cytokine receptors in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9092768
CYCLOSPORINE	Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9308575
CYCLOSPORINE	Long-term low-dose cyclosporine therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9344222
CYCLOSPORINE	Risk of cancer with cyclosporine in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9466216
CYCLOSPORINE	Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9553911

Medication Name	Title	Pubmed Link
CYCLOSPORINE	Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine efficacy in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=958580 1
CYCLOSPORINE	Effect of obesity on cyclosporine trough concentrations in psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=970618 7
CYCLOSPORINE	Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. [Review] [74 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=973878 3
CYCLOSPORINE	Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports).	https://www.ncbi.nlm.nih.gov/pubmed/?term=978404 9
CYCLOSPORINE	Eruptive angiomas after treatment with cyclosporine in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=982889 5
CYCLOSPORINE	1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=105947 56
CYCLOSPORINE	Cyclosporine in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=111075 22
CYCLOSPORINE	Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=112605 40
CYCLOSPORINE	Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=117026 20
CYCLOSPORINE	Cyclosporine in childhood psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=117089 69
CYCLOSPORINE	Bilateral femoral avascular necrosis in a man with psoriasis: responsibility of topical corticosteroids and role of cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=117528 34
CYCLOSPORINE	Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=124443 36
CYCLOSPORINE	The FDA guidelines for the treatment of psoriasis using cyclosporine A: are they adequate?. [Review] [18 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=124697 83
CYCLOSPORINE	Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=125425 24
CYCLOSPORINE	Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=127714 75
CYCLOSPORINE	Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach.	https://www.ncbi.nlm.nih.gov/pubmed/?term=154618 75
CYCLOSPORINE	Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=156247 53

Medication Name	Title	Pubmed Link
CYCLOSPORINE	Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15692507
CYCLOSPORINE	A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15743796
CYCLOSPORINE	Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16648935
CYCLOSPORINE	Cyclosporine A in the treatment of psoriasis: a clinical and mechanistic perspective. [Review] [15 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=16788634
CYCLOSPORINE	Cyclosporine resolves generalized pustular psoriasis of pregnancy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17043209
CYCLOSPORINE	Optimal time for therapeutic drug monitoring of cyclosporine microemulsion in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17614813
CYCLOSPORINE	Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17651179
CYCLOSPORINE	An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17668540
CYCLOSPORINE	A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17852632
CYCLOSPORINE	Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17941368
CYCLOSPORINE	Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18209089
CYCLOSPORINE	Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18971577
CYCLOSPORINE	Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18996858
CYCLOSPORINE	Generalized pustular psoriasis of pregnancy successfully treated with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19915261
CYCLOSPORINE	Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. [Review] [117 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=19932926
CYCLOSPORINE	Clinical outcome evaluation following cyclosporine a treatment in moderate to severe psoriasis: a retrospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20378025

Medication Name	Title	Pubmed Link
CYCLOSPORINE	Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20633803
CYCLOSPORINE	Development of pemphigus vulgaris in a patient with psoriasis treated with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20633813
CYCLOSPORINE	Eruptive nevi in a patient receiving cyclosporine A for psoriasis treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20644052
CYCLOSPORINE	Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21244763
CYCLOSPORINE	In response to "Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?".	https://www.ncbi.nlm.nih.gov/pubmed/?term=21414501
CYCLOSPORINE	Pemphigus vulgaris with plaque-type psoriasis successfully treated with cyclosporine monotherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21668035
CYCLOSPORINE	Coexistence of adult T-cell leukaemia /lymphoma and psoriasis treated with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266509
CYCLOSPORINE	Downregulation of circulating CD4+ CD25(bright) Foxp3+ T cells by cyclosporine therapy and correlation with clinical response in psoriasis patients: report of three cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22417245
CYCLOSPORINE	Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23171021
CYCLOSPORINE	Maintenance treatment of psoriasis with cyclosporine A: comparison between continuous and weekend therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23317974
CYCLOSPORINE	Levels of cyclosporine in breast milk and passage into the circulation of the infant of a mother with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23336105
CYCLOSPORINE	Cyclosporine as maintenance therapy in patients with severe psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=23866863
CYCLOSPORINE	Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=23983647
CYCLOSPORINE	Combined clinical, capillaroscopic and ultrasound evaluation during treatment of plaque psoriasis with oral cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24355242
CYCLOSPORINE	Combination therapy of cyclosporine and anti-tumor necrosis factor alpha in psoriasis: a case series of 10 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25640261
CYCLOSPORINE	Pustular Psoriasis of Pregnancy Successfully Treated With Cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26360534
CYCLOSPORINE	Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26651208

Medication Name	Title	Pubmed Link
CYCLOSPORINE	Comparison of Guidelines for the Use of Cyclosporine for Psoriasis: A Critical Appraisal and Comprehensive Review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=269543 <u>14</u>
CYCLOSPORINE	Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis: A Randomized Clinical Trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=270967 <u>09</u>
CYCLOSPORINE	Systemic cyclosporine treatment in severe childhood psoriasis: A retrospective chart review.	https://www.ncbi.nlm.nih.gov/pubmed/?term=277719 <u>82</u>
CYCLOSPORINE	Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action.	https://www.ncbi.nlm.nih.gov/pubmed/?term=284051 <u>65</u>
CYCLOSPORINE	Clinical improvement of a patient with both amyopathic dermatomyositis and psoriasis following treatment with cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=294697 <u>54</u>
CYCLOSPORINE, ETANERCEPT	Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164883 <u>28</u>
CYCLOSPORINE, ETANERCEPT	Subacute annular generalized pustular psoriasis treated with etanercept and cyclosporine combination.	https://www.ncbi.nlm.nih.gov/pubmed/?term=177636 <u>00</u>
CYCLOSPORINE, ETANERCEPT	Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection.	https://www.ncbi.nlm.nih.gov/pubmed/?term=189376 <u>72</u>
CYCLOSPORINE, ETANERCEPT	Successful treatment of von Zumbusch generalized pustular psoriasis with cyclosporine after eruption post etanercept injection.	https://www.ncbi.nlm.nih.gov/pubmed/?term=222599 <u>08</u>
CYCLOSPORINE, ETANERCEPT	Generalized pustular psoriasis of Zambusch: case report of successful disease control with cyclosporine and etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=230943 <u>12</u>
CYCLOSPORINE, ETANERCEPT	Pediatric pustular psoriasis responsive to cyclosporine bridged to etanercept: A treatment approach.	https://www.ncbi.nlm.nih.gov/pubmed/?term=294476 <u>38</u>
CYCLOSPORINE, INFILIXIMAB	Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=193095 <u>71</u>
CYCLOSPORINE, INFILIXIMAB	Erythrodermic CD8+ pseudolymphoma during infliximab treatment in a patient with psoriasis: use of cyclosporine as a rescue therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=252197 <u>41</u>
CYCLOSPORINE, METHOTREXATE	Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=118074 <u>36</u>
CYCLOSPORINE, METHOTREXATE	Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=129173 <u>02</u>

Medication Name	Title	Pubmed Link
CYCLOSPORINE, METHOTREXATE	Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. [Review] [121 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=187553 62
CYCLOSPORINE, METHOTREXATE	High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=201303 83
CYCLOSPORINE, METHOTREXATE	Disseminated, eruptive molluscum contagiosum lesions in a psoriasis patient under treatment with methotrexate and cyclosporine.	https://www.ncbi.nlm.nih.gov/pubmed/?term=220677 28
CYCLOSPORINE, METHOTREXATE	Methotrexate and cyclosporine in psoriasis revisited.	https://www.ncbi.nlm.nih.gov/pubmed/?term=249795 42
CYCLOSPORINE, METHOTREXATE, PHOTOTHERAPY	Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. [Review] [97 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=145780 93
CYCLOSPORINE, TACROLIMUS	Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=251638 29
ETANERCEPT	Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=109723 71
ETANERCEPT	Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=118413 77
ETANERCEPT	Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=122182 52
ETANERCEPT	Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=123664 52
ETANERCEPT	Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=127282 84
ETANERCEPT	Etanercept as monotherapy in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=146277 86
ETANERCEPT	Successful treatment of recalcitrant palmoplantar psoriasis with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=146557 81
ETANERCEPT	A randomized trial of etanercept as monotherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=146760 82
ETANERCEPT	Etanercept for the treatment of psoriasis: combination therapy with other modalities.	https://www.ncbi.nlm.nih.gov/pubmed/?term=151761 61
ETANERCEPT	Etanercept in psoriasis treatment. [Review] [17 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=153149 89

Medication Name	Title	Pubmed Link
ETANERCEPT	Etanercept for the treatment of psoriasis and psoriatic arthritis. [Review] [28 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=153797 75
ETANERCEPT	The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. [Review] [31 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=154503 40
ETANERCEPT	Etanercept in psoriasis. [Review] [51 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=154615 49
ETANERCEPT	Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=155836 08
ETANERCEPT	Safety and efficacy study on etanercept in patients with plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=156568 33
ETANERCEPT	Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. [Review] [43 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=157996 87
ETANERCEPT	The treatment of psoriasis with etanercept. [Review] [43 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=159007 96
ETANERCEPT	A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.	https://www.ncbi.nlm.nih.gov/pubmed/?term=159489 97
ETANERCEPT	Etanercept and psoriasis, from clinical studies to real life.	https://www.ncbi.nlm.nih.gov/pubmed/?term=161018 75
ETANERCEPT	Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=162227 85
ETANERCEPT	Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=162431 50
ETANERCEPT	Puerto Rico psoriasis study group: efficacy and safety of etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=163025 59
ETANERCEPT	Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=163076 57
ETANERCEPT	Etanercept and demyelinating disease in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=163847 77
ETANERCEPT	Spotlight on etanercept in plaque psoriasis and psoriatic arthritis. [Review] [19 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=163928 92
ETANERCEPT	Effects of etanercept on quality of life, fatigue, and depression in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=163991 33
ETANERCEPT	Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=163991 50

Medication Name	Title	Pubmed Link
ETANERCEPT	Etanercept for psoriasis: two case reports.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164026 31
ETANERCEPT	Etanercept for the treatment of severe childhood psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164031 17
ETANERCEPT	Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164430 79
ETANERCEPT	Etanercept for psoriasis in the pediatric population: experience in nine patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164454 17
ETANERCEPT	Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.[Erratum appears in J Dermatolog Treat. 2006;17(3):192]	https://www.ncbi.nlm.nih.gov/pubmed/?term=164670 18
ETANERCEPT	Etanercept for the treatment of psoriasis. [Review] [16 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=164850 60
ETANERCEPT	Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164883 20
ETANERCEPT	Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164883 21
ETANERCEPT	Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164883 23
ETANERCEPT	Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164883 25
ETANERCEPT	Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164883 35
ETANERCEPT	Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).	https://www.ncbi.nlm.nih.gov/pubmed/?term=165693 61
ETANERCEPT	Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=167134 81
ETANERCEPT	Etanercept therapy in two patients with psoriasis and concomitant hepatitis C.	https://www.ncbi.nlm.nih.gov/pubmed/?term=167134 82
ETANERCEPT	Treatment of erythrodermic psoriasis with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=167927 68
ETANERCEPT	Safety of etanercept in psoriasis: a critical review. [Review] [86 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=168722 41
ETANERCEPT	Psoriasis after treatment of juvenile idiopathic arthritis with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=169055 90

Medication Name	Title	Pubmed Link
ETANERCEPT	Etanercept for the treatment of psoriasis in the elderly.	https://www.ncbi.nlm.nih.gov/pubmed/?term=169083 65
ETANERCEPT	Initial experience with routine administration of etanercept in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=169654 32
ETANERCEPT	Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=169958 64
ETANERCEPT	Henoch-Schonlein purpura after etanercept therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=170238 11
ETANERCEPT	Ability to develop rhus allergic contact dermatitis in a patient with psoriasis receiving etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=170525 36
ETANERCEPT	Etanercept and efalizumab for the treatment of psoriasis: a systematic review. [Review] [77 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=170838 54
ETANERCEPT	Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=170973 76
ETANERCEPT	A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=171131 90
ETANERCEPT	Acute myelogenous leukemia in a patient receiving etanercept for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=171906 40
ETANERCEPT	Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=171995 80
ETANERCEPT	Severe psoriasis pustulosa palmaris et plantaris (Barber-Konigsbeck) treated successfully with soluble tumour necrosis factor receptor fusion protein (etanercept).	https://www.ncbi.nlm.nih.gov/pubmed/?term=172439 68
ETANERCEPT	Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=172447 75
ETANERCEPT	Our experience with etanercept in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=173117 38
ETANERCEPT	Two years of experience with etanercept in recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=174083 93
ETANERCEPT	Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept).	https://www.ncbi.nlm.nih.gov/pubmed/?term=174592 90
ETANERCEPT	Etanercept in infants: suberythrodermic, recalcitrant psoriasis in a 22 month-old child successfully treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=174783 89
ETANERCEPT	Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. [Review] [74 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=174928 43

Medication Name	Title	Pubmed Link
ETANERCEPT	Mechanisms of action of etanercept in psoriasis. [Review] [34 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=17502868
ETANERCEPT	Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17520463
ETANERCEPT	Development of Crohn disease in a patient on etanercept for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17573878
ETANERCEPT	Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17576937
ETANERCEPT	High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17853309
ETANERCEPT	Etanercept-induced lichenoid reaction pattern in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17853314
ETANERCEPT	The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17854370
ETANERCEPT	Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17916204
ETANERCEPT	Etanercept therapy for severe plaque psoriasis in a patient who underwent a liver transplant.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956009
ETANERCEPT	Conversion to positive tuberculosis test during etanercept treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17966185
ETANERCEPT	Effect of etanercept on insulin sensitivity in nine patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18179745
ETANERCEPT	Etanercept treatment for children and adolescents with plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18199863
ETANERCEPT	Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18285687
ETANERCEPT	Rapid response of nail psoriasis to etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18322982
ETANERCEPT	Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18355196
ETANERCEPT	Etanercept: an overview of its role in the treatment of psoriasis. [Review] [36 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=18363545
ETANERCEPT	Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18384440

Medication Name	Title	Pubmed Link
ETANERCEPT	Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus.	https://www.ncbi.nlm.nih.gov/pubmed/?term=184270 38
ETANERCEPT	Use of etanercept in the treatment of psoriasis and psoriatic arthritis. [Review] [38 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=184739 78
ETANERCEPT	Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=184896 65
ETANERCEPT	Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=185036 00
ETANERCEPT	Effective control of psoriasis by etanercept in a patient with HCV-related diseases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=185737 23
ETANERCEPT	Severe generalized exanthema due to etanercept given for severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=185928 33
ETANERCEPT	Recurrent varicella in an adult psoriasis patient treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=186678 25
ETANERCEPT	Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.	https://www.ncbi.nlm.nih.gov/pubmed/?term=186733 65
ETANERCEPT	Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=186881 71
ETANERCEPT	Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=187799 01
ETANERCEPT	Low-dose etanercept therapy in moderate to severe psoriasis in Korean.	https://www.ncbi.nlm.nih.gov/pubmed/?term=187890 67
ETANERCEPT	Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=187932 42
ETANERCEPT	Economic evaluation of etanercept in the management of chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=188084 13
ETANERCEPT	Etanercept provides a more physiological approach in the treatment of psoriasis. [Review] [93 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=188377 27
ETANERCEPT	ILVEN: is it psoriasis? Debate based on successful treatment with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=190023 57
ETANERCEPT	Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.	https://www.ncbi.nlm.nih.gov/pubmed/?term=190321 31

Medication Name	Title	Pubmed Link
ETANERCEPT	Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma.	https://www.ncbi.nlm.nih.gov/pubmed/?term=190405 08
ETANERCEPT	Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=190499 36
ETANERCEPT	Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant.	https://www.ncbi.nlm.nih.gov/pubmed/?term=190693 62
ETANERCEPT	Angiokeratoma induced by injection of etanercept for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=191191 25
ETANERCEPT	Recall injection-site reactions to etanercept in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=191203 91
ETANERCEPT	Adolescent plaque psoriasis: our experience using etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192076 68
ETANERCEPT	Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192176 93
ETANERCEPT	Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192222 52
ETANERCEPT	Efalizumab therapy for psoriasis in patients with inadequate responses to etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192222 55
ETANERCEPT	Lichen planopilaris noted during etanercept therapy in a child with severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192504 35
ETANERCEPT	Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=193095 69
ETANERCEPT	A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=193360 28
ETANERCEPT	Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=193486 56
ETANERCEPT	Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus.	https://www.ncbi.nlm.nih.gov/pubmed/?term=193895 39
ETANERCEPT	Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=194537 94
ETANERCEPT	Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.	https://www.ncbi.nlm.nih.gov/pubmed/?term=194700 56
ETANERCEPT	Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=194791 28

Medication Name	Title	Pubmed Link
ETANERCEPT	Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19563497
ETANERCEPT	Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566665
ETANERCEPT	Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19658444
ETANERCEPT	Facial granulomatous nodules during etanercept treatment for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19703000
ETANERCEPT	Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19752505
ETANERCEPT	Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19895991
ETANERCEPT	Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20071701
ETANERCEPT	Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20124563
ETANERCEPT	Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20185386
ETANERCEPT	Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=20337816
ETANERCEPT	Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20384690
ETANERCEPT	Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20403800
ETANERCEPT	Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. [Review] [65 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=20446825
ETANERCEPT	Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20459298
ETANERCEPT	Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20466184
ETANERCEPT	New-onset psoriasis associated with etanercept therapy. [Review] [10 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=20507411

Medication Name	Title	Pubmed Link
ETANERCEPT	Etanercept: an evolving role in psoriasis and psoriatic arthritis. [Review] [34 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=20586498
ETANERCEPT	Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20586506
ETANERCEPT	Beneficial neurological effects observed in a patient with psoriasis treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20586508
ETANERCEPT	A patient with psoriasis and vitiligo treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20586509
ETANERCEPT	Etanercept therapy for psoriasis in a patient with numerous comorbidities.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20586510
ETANERCEPT	Etanercept in a patient with severe psoriasis and latent viral hepatic disease and latent tuberculosis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20586514
ETANERCEPT	Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20586516
ETANERCEPT	Long-term etanercept in pediatric patients with plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20605256
ETANERCEPT	Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20619489
ETANERCEPT	The role of endothelial cell apoptosis in the effect of etanercept in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20633014
ETANERCEPT	Subgroup analyses of etanercept in pediatric patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20633781
ETANERCEPT	Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20646345
ETANERCEPT	Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20684143
ETANERCEPT	Psoriasis: Is ustekinumab superior to etanercept for psoriasis?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20808304
ETANERCEPT	Intermittent etanercept therapy in pediatric patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20833444
ETANERCEPT	Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20840349
ETANERCEPT	Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20850895

Medication Name	Title	Pubmed Link
ETANERCEPT	Transient paresis of the right recurrent laryngeal nerve after treatment with etanercept for plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=209237 47
ETANERCEPT	Efficacy and safety of etanercept in patients with psoriasis and hepatitis C.	https://www.ncbi.nlm.nih.gov/pubmed/?term=209237 49
ETANERCEPT	The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=209430 46
ETANERCEPT	Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Talpharanta Plastic Study Group.	https://www.ncbi.nlm.nih.gov/pubmed/?term=209430 50
ETANERCEPT	Etanercept therapy in patients with psoriasis and concomitant HCV infection.	https://www.ncbi.nlm.nih.gov/pubmed/?term=209430 71
ETANERCEPT	Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection?. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=209566 50
ETANERCEPT	Disseminated superficial porokeratosis secondary to immunosuppression induced by etanercept for extensive psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=209566 74
ETANERCEPT	The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=211626 44
ETANERCEPT	Treatment of severe nail psoriasis with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=212208 89
ETANERCEPT	Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=212548 86
ETANERCEPT	Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=213243 46
ETANERCEPT	Recalcitrant palmoplantar pustular psoriasis treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=213711 12
ETANERCEPT	Relapsing polychondritis-like ear disease responding to etanercept in two patients with psoriasis and psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=214967 17
ETANERCEPT	Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=215432 90
ETANERCEPT	Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=215577 78
ETANERCEPT	Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=215749 83

Medication Name	Title	Pubmed Link
ETANERCEPT	Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21574984
ETANERCEPT	The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21790728
ETANERCEPT	A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21797805
ETANERCEPT	A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21818507
ETANERCEPT	Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21839334
ETANERCEPT	Long-term efficacy of etanercept for psoriasis in daily practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21910699
ETANERCEPT	Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21983007
ETANERCEPT	Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22014541
ETANERCEPT	Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22015149
ETANERCEPT	Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22035157
ETANERCEPT	Translating clinical activity and gene expression signatures of etanercept and ciclosporin to the psoriasis xenograft SCID mouse model.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22050597
ETANERCEPT	Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22068796
ETANERCEPT	Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22098006
ETANERCEPT	Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22188302

Medication Name	Title	Pubmed Link
ETANERCEPT	Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=222121 12
ETANERCEPT	The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).	https://www.ncbi.nlm.nih.gov/pubmed/?term=222512 26
ETANERCEPT	Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=222584 82
ETANERCEPT	Marked improvement in nail psoriasis during treatment with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=223531 56
ETANERCEPT	Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=223955 96
ETANERCEPT	Membranous glomerulonephritis, psoriasis and etanercept. A chance or causal association?. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=224219 53
ETANERCEPT	Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.	https://www.ncbi.nlm.nih.gov/pubmed/?term=224585 49
ETANERCEPT	Severe cutaneous and arthritic psoriasis in patient with AIDS: a good outcome with therapy using etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=224816 64
ETANERCEPT	Psoriasis, lymphoma and etanercept: is there a correlation?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=224816 65
ETANERCEPT	Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=226865 44
ETANERCEPT	Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=226997 61
ETANERCEPT	Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=228125 68
ETANERCEPT	Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=228466 89
ETANERCEPT	Open label study to evaluate the efficacy of re-treatment with etanercept in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=228592 40
ETANERCEPT	A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=230132 07

Medication Name	Title	Pubmed Link
ETANERCEPT	The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=230650 20
ETANERCEPT	Treatment of severe psoriasis with etanercept in a pancreas-kidney transplant recipient.	https://www.ncbi.nlm.nih.gov/pubmed/?term=231465 21
ETANERCEPT	Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=231477 55
ETANERCEPT	Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=231491 96
ETANERCEPT	Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA.	https://www.ncbi.nlm.nih.gov/pubmed/?term=232107 71
ETANERCEPT	Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=233431 37
ETANERCEPT	OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=233575 69
ETANERCEPT	Crusted scabies complicates etanercept therapy in a patient with severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=235224 26
ETANERCEPT	Long-term management of HIV/hepatitis C virus associated psoriasis with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=236194 59
ETANERCEPT	A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=236432 56
ETANERCEPT	Etanercept decreases the innate immune wounding response in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=238025 69
ETANERCEPT	Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=238489 89
ETANERCEPT	Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.	https://www.ncbi.nlm.nih.gov/pubmed/?term=239757 39
ETANERCEPT	Etanercept urticaria in a patient with psoriasis desensitized using a new method.	https://www.ncbi.nlm.nih.gov/pubmed/?term=240850 54
ETANERCEPT	Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=241170 23
ETANERCEPT	Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=242190 12

Medication Name	Title	Pubmed Link
ETANERCEPT	Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=243552 80
ETANERCEPT	Italian perspective on psoriasis, spondyloarthritis, rheumatoid arthritis and juvenile idiopathic arthritis: immunopathology and role of etanercept. Abstracts of a Seminars in Research. October 14-15, 2011. Italy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=244045 71
ETANERCEPT	Manifestation of Crohn's disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=245485 37
ETANERCEPT	Early tissue responses in psoriasis to the antitumour necrosis factor-alpha biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.	https://www.ncbi.nlm.nih.gov/pubmed/?term=246019 97
ETANERCEPT	First fatal case of systemic suppurative/necrotizing granulomatous disease following etanercept therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=246461 44
ETANERCEPT	Etanercept for psoriasis and psoriatic arthritis in a patient with Charcot-Marie-Tooth disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=246586 37
ETANERCEPT	Juvenile generalized pustular psoriasis treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=247032 68
ETANERCEPT	Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=248616 96
ETANERCEPT	A Randomized, blinded assessor study to Evaluate the efIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).	https://www.ncbi.nlm.nih.gov/pubmed/?term=249809 88
ETANERCEPT	Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=250340 81
ETANERCEPT	Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=250878 39
ETANERCEPT	Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=250910 90
ETANERCEPT	Survival rate of etanercept for psoriasis in real life: a multicentre observational study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=251151 94
ETANERCEPT	OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.	https://www.ncbi.nlm.nih.gov/pubmed/?term=252642 39

Medication Name	Title	Pubmed Link
ETANERCEPT	Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=253819 71
ETANERCEPT	Hepatotoxicity due to etanercept abated after dose reduction in a patient with pustular psoriasis and without compromised efficacy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=254901 72
ETANERCEPT	Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.	https://www.ncbi.nlm.nih.gov/pubmed/?term=256110 84
ETANERCEPT	Tumor necrosis factor-alpha antagonism with etanercept improves endothelial progenitor cell counts in patients with psoriasis: etanercept, vascular function and endothelial progenitor cells in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=256176 05
ETANERCEPT	Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=259135 50
ETANERCEPT	Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=259518 25
ETANERCEPT	Multiple lentigines in psoriasis patients treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=260656 90
ETANERCEPT	Efficacy and cost of etanercept in long-term psoriasis: Rational use in clinical practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=260845 90
ETANERCEPT	Anal canal adenocarcinoma in a patient with psoriasis treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=267288 30
ETANERCEPT	Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=267757 75
ETANERCEPT	The effects of etanercept on replication, proliferation, survival, and apoptosis markers in moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=268055 56
ETANERCEPT	Treatment of psoriasis with etanercept: the typical patient profile. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=270730 46
ETANERCEPT	Interleukin levels and macrophagic density in perumbilical fat tissue in patients affected by moderate-to-severe psoriasis with metabolic syndrome, before and after etanercept treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=272847 77
ETANERCEPT	An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=272979 81
ETANERCEPT	Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value.	https://www.ncbi.nlm.nih.gov/pubmed/?term=274361 93
ETANERCEPT	Persistence and Failure Rates of Monotherapy Etanercept in Biologic-Naive Psoriasis Patients: A Retrospective Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=275380 08

Medication Name	Title	Pubmed Link
ETANERCEPT	Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27576483
ETANERCEPT	Cardiovascular Risk Evaluation through Heart Rate Variability (HRV) Analysis in Patients with Psoriasis before and after 12 Weeks of Etanercept Therapy: A Preliminary Prospective Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27663918
ETANERCEPT	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27787890
ETANERCEPT	The utility of etanercept in chronic stable plaque psoriasis: Results from an open-label, prospective, single arm study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27852990
ETANERCEPT	The association between etanercept serum concentration and psoriasis severity is highly age-dependent.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28420676
ETANERCEPT	Polymorphisms associated with etanercept response in moderate-to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28470127
ETANERCEPT	Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28750567
ETANERCEPT	Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28758274
ETANERCEPT	Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28783991
ETANERCEPT	A 12-year-old Girl with Severe Plaque Psoriasis and Down Syndrome Treated Successfully with Etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28871932
ETANERCEPT	Erythrodermic Psoriasis and Hepatitis C Infection Treated with Pegylated Interferon and Anti-TNFalpha alpha(Etanercept) Therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28969730
ETANERCEPT	Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29270758
ETANERCEPT, EXCIMER LASER, PHOTOTHERAPY	Effective treatment of etanercept and phototherapy-resistant psoriasis using the excimer laser.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22483513
ETANERCEPT, INFILIXIMAB	Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept. [Review] [15 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=12553627

Medication Name	Title	Pubmed Link
ETANERCEPT, INFILIXIMAB	Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept. [Review] [22 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=12851990
ETANERCEPT, INFILIXIMAB	An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. [Review] [41 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=14667953
ETANERCEPT, INFILIXIMAB	Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept. [Review] [34 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=14730466
ETANERCEPT, INFILIXIMAB	Infliximab in the treatment of psoriasis in patients previously treated with etanercept.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17482715
ETANERCEPT, INFILIXIMAB	Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19479148
ETANERCEPT, INFILIXIMAB	The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22153792
ETANERCEPT, INFILIXIMAB	Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23986160
ETANERCEPT, INFILIXIMAB	Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO).	https://www.ncbi.nlm.nih.gov/pubmed/?term=25231176
ETANERCEPT, INFILIXIMAB	A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27416891
ETANERCEPT, INFILIXIMAB	Etanercept or infliximab for psoriasis? An independent randomized clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28300301
ETANERCEPT, INFILIXIMAB, METHOTREXATE	Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15023789
ETANERCEPT, IXEKIZUMAB	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26072109
ETANERCEPT, IXEKIZUMAB	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27889292

Medication Name	Title	Pubmed Link
ETANERCEPT, IXEKIZUMAB	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).[Erratum appears in Am J Clin Dermatol. 2018 Mar 29;:: PMID:	https://www.ncbi.nlm.nih.gov/pubmed/?term=28074446
ETANERCEPT, IXEKIZUMAB	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).	https://www.ncbi.nlm.nih.gov/pubmed/?term=28322474
ETANERCEPT, IXEKIZUMAB	Cost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29036249
ETANERCEPT, METHOTREXATE	Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18211500
ETANERCEPT, METHOTREXATE	Etanercept combined with methotrexate for high-need psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18547310
ETANERCEPT, METHOTREXATE	The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18779890
ETANERCEPT, METHOTREXATE	A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22533447
ETANERCEPT, METHOTREXATE	Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28779637
ETANERCEPT, PHOTOTHERAPY	Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18380206
ETANERCEPT, PHOTOTHERAPY	Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21466532
ETANERCEPT, PHOTOTHERAPY	Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21697032
ETANERCEPT, PHOTOTHERAPY	A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22702846

Medication Name	Title	Pubmed Link
ETANERCEPT, PHOTOTHERAPY	Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=238341 <u>13</u>
ETANERCEPT, PHOTOTHERAPY	Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=238341 <u>17</u>
ETANERCEPT, PHOTOTHERAPY	Etanercept combined with systemic drugs or phototherapy for treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=255294 <u>63</u>
ETANERCEPT, TILDRAKIZUMAB	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.[Erratum appears in Lancet. 2017 Jul 15;390(10091):230; PMID: 28721878]	https://www.ncbi.nlm.nih.gov/pubmed/?term=285960 <u>43</u>
ETANERCEPT, TOFACITINIB	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=260513 <u>65</u>
ETANERCEPT, TOFACITINIB	Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=272711 <u>95</u>
ETANERCEPT, USTEKINUMAB	Sacroiliitis in a psoriasis patient after switching from etanercept to ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=241923 <u>18</u>
ETANERCEPT,INFLIXIMAB	Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. [Review] [64 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=185473 <u>00</u>
ETANERCEPT,IXEKIZUMAB	Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=292408 <u>60</u>
ETANERCEPT,SECUKINUMAB	Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=278327 <u>17</u>
ETANERCEPTINFLIXIMAB	Sequential use of infliximab and etanercept in generalized pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=170366 <u>64</u>
EXCIMER LASER	308 nm UVB excimer laser for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=938840 <u>8</u>
EXCIMER LASER	308-nm excimer laser for the treatment of psoriasis: a dose-response study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=108158 <u>55</u>
EXCIMER LASER	308-nm excimer laser therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=111766 <u>74</u>
EXCIMER LASER	A review of the 308-nm excimer laser in the treatment of psoriasis. [Review] [5 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=117661 <u>21</u>

Medication Name	Title	Pubmed Link
EXCIMER LASER	High-dose 308-nm excimer laser for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12004316
EXCIMER LASER	Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12063488
EXCIMER LASER	Treatment of inverse psoriasis with the 308 nm excimer laser.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12081686
EXCIMER LASER	Medium-dose 308-nm excimer laser for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12399761
EXCIMER LASER	Remissions of psoriasis with excimer laser treatment. [Review] [6 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=12546777
EXCIMER LASER	308-nm excimer laser for the treatment of psoriasis: induration-based dosimetry.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12810507
EXCIMER LASER	Remissions of psoriasis with excimer laser treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12847749
EXCIMER LASER	A 308-nm excimer laser for the treatment of scalp psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15004825
EXCIMER LASER	308-nm excimer laser for the treatment of scalp psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15148093
EXCIMER LASER	A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15204159
EXCIMER LASER	Comparison of the efficacy and safety of the 308 nm excimer laser for the treatment of localized psoriasis in adults and in children: a pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15804309
EXCIMER LASER	Use of the 308-nm excimer laser for psoriasis and vitiligo. [Review] [45 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=16427504
EXCIMER LASER	Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16902290
EXCIMER LASER	Clinical efficacy of a 308 nm excimer laser for treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17986060
EXCIMER LASER	The effectiveness of PUVA treatment in severe psoriasis is significantly increased by additional UV 308-nm excimer laser sessions.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18086590
EXCIMER LASER	308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. [Review] [31 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=18717744
EXCIMER LASER	Treating vitiligo and psoriasis with the excimer laser.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19253596

Medication Name	Title	Pubmed Link
EXCIMER LASER	The use of the 308-nm excimer laser for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20932176
EXCIMER LASER	308-nm Excimer laser treatment of palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21401376
EXCIMER LASER	Treatment of plaque-type psoriasis with the 308 nm excimer laser in combination with dithranol or calcipotriol.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22335232
EXCIMER LASER	Clinical efficacy of flumetasone/salicylic acid ointment combined with 308-nm excimer laser for treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22548394
EXCIMER LASER	Excimer laser therapy for hairline psoriasis: a useful addition to the scalp psoriasis treatment algorithm.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22622280
EXCIMER LASER	Treatment of psoriasis and long-term maintenance using 308 nm excimer laser, clobetasol spray, and calcitriol ointment: a case series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22859247
EXCIMER LASER	Supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis: Interim results of an open label pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24547791
EXCIMER LASER	Plaque-based sub-blistering dosimetry: Reaching PASI-75 after two treatments with 308-nm excimer laser in a generalized psoriasis patient.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24552548
EXCIMER LASER	Successful use of the excimer laser for generalized psoriasis in an ustekinumab non-responder.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25780961
EXCIMER LASER	An open label pilot study of supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26329774
EXCIMER LASER	A randomised half body prospective study of low and medium dose regimens using the 308nm excimer laser in the treatment of localised psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27680219
EXCIMER LASER	Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) therapy in psoriasis patients?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28168735
EXCIMER LASER, PHOTOTHERAPY	Ultraviolet B 308-nm excimer laser treatment of psoriasis: a new phototherapeutic approach.	https://www.ncbi.nlm.nih.gov/pubmed/?term=14674904
EXCIMER LASER, PHOTOTHERAPY	Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15840108
EXCIMER LASER, PHOTOTHERAPY	Excimer laser for psoriasis: a review of theories regarding enhanced efficacy over traditional UVB phototherapy. [Review] [13 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=17763609

Medication Name	Title	Pubmed Link
EXCIMER LASER, PHOTOTHERAPY	Pilot evaluation of supra-erythemogenic phototherapy with excimer laser in the treatment of patients with moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=197112 <u>19</u>
EXCIMER LASER, PHOTOTHERAPY	A review of protocols for 308 nm excimer laser phototherapy in psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=222060 <u>83</u>
EXCIMER LASER, PHOTOTHERAPY	Targeted phototherapy using 308 nm XeCl monochromatic excimer laser for psoriasis at difficult to treat sites.	https://www.ncbi.nlm.nih.gov/pubmed/?term=230532 <u>47</u>
EXCIMER LASER, PHOTOTHERAPY	Single administration of lesion-limited high-dose (TURBO) ultraviolet B using the excimer laser: clinical clearing in association with apoptosis of epidermal and dermal T cell subsets in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=231262 <u>90</u>
EXCIMER LASER,PHOTOTHERAPY	Therapeutic modalities for localized psoriasis: 308-nm UVB excimer laser versus nontargeted phototherapy. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=230943 <u>16</u>
GUSELKUMAB	Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=246794 <u>69</u>
GUSELKUMAB	Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=248520 <u>42</u>
GUSELKUMAB	First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=275159 <u>78</u>
GUSELKUMAB	A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=283294 <u>05</u>
GUSELKUMAB	Guselkumab for psoriasis: a critical appraisal of Phase III studies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=290438 <u>84</u>
GUSELKUMAB	Guselkumab for the Treatment of Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=294707 <u>78</u>
GUSELKUMAB	Guselkumab for the treatment of moderate-to-severe plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=294783 <u>44</u>
GUSELKUMAB	Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=297712 <u>54</u>
GUSELKUMAB	A safety evaluation of guselkumab for the treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=298977 <u>90</u>
GUSELKUMAB,TILD RAKIZUMAB	Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=286677 <u>77</u>

Medication Name	Title	Pubmed Link
HYDROXYUREA	Hydroxyurea in the management of therapy resistant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2597635
HYDROXYUREA	Combination low-dose cyclosporin (Neoral) and hydroxyurea for severe recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10215804
HYDROXYUREA	Use of hydroxyurea in psoriasis. [Review] [33 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=10233638
HYDROXYUREA	Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10354169
HYDROXYUREA	Hydroxyurea in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10681171
HYDROXYUREA	Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10844510
HYDROXYUREA	Rediscovering hydroxyurea: its role in recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11703528
HYDROXYUREA	Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11952660
HYDROXYUREA, INFILIXIMAB	Successful treatment of recalcitrant psoriasis with a combination of infliximab and hydroxyurea.	https://www.ncbi.nlm.nih.gov/pubmed/?term=14660269
HYDROXYUREA, METHOTREXATE	Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17852635
INFILIXIMAB	Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11410193
INFILIXIMAB	Response of severe psoriasis to infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11937748
INFILIXIMAB	The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12020227
INFILIXIMAB	Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12063486
INFILIXIMAB	Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12121565
INFILIXIMAB	Infliximab for the treatment of severe pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12399781
INFILIXIMAB	Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426660
INFILIXIMAB	Infliximab for psoriasis and psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12463461

Medication Name	Title	Pubmed Link
INFILIXIMAB	Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=125223 73
INFILIXIMAB	Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab).	https://www.ncbi.nlm.nih.gov/pubmed/?term=127521 84
INFILIXIMAB	Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=127891 71
INFILIXIMAB	Striking and rapid improvement of plaque psoriasis with infliximab. A report of two cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=128355 50
INFILIXIMAB	CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. [Review] [17 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=128902 13
INFILIXIMAB	Infliximab for psoriasis. [Review] [32 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=128941 34
INFILIXIMAB	Infliximab-induced remission of extensive plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=146501 14
INFILIXIMAB	Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=146602 68
INFILIXIMAB	Successful treatment of pediatric psoriasis with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=148713 37
INFILIXIMAB	Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab).	https://www.ncbi.nlm.nih.gov/pubmed/?term=149961 14
INFILIXIMAB	Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.	https://www.ncbi.nlm.nih.gov/pubmed/?term=150900 21
INFILIXIMAB	Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab.[Erratum appears in Br J Dermatol. 2004 Jun;150(6):1235 Note: Gabbay, S [corrected to Gubbay, S]]	https://www.ncbi.nlm.nih.gov/pubmed/?term=150993 88
INFILIXIMAB	Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.	https://www.ncbi.nlm.nih.gov/pubmed/?term=151495 18
INFILIXIMAB	Serum sickness due to infliximab in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=151761 66
INFILIXIMAB	Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=152028 53
INFILIXIMAB	Use of infliximab in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=152509 04
INFILIXIMAB	Pustular psoriasis induced by infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=153037 90

Medication Name	Title	Pubmed Link
INFliximab	New development in the treatment of psoriasis--infliximab. [Review] [22 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=153150 08
INFliximab	Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=153891 87
INFliximab	Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. [Review] [86 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=154503 39
INFliximab	Infliximab monotherapy for refractory psoriasis: preliminary results.	https://www.ncbi.nlm.nih.gov/pubmed/?term=154618 71
INFliximab	Fatal fulminant legionnaires' disease in a patient with severe erythodermic psoriasis treated with infliximab after long-term steroid therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=157878 43
INFliximab	Remission and time of resolution of nail psoriasis during infliximab therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=157935 54
INFliximab	Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al.	https://www.ncbi.nlm.nih.gov/pubmed/?term=158186 79
INFliximab	Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=158881 52
INFliximab	Successful infliximab therapy of psoriasis vulgaris and psoriatic arthritis in a patient with cirrhosis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=160293 57
INFliximab	Successful treatment of Von Zumbusch pustular psoriasis with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=160919 99
INFliximab	Onset of flexural psoriasis during infliximab treatment for Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=161973 98
INFliximab	Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.	https://www.ncbi.nlm.nih.gov/pubmed/?term=161987 81
INFliximab	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=162266 14
INFliximab	The role of lesional T cells in recalcitrant psoriasis during infliximab therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=162802 98
INFliximab	Infliximab for inpatient psoriasis management--is there a role?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164281 51
INFliximab	Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164457 76
INFliximab	Infliximab associated new-onset psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164858 87

Medication Name	Title	Pubmed Link
INFILXIMAB	Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16573258
INFILXIMAB	Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16681606
INFILXIMAB	Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16704649
INFILXIMAB	Chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16707820
INFILXIMAB	Psoriasis onset during infliximab treatment: description of two cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16738903
INFILXIMAB	Life-threatening pustular and erythrodermic psoriasis responding to infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16774108
INFILXIMAB	Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16792769
INFILXIMAB	Infliximab for the treatment of psoriasis. [Review] [50 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=16856801
INFILXIMAB	Three years' experience with infliximab in recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16901301
INFILXIMAB	Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17039656
INFILXIMAB	Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17068063
INFILXIMAB	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17097378
INFILXIMAB	Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17107388
INFILXIMAB	A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17223874
INFILXIMAB	Osteomyelitis occurring during infliximab treatment of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17373180
INFILXIMAB	Treatment of pustular psoriasis with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17451384

Medication Name	Title	Pubmed Link
INFliximab	A review of biologic treatments for psoriasis with emphasis on infliximab. [Review] [11 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=17487347
INFliximab	Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17578445
INFliximab	Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17673380
INFliximab	Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. [Review] [10 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=17711530
INFliximab	Severe bout of cutaneous psoriasis in a patient with psoriatic arthritis undergoing treatment with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17888230
INFliximab	Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17894730
INFliximab	Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956013
INFliximab	Pustular psoriasis induced by infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17958859
INFliximab	Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17963173
INFliximab	Severe neutrophilia induced by infliximab for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18028489
INFliximab	Infliximab in dermatological treatment: beyond psoriasis. [Review] [106 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=18081542
INFliximab	Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18083272
INFliximab	Infliximab in recalcitrant generalized pustular arthropathic psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18086593
INFliximab	Severe psoriasis in an African American woman treated with infliximab therapy for 6 years.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18173534
INFliximab	Infliximab for patients with plaque psoriasis and severe psychiatric comorbidity.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18211435
INFliximab	Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18239925
INFliximab	Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18311451
INFliximab	Infliximab for the treatment of severe pustular psoriasis: 6 years later.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18341534

Medication Name	Title	Pubmed Link
INFILIXIMAB	Guttate psoriasis induced by infliximab in a child with Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18383177
INFILIXIMAB	Onset of psoriasis induced by infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18391690
INFILIXIMAB	Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18462438
INFILIXIMAB	A review of the treatment of psoriasis with infliximab. [Review] [20 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=18473973
INFILIXIMAB	Gastric MALT lymphoma in a patient receiving infliximab for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18547313
INFILIXIMAB	Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18627375
INFILIXIMAB	Long-term management of generalized pustular psoriasis with infliximab: case series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18627699
INFILIXIMAB	Infliximab-induced pityriasis lichenoides chronica in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18680531
INFILIXIMAB	Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. [6 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=18685261
INFILIXIMAB	The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. [Review] [38 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=18784934
INFILIXIMAB	Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18837702
INFILIXIMAB	Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18853077
INFILIXIMAB	Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18855796
INFILIXIMAB	Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19061594
INFILIXIMAB	A case of infliximab-induced psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19094847
INFILIXIMAB	Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19137767
INFILIXIMAB	Generalized pustular psoriasis of pregnancy treated with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19196309
INFILIXIMAB	Development of primary varicella infection during infliximab treatment for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19293027

Medication Name	Title	Pubmed Link
INFILIXIMAB	Occurrence of plantar pustular psoriasis during treatment with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192987 70
INFILIXIMAB	Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection.	https://www.ncbi.nlm.nih.gov/pubmed/?term=194673 87
INFILIXIMAB	Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=195015 34
INFILIXIMAB	Infliximab for the treatment of adults with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=195672 15
INFILIXIMAB	Peripheral neuropathy in two patients with psoriasis in treatment with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=196236 30
INFILIXIMAB	Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=196843 81
INFILIXIMAB	Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.	https://www.ncbi.nlm.nih.gov/pubmed/?term=197349 82
INFILIXIMAB	Treatment of severe psoriasis with infliximab: report of two cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=198182 21
INFILIXIMAB	Psoriasis induced by infliximab in a patient suffering from Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=198220 70
INFILIXIMAB	Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199060 69
INFILIXIMAB	Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=201204 26
INFILIXIMAB	Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=201384 48
INFILIXIMAB	A dramatic response to a single dose of infliximab as rescue therapy in acute generalized pustular psoriasis of von Zumbusch associated with a neutrophilic cholangitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=201488 38
INFILIXIMAB	Infliximab therapy induces increased polyclonality of CD4+CD25+ regulatory T cells in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=201995 42
INFILIXIMAB	Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. [Review] [26 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=203381 27
INFILIXIMAB	Therapeutic hotline: Re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: a retrospective analysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=204158 28
INFILIXIMAB	Influence of infliximab on keratinocyte apoptosis in psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=205072 13

Medication Name	Title	Pubmed Link
INFILIXIMAB	Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=205470 <u>39</u>
INFILIXIMAB	Fatal influenza A(H1N1) respiratory tract infection in a patient having psoriasis treated with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=205669 <u>28</u>
INFILIXIMAB	Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial.[Erratum appears in Dermatology. 2011 Feb;222(1):4]	https://www.ncbi.nlm.nih.gov/pubmed/?term=206282 <u>38</u>
INFILIXIMAB	Successful treatment of hand and foot psoriasis with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=206735 <u>36</u>
INFILIXIMAB	Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=207078 <u>29</u>
INFILIXIMAB	The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=207333 <u>14</u>
INFILIXIMAB	Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=207962 <u>41</u>
INFILIXIMAB	Psoriasis induced by infliximab in a Saudi patient with ankylosing spondylitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=208448 <u>21</u>
INFILIXIMAB	Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report.	https://www.ncbi.nlm.nih.gov/pubmed/?term=208684 <u>08</u>
INFILIXIMAB	Central retinal vein occlusion following infliximab treatment for plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=208834 <u>14</u>
INFILIXIMAB	Infliximab-induced psoriasis in children with inflammatory bowel disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=212400 <u>20</u>
INFILIXIMAB	Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=212548 <u>68</u>
INFILIXIMAB	Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.	https://www.ncbi.nlm.nih.gov/pubmed/?term=215333 <u>02</u>
INFILIXIMAB	Moderate to severe psoriasis treated with infliximab - 53 patients: patients profile, efficacy and adverse effects.	https://www.ncbi.nlm.nih.gov/pubmed/?term=216038 <u>08</u>
INFILIXIMAB	Infliximab partially impairs the anti-Mycobacterium tuberculosis immune responses of severe psoriasis patients with positive tuberculin skin-test.	https://www.ncbi.nlm.nih.gov/pubmed/?term=216239 <u>25</u>

Medication Name	Title	Pubmed Link
INFliximab	"Paradoxical" adverse effects caused by anti-tumor necrosis factor-alpha biological drugs: appearance of psoriasis in a patient treated with infliximab for rheumatoid arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21727719
INFliximab	Secondary leprosy infection in a patient with psoriasis during treatment with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21778902
INFliximab	Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21801160
INFliximab	Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21808187
INFliximab	Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21946468
INFliximab	Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22134100
INFliximab	Sequential therapy in plaque psoriasis using the " Hit and Run " approach: infliximab followed by efalizumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22250639
INFliximab	Infliximab-induced psoriasis during therapy for Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22398095
INFliximab	Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22404545
INFliximab	Development of diffuse alopecia with psoriasis-like eruptions during administration of infliximab for Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22508420
INFliximab	Letter: Human papilloma virus and molluscum contagiosum lesions related to infliximab therapy for psoriasis: a case series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22559024
INFliximab	Body weight increment in patients treated with infliximab for plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22621415
INFliximab	The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22767007
INFliximab	Acute alveolitis following infliximab therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22780696
INFliximab	Cutaneous Mycobacterium haemophilum infection in a patient receiving infliximab for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22816532
INFliximab	Immunosuppressant and infliximab-resistant generalized pustular psoriasis successfully treated with granulocyte and monocyte adsorption apheresis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22817129

Medication Name	Title	Pubmed Link
INFILXIMAB	Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=228840 <u>40</u>
INFILXIMAB	Combination therapy of infliximab and granulocyte/monocyte adsorption apheresis for refractory pustular psoriasis with psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=230072 <u>91</u>
INFILXIMAB	Psoriasis triggered by infliximab in a patient with Behcet's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=230904 <u>23</u>
INFILXIMAB	Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=231107 <u>08</u>
INFILXIMAB	Flexural or inverse psoriasis in a patient with hidradenitis suppurativa receiving treatment with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=231490 <u>48</u>
INFILXIMAB	Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms.	https://www.ncbi.nlm.nih.gov/pubmed/?term=232743 <u>41</u>
INFILXIMAB	Incidence and risk factors for treatment failure with infliximab in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=232942 <u>58</u>
INFILXIMAB	Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=234354 <u>03</u>
INFILXIMAB	Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=235724 <u>29</u>
INFILXIMAB	Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2).	https://www.ncbi.nlm.nih.gov/pubmed/?term=236216 <u>98</u>
INFILXIMAB	Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=236511 <u>82</u>
INFILXIMAB	Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=236802 <u>15</u>
INFILXIMAB	Infliximab does not lead to reduction in the interferon-gamma and lymphoproliferative responses of patients with moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=238242 <u>43</u>
INFILXIMAB	Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=239094 <u>40</u>
INFILXIMAB	Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=239861 <u>69</u>

Medication Name	Title	Pubmed Link
INFILXIMAB	Infliximab in psoriasis and psoriatic arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=23990278
INFILXIMAB	Generalized pustular psoriasis triggered by infliximab in two patients with Crohn's disease.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24127642
INFILXIMAB	Long-term durability and dose escalation patterns in infliximab therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24388425
INFILXIMAB	Pityriasis rosea-like arranged eruption after infliximab therapy in a patient with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24617533
INFILXIMAB	Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24673357
INFILXIMAB	Treatment of psoriasis: focus on clinic-based management with infliximab. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=24777571
INFILXIMAB	Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24910924
INFILXIMAB	Rapidly developed neurosyphilis in a psoriasis patient under treatment with infliximab: a case report.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25111397
INFILXIMAB	Complementary data for long-term infliximab use in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25128111
INFILXIMAB	Reply to 'complementary data for long-term infliximab use in psoriasis'.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25128112
INFILXIMAB	Pustular psoriasis occurring after total colectomy for ulcerative colitis and relieved by administration of infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25297877
INFILXIMAB	Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25333715
INFILXIMAB	First experience with therapy of severe forms of psoriasis with biosimilar infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25418715
INFILXIMAB	Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25493314
INFILXIMAB	Psoriasis-associated IgA nephropathy under infliximab therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25515529
INFILXIMAB	Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25607786

Medication Name	Title	Pubmed Link
INFILIXIMAB	Absence of varicella zoster virus reactivation after infliximab administration for plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=256763 41
INFILIXIMAB	Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=257865 92
INFILIXIMAB	Serum infliximab concentrations and disease activity: a descriptive study of patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=258647 03
INFILIXIMAB	Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=264033 78
INFILIXIMAB	A systematic review on the efficacy and safety of Infliximab in patients with psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=265289 24
INFILIXIMAB	Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=266271 98
INFILIXIMAB	Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance.	https://www.ncbi.nlm.nih.gov/pubmed/?term=267049 26
INFILIXIMAB	Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.	https://www.ncbi.nlm.nih.gov/pubmed/?term=268694 77
INFILIXIMAB	Pneumocystis jirovecii pneumonia in a patient with pustular psoriasis with an IL-36RN deficiency treated with infliximab: Case report and review of the literature.	https://www.ncbi.nlm.nih.gov/pubmed/?term=271705 13
INFILIXIMAB	Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=274381 97
INFILIXIMAB	The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=274734 52
INFILIXIMAB	Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=278825 86
INFILIXIMAB	Combination therapy of infliximab and cyclosporin in the treatment of recalcitrant psoriasis: a case series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=279432 38
INFILIXIMAB	Lewis-Sumner syndrome associated with infliximab therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=282259 83
INFILIXIMAB	A dramatic response to a single dose of infliximab in a patient with prolonged pustular psoriasis derived from inverse psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=284196 47
INFILIXIMAB	Hepatitis due to EBV-reactivation under infliximab in a psoriasis patient.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287719 53

Medication Name	Title	Pubmed Link
INFILIXIMAB	Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=291665 26
INFILIXIMAB	Psoriasis improvement after gastric bandage in a patient partial responder to infliximab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=292146 95
INFILIXIMAB, METHOTREXATE	Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=112601 72
INFILIXIMAB, METHOTREXATE	Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=128739 07
INFILIXIMAB, METHOTREXATE	Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=163652 75
INFILIXIMAB, METHOTREXATE	Sustained effects of low dose infliximab in combination with methotrexate in the management of chronic recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=164099 17
INFILIXIMAB, METHOTREXATE	Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).	https://www.ncbi.nlm.nih.gov/pubmed/?term=169654 44
INFILIXIMAB, METHOTREXATE	Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=191203 90
INFILIXIMAB, METHOTREXATE	Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).	https://www.ncbi.nlm.nih.gov/pubmed/?term=219107 13
INFILIXIMAB, METHOTREXATE	Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=256440 44
INFILIXIMAB, METHOTREXATE	Complete reversion of anti-infliximab immunization by methotrexate combination in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=261192 28
INFILIXIMAB, USTEKINUMAB	Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=241743 69
IXEKIZUMAB	Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=224554 13
IXEKIZUMAB	Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=228089 66
IXEKIZUMAB	Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=228089 67
IXEKIZUMAB	Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=240325 54
IXEKIZUMAB	Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=247528 80

Medication Name	Title	Pubmed Link
IXEKIZUMAB	IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24999591
IXEKIZUMAB	A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25242558
IXEKIZUMAB	Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25693783
IXEKIZUMAB	Ixekizumab for treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=25748485
IXEKIZUMAB	A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25773781
IXEKIZUMAB	Targeting IL-17 with ixekizumab in patients with psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26569072
IXEKIZUMAB	Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26666707
IXEKIZUMAB	Ixekizumab for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26842296
IXEKIZUMAB	Ixekizumab for psoriasis--Authors' reply.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26842297
IXEKIZUMAB	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26953848
IXEKIZUMAB	Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27148922
IXEKIZUMAB	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27299809
IXEKIZUMAB	Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A).	https://www.ncbi.nlm.nih.gov/pubmed/?term=27500949
IXEKIZUMAB	Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27537996
IXEKIZUMAB	Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27690669

Medication Name	Title	Pubmed Link
IXEKIZUMAB	Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27692498
IXEKIZUMAB	Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27696577
IXEKIZUMAB	Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).	https://www.ncbi.nlm.nih.gov/pubmed/?term=27759463
IXEKIZUMAB	A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27825174
IXEKIZUMAB	Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27887675
IXEKIZUMAB	Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27910156
IXEKIZUMAB	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27959738
IXEKIZUMAB	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27959739
IXEKIZUMAB	Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.[Erratum appears in J Am Acad Dermatol. 2017 Aug;77(2):390-	https://www.ncbi.nlm.nih.gov/pubmed/?term=28027825
IXEKIZUMAB	Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28138946
IXEKIZUMAB	Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.[Erratum appears in J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1764; PMID: 29059512]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28190255
IXEKIZUMAB	The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28370467
IXEKIZUMAB	Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28542874

Medication Name	Title	Pubmed Link
IXEKIZUMAB	Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=285737 43
IXEKIZUMAB	Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).	https://www.ncbi.nlm.nih.gov/pubmed/?term=286350 26
IXEKIZUMAB	Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=286527 02
IXEKIZUMAB	Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287600 56
IXEKIZUMAB	Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287922 59
IXEKIZUMAB	Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=288814 62
IXEKIZUMAB	Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=289031 22
IXEKIZUMAB	Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).	https://www.ncbi.nlm.nih.gov/pubmed/?term=289173 83
IXEKIZUMAB	Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.	https://www.ncbi.nlm.nih.gov/pubmed/?term=289291 68
METHOTREXATE	The efficacy of methotrexate in psoriasis--a review of 40 cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=145131 5
METHOTREXATE	Psoriasis symposium. Methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=149309 9
METHOTREXATE	Liver biopsy versus ultrasound in methotrexate-treated psoriasis: a decision analysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=151209 2
METHOTREXATE	Disseminated histoplasmosis in patients receiving low-dose methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=173929 3
METHOTREXATE	Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal.	https://www.ncbi.nlm.nih.gov/pubmed/?term=192182 0
METHOTREXATE	Cyclosporin versus methotrexate toxicity in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=197001 8

Medication Name	Title	Pubmed Link
METHOTREXATE	Methotrexate induced pneumonitis in a young woman with psoriasis and rheumatoid arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2213769
METHOTREXATE	Cytotoxic and immunologic effects of methotrexate in psoriasis. [Review] [17 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=2230211
METHOTREXATE	The practical use of methotrexate in psoriasis. [Review] [94 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=2292232
METHOTREXATE	Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2327848
METHOTREXATE	Pharmacokinetics of small doses of methotrexate in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2455425
METHOTREXATE	Methotrexate dosage in patients aged over 50 with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2496860
METHOTREXATE	Development of metastatic skin cancer during methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2566246
METHOTREXATE	Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2582708
METHOTREXATE	Short-term methotrexate administration by low-dose infusion--does it influence clearance of psoriasis?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2591092
METHOTREXATE	Detection of hepatotoxicity associated with methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2774596
METHOTREXATE	Topical methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2913960
METHOTREXATE	Methotrexate in psoriasis: revised guidelines. [Review] [99 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=3042816
METHOTREXATE	Methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3184363
METHOTREXATE	Reactivation of cutaneous radionecrosis associated with methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3256453
METHOTREXATE	Pancytopenia following low-dose oral methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3373706
METHOTREXATE	Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=7678843
METHOTREXATE	Short term methotrexate therapy in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=7829167

Medication Name	Title	Pubmed Link
METHOTREXATE	Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=782987 3
METHOTREXATE	PUVA and methotrexate therapy of psoriasis: how closely do dermatology departments follow treatment guidelines? Psoriasis Audit Workgroup of the British Association of Dermatologists.	https://www.ncbi.nlm.nih.gov/pubmed/?term=791798 6
METHOTREXATE	Methotrexate in childhood psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=797156 5
METHOTREXATE	The use of methotrexate for treatment of psoriasis in patients with HIV infection. [Review] [20 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=803480 7
METHOTREXATE	Methotrexate dose in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=807152 8
METHOTREXATE	Methotrexate revisited: effects of long-term treatment in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=812357 3
METHOTREXATE	Fulminant hepatic failure after methotrexate and PUVA therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=830821 8
METHOTREXATE	Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=834986 7
METHOTREXATE	Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=844506 4
METHOTREXATE	Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal.	https://www.ncbi.nlm.nih.gov/pubmed/?term=855503 2
METHOTREXATE	Interruption of long-term methotrexate treatment in psoriasis. Evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=861506 2
METHOTREXATE	Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=862982 7
METHOTREXATE	The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=873167 3
METHOTREXATE	Methotrexate and other chemotherapeutic agents used to treat psoriasis. [Review] [128 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=878589 1
METHOTREXATE	Accelerated nodulosis in a patient with psoriasis and arthritis during treatment with methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=883557 7
METHOTREXATE	Accelerated nodulosis in a patient with psoriasis and arthritis during treatment with methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=892338 9

Medication Name	Title	Pubmed Link
METHOTREXATE	Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=914655 6
METHOTREXATE	Methotrexate for psoriasis. [Review] [113 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=916733 3
METHOTREXATE	Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=923652 5
METHOTREXATE	Methotrexate use in psoriasis and psoriatic arthritis. [Review] [75 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=936115 6
METHOTREXATE	Intermittent, short term use of methotrexate for exacerbations of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=946620 9
METHOTREXATE	Methotrexate in psoriasis: consensus conference. [Review] [18 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=952003 2
METHOTREXATE	Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=955170 2
METHOTREXATE	Cutaneous ulceration: an unusual sign of methotrexate toxicity--first report in a patient without psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=964048 3
METHOTREXATE	Cost-effectiveness and cost-benefit analysis of using methotrexate vs Goeckerman therapy for psoriasis. A pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=987520 1
METHOTREXATE	Low dose cyclosporin A and methotrexate in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=100868 72
METHOTREXATE	Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=104111 56
METHOTREXATE	Pulmonary function changes in patients with psoriasis on methotrexate therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=104580 81
METHOTREXATE	Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=104688 00
METHOTREXATE	Exfoliative dermatitis after long-term methotrexate treatment of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=104947 23
METHOTREXATE	Methotrexate in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=105821 58
METHOTREXATE	Pulmonary toxicity in a patient with psoriasis receiving methotrexate therapy. [Review] [21 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=106719 65
METHOTREXATE	The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom.	https://www.ncbi.nlm.nih.gov/pubmed/?term=109714 81
METHOTREXATE	Systemic therapy of psoriasis using methotrexate. [Review] [9 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=111760 41

Medication Name	Title	Pubmed Link
METHOTREXATE	Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=112600 20
METHOTREXATE	Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=113053 80
METHOTREXATE	A clinical study to determine the efficacy and safety of 1% methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=116790 05
METHOTREXATE	Pneumonitis complicating methotrexate therapy for pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=116832 90
METHOTREXATE	Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. [Review] [122 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=117023 02
METHOTREXATE	Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis -short- and long-term toxicity in 104 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=117715 23
METHOTREXATE	Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=119078 39
METHOTREXATE	Short-term methotrexate therapy in psoriasis: a study of 197 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=121215 64
METHOTREXATE	Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=122076 34
METHOTREXATE	The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=125883 86
METHOTREXATE	Psoriasis, vasculitis and methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=128344 65
METHOTREXATE	Methotrexate and psoriasis in the era of new biologic agents. [Review] [83 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=147268 93
METHOTREXATE	Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=148712 78
METHOTREXATE	Liver biopsy in patients without psoriasis receiving methotrexate: what guidelines are medical dermatologists following?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=151539 17
METHOTREXATE	Methotrexate in severe childhood psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=151652 22
METHOTREXATE	Efficacy of concomitant use of PUVA and methotrexate in disease clearance time in plaque type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=155183 66
METHOTREXATE	Methotrexate for generalized pustular psoriasis in a 2-year-old child.	https://www.ncbi.nlm.nih.gov/pubmed/?term=156609 09

Medication Name	Title	Pubmed Link
METHOTREXATE	Topical 0.25% methotrexate gel in a hydrogel base for palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=156727 06
METHOTREXATE	Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. [Review] [32 refs][Erratum appears in J Am Acad Dermatol. 2005 Apr;52(4):670 Note: Prodanowich, Srdjan [corrected to Prodanovich, Srdjan]]	https://www.ncbi.nlm.nih.gov/pubmed/?term=156924 71
METHOTREXATE	Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=157332 24
METHOTREXATE	Methotrexate for psoriasis: current European practice. A postal survey.	https://www.ncbi.nlm.nih.gov/pubmed/?term=157522 90
METHOTREXATE	Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=157878 12
METHOTREXATE	Severe vertigo requiring hospitalization whilst taking low-dose oral methotrexate for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=158076 94
METHOTREXATE	Folate supplementation during methotrexate therapy for patients with psoriasis. [Review] [29 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=161987 87
METHOTREXATE	The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. [Review] [51 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=162255 93
METHOTREXATE	Gynaecomastia with oligospermia: an unusual complication of low-dose methotrexate for pustular psoriasis. [Review] [10 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=163095 12
METHOTREXATE	A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=163164 60
METHOTREXATE	Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?. [Review] [49 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=163430 24
METHOTREXATE	Use of amino terminal type III procollagen peptide (P3NP) assay in methotrexate therapy for psoriasis.[Erratum appears in Postgrad Med J. 2006 Aug;82(970):482]	https://www.ncbi.nlm.nih.gov/pubmed/?term=166794 77
METHOTREXATE	Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=167046 50
METHOTREXATE	Modified combined methotrexate PUVA therapy in the treatment of recalcitrant psoriasis: a preliminary report.	https://www.ncbi.nlm.nih.gov/pubmed/?term=167078 28
METHOTREXATE	Methotrexate and ciclosporin combination for the treatment of severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=167161 53
METHOTREXATE	Cytotoxic and immunologic effects of methotrexate in psoriasis. [Review] [17 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=167886 33

Medication Name	Title	Pubmed Link
METHOTREXATE	Folic acid supplementation and methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=168445 40
METHOTREXATE	The treatment of psoriasis vulgaris: 1% topical methotrexate gel.	https://www.ncbi.nlm.nih.gov/pubmed/?term=169113 86
METHOTREXATE	Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent.	https://www.ncbi.nlm.nih.gov/pubmed/?term=169188 84
METHOTREXATE	Nitric oxide levels in patients with psoriasis treated with methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=169514 86
METHOTREXATE	Differential clinical response to alefacept in combination with methotrexate in two patients with refractory palmar psoriasis. [Review] [12 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=171995 93
METHOTREXATE	Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=172699 67
METHOTREXATE	The effect of methotrexate on the expression of cell adhesion molecules and activation molecule CD69 in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=173094 54
METHOTREXATE	Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=173998 48
METHOTREXATE	Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis.[Erratum appears in J Invest Dermatol. 2008 Oct;128(10):2545-61]	https://www.ncbi.nlm.nih.gov/pubmed/?term=174101 98
METHOTREXATE	Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=175580 46
METHOTREXATE	Disseminated molluscum contagiosum in a patient with chronic plaque psoriasis taking methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=176920 62
METHOTREXATE	Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and ciclosporin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=178543 58
METHOTREXATE	Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=178750 71
METHOTREXATE	Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=179863 02
METHOTREXATE	A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=180315 04
METHOTREXATE	Detection of subclinical joint involvement in psoriasis with bone scintigraphy and its response to oral methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=180766 89

Medication Name	Title	Pubmed Link
METHOTREXATE	Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18087000
METHOTREXATE	Methotrexate-induced papular eruption following treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18094347
METHOTREXATE	The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18163165
METHOTREXATE	Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18181969
METHOTREXATE	Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18256692
METHOTREXATE	Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18429775
METHOTREXATE	Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18797063
METHOTREXATE	Methotrexate for psoriasis in the era of biological therapy. [Review] [25 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=18801095
METHOTREXATE	Multiple toxic effects of low-dose methotrexate in a patient treated for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18997139
METHOTREXATE	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19016697
METHOTREXATE	Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19043379
METHOTREXATE	Methotrexate treatment in 13 children with severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19175782
METHOTREXATE	Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19213235
METHOTREXATE	Liver fibrosis in patients with psoriasis and psoriatic arthritis on long term, high cumulative dose methotrexate therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19273538
METHOTREXATE	Methotrexate: understanding the risk in psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19363738
METHOTREXATE	Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. [104 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=19389524

Medication Name	Title	Pubmed Link
METHOTREXATE	Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=195781 36
METHOTREXATE	Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=196716 97
METHOTREXATE	Comment on: Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=198581 19
METHOTREXATE	Daily practice assessment of liver injury in patients with psoriasis on methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199031 79
METHOTREXATE	Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199254 89
METHOTREXATE	Severe 20-nail psoriasis successfully treated by low dose methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199516 44
METHOTREXATE	A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=201787 09
METHOTREXATE	Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=203846 73
METHOTREXATE	Erythema gyratum repens-like eruption occurring in resolving psoriasis during methotrexate therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=204656 70
METHOTREXATE	Use of methotrexate in patients with psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=210444 48
METHOTREXATE	Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=211755 64
METHOTREXATE	Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=211989 46
METHOTREXATE	Nail psoriasis successfully treated with intralesional methotrexate: case report.	https://www.ncbi.nlm.nih.gov/pubmed/?term=212285 54
METHOTREXATE	Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=213884 54
METHOTREXATE	Methotrexate or fumarates: which is the best oral treatment for psoriasis?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=214571 99

Medication Name	Title	Pubmed Link
METHOTREXATE	Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21564071
METHOTREXATE	Methotrexate and psoriasis: consensus conference.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21571176
METHOTREXATE	Effect of methotrexate on serum levels of IL-22 in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21659065
METHOTREXATE	Familial juvenile generalized pustular psoriasis: response to methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21675502
METHOTREXATE	Rapidly fatal acute ATLL emerging after methotrexate therapy for disseminated psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21729685
METHOTREXATE	Systemic therapy of psoriasis: methotrexate. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21744734
METHOTREXATE	Monitoring methotrexate hepatotoxicity in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21860151
METHOTREXATE	Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21950300
METHOTREXATE	Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21967341
METHOTREXATE	A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22029980
METHOTREXATE	Acute methotrexate toxicity seen as plaque psoriasis ulceration and necrosis: A diagnostic clue.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22136858
METHOTREXATE	Briakinumab versus Methotrexate for Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22276832
METHOTREXATE	Briakinumab versus Methotrexate for Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22276833
METHOTREXATE	Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22309614
METHOTREXATE	Response to the letter to editor re: "Methotrexate and psoriasis: consensus conference".	https://www.ncbi.nlm.nih.gov/pubmed/?term=22421115
METHOTREXATE	Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22429144
METHOTREXATE	Methotrexate in psoriasis: do we need to give a test dose?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22440152

Medication Name	Title	Pubmed Link
METHOTREXATE	Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22672248
METHOTREXATE	Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22830389
METHOTREXATE	Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22882190
METHOTREXATE	Methotrexate-induced liver cirrhosis in a patient of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23029724
METHOTREXATE	Antiangiogenic effect of methotrexate and PUVA on psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23504632
METHOTREXATE	The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=23575550
METHOTREXATE	Remission of bullous pemphigoid after rituximab treatment in a psoriasis patient on regular low-dose methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23624752
METHOTREXATE	Effect of the systemic use of methotrexate on the oxidative stress and paraoxonase enzyme in psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23660995
METHOTREXATE	The role of systemic use of methotrexate on the oxidative stress in patients with psoriasis should be evaluated with a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23771155
METHOTREXATE	Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23830989
METHOTREXATE	Systemic methotrexate therapy for psoriasis: past, present and future. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=23837932
METHOTREXATE	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24116868
METHOTREXATE	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).	https://www.ncbi.nlm.nih.gov/pubmed/?term=24116959
METHOTREXATE	Bullous drug eruption in a patient with psoriasis after a test dose of methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24124857

Medication Name	Title	Pubmed Link
METHOTREXATE	Partial reversal of androgenetic alopecia with methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24153140
METHOTREXATE	Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24283773
METHOTREXATE	Low-dose methotrexate - a therapeutical kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24502314
METHOTREXATE	Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=24588075
METHOTREXATE	Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=24606161
METHOTREXATE	'Short-term treatment with methotrexate does not affect microvascular endothelial function in patients with psoriasis'.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24673617
METHOTREXATE	Disseminated molluscum contagiosum in a patient on methotrexate therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24685870
METHOTREXATE	Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24731093
METHOTREXATE	Erythrodermic psoriasis with bullous pemphigoid: combination treatment with methotrexate and compound glycyrrhizin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24885087
METHOTREXATE	The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24964792
METHOTREXATE	Folate supplementation reduces the side effects of methotrexate therapy for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=24972718
METHOTREXATE	The use of self-administered subcutaneous methotrexate for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25116970
METHOTREXATE	The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25209868
METHOTREXATE	Palmoplantar pustular psoriasis following initiation of a beta-blocker: disease control with low-dose methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25279477
METHOTREXATE	Fatal thrombotic thrombocytopenic purpura in a psoriasis patient treated with ustekinumab and methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25325260
METHOTREXATE	Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25401478
METHOTREXATE	Combining biologics with methotrexate in psoriasis: a systematic review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=25470815

Medication Name	Title	Pubmed Link
METHOTREXATE	Methotrexate in pediatric plaque-type psoriasis: Long-term daily clinical practice results from the Child-CAPTURE registry.	https://www.ncbi.nlm.nih.gov/pubmed/?term=254858 70
METHOTREXATE	The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=255613 62
METHOTREXATE	No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=256898 11
METHOTREXATE	Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=257213 72
METHOTREXATE	Relapse in psoriasis with two different tapering regimens of methotrexate: a randomized open-label controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=257513 29
METHOTREXATE	Nilotinib-induced psoriasis in a patient of chronic myeloid leukemia responding to methotrexate. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=257513 56
METHOTREXATE	Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=257701 13
METHOTREXATE	Systemic methotrexate for the treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=257795 51
METHOTREXATE	Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=259630 62
METHOTREXATE	Diffuse Large B-Cell Lymphoma of the Gingiva in a Patient on Long-Term Use of Methotrexate Being Treated for Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=260537 81
METHOTREXATE	Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate?. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=261082 62
METHOTREXATE	ACP Journal Club. Review: Methotrexate does not increase risk for lung disease in psoriasis, psoriatic arthritis, or IBD.	https://www.ncbi.nlm.nih.gov/pubmed/?term=261925 87
METHOTREXATE	Microemulsions mediated effective delivery of methotrexate hydrogel: more than a tour de force in psoriasis therapeutics.	https://www.ncbi.nlm.nih.gov/pubmed/?term=262043 26

Medication Name	Title	Pubmed Link
METHOTREXATE	The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=262677 35
METHOTREXATE	Can pretreatment serum calcium level predict the efficacy of methotrexate in the treatment of severe plaque psoriasis?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=264163 03
METHOTREXATE	Adherence of self-administered subcutaneous methotrexate in patients with chronic plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=264463 58
METHOTREXATE	Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data.	https://www.ncbi.nlm.nih.gov/pubmed/?term=264673 56
METHOTREXATE	Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=266144 86
METHOTREXATE	Methotrexate regulates Th-1 response by suppressing caspase-1 and cytokines in psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=267079 13
METHOTREXATE	Methotrexate in psoriasis under real-world conditions: long-term efficacy and tolerability.	https://www.ncbi.nlm.nih.gov/pubmed/?term=268520 10
METHOTREXATE	Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=268520 97
METHOTREXATE	Topical psoriasis therapies and unmet patient needs: the importance of optimizing methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=269193 56
METHOTREXATE	Pharmacokinetic profile of methotrexate in psoriatic skin via the oral or subcutaneous route using dermal microdialysis showing higher methotrexate bioavailability in psoriasis plaques than in non-lesional skin.	https://www.ncbi.nlm.nih.gov/pubmed/?term=270050 05
METHOTREXATE	Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.[Erratum appears in PLoS One. 2016;11(7):e0158928; PMID: 27380015]	https://www.ncbi.nlm.nih.gov/pubmed/?term=271681 93
METHOTREXATE	Psoriasis Patients Treated With Biologics and Methotrexate Have a Reduced Rate of Myocardial Infarction: A Collaborative Analysis Using International Cohorts.	https://www.ncbi.nlm.nih.gov/pubmed/?term=274027 17
METHOTREXATE	Methotrexate treatment provokes apoptosis of proliferating keratinocyte in psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=274354 83
METHOTREXATE	Ulcerations due to methotrexate toxicity in a psoriasis patient.	https://www.ncbi.nlm.nih.gov/pubmed/?term=274382 11
METHOTREXATE	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=275150 70

Medication Name	Title	Pubmed Link
METHOTREXATE	Image Gallery: Complete remission of aggressive desmoid-type fibromatosis after low-dose methotrexate for 2 weeks in a child with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=276507 49
METHOTREXATE	Low dose methotrexate induced asymptomatic keratinocyte dystrophy in a patient of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=277148 34
METHOTREXATE	A case of methotrexate intoxication in a patient with psoriasis who drank beetroot juice during methotrexate treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=278596 05
METHOTREXATE	Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=278947 89
METHOTREXATE	Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=280014 99
METHOTREXATE	Should methotrexate remain the first-line drug for psoriasis?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=280125 63
METHOTREXATE	An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=280125 64
METHOTREXATE	The investigation of antimicrobial peptides expression and its related interaction with methotrexate treatment in patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=280670 65
METHOTREXATE	Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE.	https://www.ncbi.nlm.nih.gov/pubmed/?term=280786 72
METHOTREXATE	Diagnostic performance of transient elastography for detection of methotrexate-induced liver injury using Roenigk classification in Asian patients with psoriasis: a retrospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=283033 29
METHOTREXATE	Evaluation of psoriasis severity and inflammatory responses under concomitant treatment with methotrexate plus micronutrients for psoriasis vulgaris: a randomized double blind trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=283529 28
METHOTREXATE	Transient Elastography May Improve Detection of Liver Fibrosis in Psoriasis Patients Treated with Methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=284222 66
METHOTREXATE	HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=285129 93
METHOTREXATE	Methotrexate in the Treatment of Psoriasis and Rheumatoid Arthritis: Mechanistic Insights, Current Issues and Novel Delivery Approaches. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=285715 54

Medication Name	Title	Pubmed Link
METHOTREXATE	Drug survival of methotrexate in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28833007
METHOTREXATE	Evaluation of oxidative stress via protein expression of glutathione S-transferase and cytochrome p450 (CYP450) isoenzymes in <i>psoriasis vulgaris</i> patients treated with methotrexate.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28838263
METHOTREXATE	Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28993007
METHOTREXATE	Combination Topical PUVAsol with Methotrexate Versus Methotrexate in the Treatment of Palmoplantar Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29336426
METHOTREXATE	Effectiveness of and factors associated with clinical response to methotrexate under daily life conditions in Asian patients with psoriasis: A retrospective cohort study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29512181
METHOTREXATE, PHOTOTHERAPY	Comparison of the Efficacy of Methotrexate and Narrow-Band Ultraviolet B for the Treatment of Plaque-Type Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25470611
METHOTREXATE, PHOTOTHERAPY	Methotrexate, but not narrowband ultraviolet B radiation, suppresses interleukin-33 mRNA levels in psoriatic plaques and protein levels in serum of patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28836690
PACLITAXEL	Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15034502
PHOTOTHERAPY	Lesional blistering following narrow-band (TL-01) UVB phototherapy for psoriasis: a report of four cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1419769
PHOTOTHERAPY	Psoriasis symposium. Phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1493096
PHOTOTHERAPY	Multiple carcinoma in patients with psoriasis caused by psoralen-ultraviolet A therapy, natural killer cell insufficiency, or intensified sun exposure?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1628511
PHOTOTHERAPY	Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation? A review of the literature. [Review] [17 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=1952979
PHOTOTHERAPY	Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1972833
PHOTOTHERAPY	Vitamin D metabolism in psoriasis before and after phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=1977266
PHOTOTHERAPY	Induction of disseminated superficial actinic porokeratosis by phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2007687

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2320078
PHOTOTHERAPY	Is the effect of phototherapy in psoriasis partly due to an impact on vitamin D metabolism?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2461030
PHOTOTHERAPY	Tin-protoporphyrin and long wave length ultraviolet light in treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2566782
PHOTOTHERAPY	Salicylic acid and ultraviolet B for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2572842
PHOTOTHERAPY	Are topical corticosteroids useful in phototherapy for psoriasis?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2654215
PHOTOTHERAPY	Palmoplantar psoriasis: experience with 8-methoxysoralen soaks plus ultraviolet A with the use of a high-output metal halide device.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2754058
PHOTOTHERAPY	Elevated plasma interleukin-1 levels in humans following ultraviolet light therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2783951
PHOTOTHERAPY	Effectiveness of relaxation and visualization techniques as an adjunct to phototherapy and photochemotherapy of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3049703
PHOTOTHERAPY	311 nm UVB phototherapy--an effective treatment for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3203066
PHOTOTHERAPY	UVB phototherapy for psoriasis of skin type V.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3246075
PHOTOTHERAPY	Combination of photochemotherapy (PUVA) and ultraviolet B (UVB) in the treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3292621
PHOTOTHERAPY	Photosensitive psoriasis provoked by a suberythematous dose of ultraviolet-B light.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3378651
PHOTOTHERAPY	A new development in UVB phototherapy of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=3408653
PHOTOTHERAPY	Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells.	https://www.ncbi.nlm.nih.gov/pubmed/?term=7500051
PHOTOTHERAPY	Combination of methoxsalen and ultraviolet B (UVB) versus UVB radiation alone in treatment of psoriasis: a bilateral comparison study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=7654566
PHOTOTHERAPY	UVB phototherapy in childhood psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=7792227
PHOTOTHERAPY	Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=7868718

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxysoralen and 5-methoxysoralen.	https://www.ncbi.nlm.nih.gov/pubmed/?term=788076 2
PHOTOTHERAPY	Evaluation of psoralen with solar ultraviolet light (puvasol) and adjunctive topical tar therapy in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=808355 0
PHOTOTHERAPY	Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB.	https://www.ncbi.nlm.nih.gov/pubmed/?term=810517 7
PHOTOTHERAPY	Photoprotective action of emollients in ultraviolet therapy of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=814827 9
PHOTOTHERAPY	Determination of 8-methoxysoralen kinetics: a relevant factor in the treatment of psoriasis by psoralen plus ultraviolet A therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=818009 8
PHOTOTHERAPY	Psoriasis and ultraviolet radiation. [Review] [54 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=824309 7
PHOTOTHERAPY	Narrow-band UVB (311 nm) versus conventional broad-band UVB with and without dithranol in phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=843292 0
PHOTOTHERAPY	Failure of coconut oil to accelerate psoriasis clearance in narrow-band UVB phototherapy or photochemotherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=847151 4
PHOTOTHERAPY	Efficacy of ultraviolet B phototherapy for psoriasis in patients infected with human immunodeficiency virus.	https://www.ncbi.nlm.nih.gov/pubmed/?term=855500 8
PHOTOTHERAPY	Oral calcitriol (1,25-dihydroxyvitamin D3) does not augment UVB phototherapy for plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=870803 8
PHOTOTHERAPY	A review of ultraviolet treatment for psoriasis at Waikato Hospital.	https://www.ncbi.nlm.nih.gov/pubmed/?term=877186 5
PHOTOTHERAPY	An assessment of potential problems of home phototherapy treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=882355 4
PHOTOTHERAPY	Development of cutaneous tolerance to ultraviolet B during ultraviolet B phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=889759 2
PHOTOTHERAPY	Effect of UVB phototherapy and oral calcitriol (1,25-dihydroxyvitamin D3) on vitamin D photosynthesis in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=891256 2
PHOTOTHERAPY	Surface dosimetry in phototherapy: comparison of three ultraviolet B lamps used in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=897771 7
PHOTOTHERAPY	Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=909179 9
PHOTOTHERAPY	Effects of phototherapy on the production of cytokines by peripheral blood mononuclear cells and on systemic antibody responses in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=911227 9

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Comparison of phototherapy with near vs. far erythemogenic doses of narrow-band ultraviolet B in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=953622 9
PHOTOTHERAPY	Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=966683 0
PHOTOTHERAPY	Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=966911 7
PHOTOTHERAPY	Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=973173 4
PHOTOTHERAPY	Dithranol embedded in crystalline monoglycerides combined with phototherapy (UVB): a new approach in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=974514 0
PHOTOTHERAPY	Narrowband ultraviolet B (TL-01) phototherapy for psoriasis: which incremental regimen?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=976728 4
PHOTOTHERAPY	Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA).	https://www.ncbi.nlm.nih.gov/pubmed/?term=977376 9
PHOTOTHERAPY	Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=992201 2
PHOTOTHERAPY	Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?. [Review] [115 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=102305 79
PHOTOTHERAPY	Coexistence of psoriasis and familial benign chronic pemphigus: efficacy of ultraviolet B treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=102332 50
PHOTOTHERAPY	Large increments in psoralen-ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=102333 17
PHOTOTHERAPY	Narrowband UVB phototherapy for psoriasis: results with fixed increments by skin type (as opposed to percentage increments).	https://www.ncbi.nlm.nih.gov/pubmed/?term=103215 20
PHOTOTHERAPY	Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=103281 90
PHOTOTHERAPY	The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures.	https://www.ncbi.nlm.nih.gov/pubmed/?term=103540 27
PHOTOTHERAPY	Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. [Review] [31 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=104902 97

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534635
PHOTOTHERAPY	No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570386
PHOTOTHERAPY	Evaluation of a multicentre study of synchronous application of narrowband ultraviolet B phototherapy (TL-01) and bathing in Dead Sea salt solution for psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10792225
PHOTOTHERAPY	Photoadaptation to ultraviolet (UV) radiation in vivo: photoproducts in epidermal cells following UVB therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10971317
PHOTOTHERAPY	A controlled study of ultraviolet A sunbed treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11069495
PHOTOTHERAPY	A controlled study of ultraviolet A sunbed treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11069502
PHOTOTHERAPY	Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with fitzpatrick skin type IV.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11123453
PHOTOTHERAPY	Transmittance properties of flurandrenolide tape for psoriasis: helpful adjunct to phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11231197
PHOTOTHERAPY	Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11260005
PHOTOTHERAPY	Pretreatment of psoriasis with the vitamin D3 derivative tacalcitol increases the responsiveness to 311-nm ultraviolet B: results of a controlled, right/left study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11260031
PHOTOTHERAPY	Human papillomavirus in cutaneous squamous cell carcinoma and cervix of a patient with psoriasis and extensive ultraviolet radiation exposure.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11260548
PHOTOTHERAPY	Balneophototherapy--combined treatment of psoriasis vulgaris and atopic dermatitis with salt water baths and artificial ultraviolet radiation. [Review] [30 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=11305394
PHOTOTHERAPY	Phototherapy of psoriasis: comparative experience of different phototherapeutic approaches.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306830
PHOTOTHERAPY	Vitiligo following narrow-band TL-01 phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11422056
PHOTOTHERAPY	Phototherapy for psoriasis. [Review] [44 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=11422187

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis.[Erratum appears in J Invest Dermatol 2001 Dec;117(6):1688]	https://www.ncbi.nlm.nih.gov/pubmed/?term=115113 <u>17</u>
PHOTOTHERAPY	A comparison of the effect of narrow-band ultraviolet B in the treatment of psoriasis after salt-water baths and after 8-methoxysoralen baths.	https://www.ncbi.nlm.nih.gov/pubmed/?term=115318 <u>11</u>
PHOTOTHERAPY	Treatment of psoriasis. Part 1. Topical therapy and phototherapy. [Review] [99 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=115687 <u>37</u>
PHOTOTHERAPY	Narrowband UVB phototherapy for the treatment of psoriasis: a review and update. [Review] [15 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=117661 <u>20</u>
PHOTOTHERAPY	Phototherapy utilization for psoriasis is declining in the United States.	https://www.ncbi.nlm.nih.gov/pubmed/?term=119075 <u>08</u>
PHOTOTHERAPY	Phototherapy of psoriasis: update with practical pearls. [Review] [31 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=119769 <u>82</u>
PHOTOTHERAPY	Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B.	https://www.ncbi.nlm.nih.gov/pubmed/?term=120074 <u>65</u>
PHOTOTHERAPY	Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=120604 <u>00</u>
PHOTOTHERAPY	The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=120775 <u>78</u>
PHOTOTHERAPY	UV-B phototherapy clears psoriasis through local effects.	https://www.ncbi.nlm.nih.gov/pubmed/?term=121647 <u>45</u>
PHOTOTHERAPY	Chronic actinic dermatitis developed during phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=122076 <u>82</u>
PHOTOTHERAPY	Remarkable success of Chinese herbs in combination with a short course of low-dose narrow-band UVB phototherapy in severe recalcitrant plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=123611 <u>38</u>
PHOTOTHERAPY	Response of psoriasis to sunbed treatment: comparison of conventional ultraviolet A lamps with new higher ultraviolet B-emitting lamps.	https://www.ncbi.nlm.nih.gov/pubmed/?term=124107 <u>08</u>
PHOTOTHERAPY	A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=124107 <u>09</u>

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxysoralen psoralen-UV-A for the treatment of chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12622624
PHOTOTHERAPY	Balneo phototherapy for psoriasis. Modern application of an age-old treatment. [Review] [15 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=12630261
PHOTOTHERAPY	High frequency of ultraviolet mutations at the INK4a-ARF locus in squamous cell carcinomas from psoralen-plus-ultraviolet-A-treated psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12648234
PHOTOTHERAPY	Calcitriol vs. dithranol in combination with narrow-band ultraviolet B (311 nm) in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12752138
PHOTOTHERAPY	Narrowband UV-B phototherapy clears psoriasis through a combination of local and systemic effects.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12756108
PHOTOTHERAPY	The effects of ultraviolet B treatment on the expression of adhesion molecules by circulating T lymphocytes in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12786832
PHOTOTHERAPY	Reactivation of herpes simplex keratitis during TL01 phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12823318
PHOTOTHERAPY	A randomized controlled trial of narrowband ultraviolet B vs bath-psoralen plus ultraviolet A photochemotherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12828749
PHOTOTHERAPY	Photometric and clinical assessment of localized UVB phototherapy systems for the high-dosage treatment of stable plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12850797
PHOTOTHERAPY	Balneo-phototherapy: a new holistic approach to treating psoriasis. [Review] [15 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=12861891
PHOTOTHERAPY	Quantitative real-time reverse transcription-polymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12880432
PHOTOTHERAPY	Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12890208
PHOTOTHERAPY	Phototherapy treatment of psoriasis today. [Review] [26 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=12894130
PHOTOTHERAPY	A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis. [Review] [14 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=14511017
PHOTOTHERAPY	Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=14674905

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Chronic actinic dermatitis developing during narrowband UVB phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=147385 38
PHOTOTHERAPY	The ultraviolet fingerprint dominates the mutational spectrum of the p53 and Ha-ras genes in psoralen + ultraviolet A keratoses from psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=149621 08
PHOTOTHERAPY	Phototherapy of psoriasis: review and update. [Review] [93 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=150957 60
PHOTOTHERAPY	History of psoriasis response to sunlight does not predict outcome of UVB phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=152455 44
PHOTOTHERAPY	Effectiveness and side effects of UVB-phototherapy, dithranol inpatient therapy and a care instruction programme of short contact dithranol in moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=152469 41
PHOTOTHERAPY	Towards optimal regimens for the UVB phototherapy of psoriasis: a mathematical model.	https://www.ncbi.nlm.nih.gov/pubmed/?term=153390 68
PHOTOTHERAPY	Lack of efficacy and tolerability of topical PDT for psoriasis in comparison with narrowband UVB phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=153473 56
PHOTOTHERAPY	No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=153707 03
PHOTOTHERAPY	Phototherapy arsenal in the treatment of psoriasis. [Review] [26 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=154503 36
PHOTOTHERAPY	Comparative efficacy of psoralen - UVA photochemotherapy versus narrow band UVB phototherapy in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=154565 47
PHOTOTHERAPY	The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.	https://www.ncbi.nlm.nih.gov/pubmed/?term=157012 11
PHOTOTHERAPY	Narrowband UVB phototherapy in skin conditions beyond psoriasis. [Review] [61 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=157935 18
PHOTOTHERAPY	Evaluation of vaseline oil applied prior to UVB TL01 phototherapy in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=158881 30
PHOTOTHERAPY	Comparison of Psoralen ultraviolet A (PUVA) photochemotherapy plus topical corticosteroids with PUVA plus bland emollients in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=159295 24
PHOTOTHERAPY	Wide-area 308-nm phototherapy with nonlaser light in the treatment of psoriasis: results of a pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=159490 22

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	A positive correlation between history of psoriasis response to sunlight and the response to UVB phototherapy. What are the consequences?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15953105
PHOTOTHERAPY	Soluble tumor necrosis factor alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15998370
PHOTOTHERAPY	Audit of the use of psoralen photochemotherapy (PUVA) and narrowband UVB phototherapy in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16019625
PHOTOTHERAPY	Narrow-band ultraviolet B phototherapy in patients with psoriasis: for which types of psoriasis is it more effective?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16043915
PHOTOTHERAPY	Treatment of localized persistent plaque psoriasis with incoherent narrowband ultraviolet B phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16096183
PHOTOTHERAPY	A randomized controlled comparison of the efficacy of Dead Sea salt balneophototherapy vs. narrowband ultraviolet B monotherapy for chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16120152
PHOTOTHERAPY	Limited availability of psoriasis and phototherapy care: an analysis of advertisements.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16150214
PHOTOTHERAPY	Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B phototherapy with total clearing of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16150215
PHOTOTHERAPY	A comparative non randomized study of narrow-band (NB) (312 +/- 2 nm) UVB phototherapy versus sequential therapy with oral administration of low-dose Cyclosporin A and NB-UVB phototherapy in patients with severe psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16280301
PHOTOTHERAPY	Narrowband ultraviolet B therapy for psoriasis and other skin disorders. [Review] [52 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=16350445
PHOTOTHERAPY	A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16384765
PHOTOTHERAPY	Subepidermal bullous dermatosis with IgA antibodies against 200- and 280-kDa epidermal antigens after initiation of ultraviolet B therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16403123
PHOTOTHERAPY	Quality of life in psoriasis improves after standardized administration of narrowband UVB phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16405481
PHOTOTHERAPY	The role of commercial tanning beds and ultraviolet A light in the treatment of psoriasis. [Review] [12 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=16428153

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Paired comparison of bathwater versus oral delivery of 8-methoxysoralen in psoralen plus ultraviolet: A therapy for chronic palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16436174
PHOTOTHERAPY	Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16453993
PHOTOTHERAPY	The effect of maintenance narrow-band ultraviolet B therapy on the duration of remission for psoriasis: a prospective randomized clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16533223
PHOTOTHERAPY	Pseudoporphyria secondary to narrowband UVB phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16637812
PHOTOTHERAPY	Depigmentation following narrowband ultraviolet B phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16713483
PHOTOTHERAPY	Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16829029
PHOTOTHERAPY	Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study.[Erratum appears in J Drugs Dermatol. 2006 Sep;5(8):706]	https://www.ncbi.nlm.nih.gov/pubmed/?term=16865867
PHOTOTHERAPY	Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16892660
PHOTOTHERAPY	Comparison of weekly and daily incremental protocols of narrowband ultraviolet B phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16987261
PHOTOTHERAPY	Nonlaser UVB-targeted phototherapy treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17036665
PHOTOTHERAPY	8-Methoxysoralen cream plus targeted narrowband ultraviolet B for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17100735
PHOTOTHERAPY	Narrow-band UV-B phototherapy in childhood psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17343596
PHOTOTHERAPY	Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17519218
PHOTOTHERAPY	Comparison of the efficacy of local narrowband ultraviolet B (NB-UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17584319
PHOTOTHERAPY	Tumour necrosis factor alpha (TNF-alpha)-converting enzyme (TACE) and soluble TNF-alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17598866

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Psoralen and ultraviolet a light therapy for psoriasis. [Review] [48 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=176998 18
PHOTOTHERAPY	Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=177096 60
PHOTOTHERAPY	A pragmatic randomized controlled trial on the effectiveness of low concentrated saline spa water baths followed by ultraviolet B (UVB) compared to UVB only in moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=177141 21
PHOTOTHERAPY	Soluble tumour necrosis factor-alpha receptor type 1 as a biomarker of response to phototherapy in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=178520 84
PHOTOTHERAPY	Targeted UVB phototherapy for psoriasis: a preliminary study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=179536 32
PHOTOTHERAPY	Efficacy of local psoralen ultraviolet A treatments in psoriasis, vitiligo and eczema.	https://www.ncbi.nlm.nih.gov/pubmed/?term=180932 41
PHOTOTHERAPY	Topical 8-methoxysoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=181819 73
PHOTOTHERAPY	Comparison of the efficacy of psoralen ultraviolet A with narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis in patients with skin types IV and V.	https://www.ncbi.nlm.nih.gov/pubmed/?term=184624 46
PHOTOTHERAPY	The duration of clinical remission of photochemotherapy and narrow-band UV-B phototherapy in the treatment of psoriasis: a retrospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=185474 98
PHOTOTHERAPY	Patients' views on care and treatment after phototherapy for psoriasis and atopic eczema including a gender perspective.	https://www.ncbi.nlm.nih.gov/pubmed/?term=186087 25
PHOTOTHERAPY	Photosensitive psoriasis vulgaris inducible by a single suberythematous dose of ultraviolet B irradiation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=187093 24
PHOTOTHERAPY	Local effects of TL01 phototherapy in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=188118 69
PHOTOTHERAPY	Enhanced response of childhood psoriasis to narrow-band UV-B phototherapy with preirradiation use of mineral oil.	https://www.ncbi.nlm.nih.gov/pubmed/?term=189504 02
PHOTOTHERAPY	Serum 5-S-cysteinyl-dopa levels in patients with psoriasis undergoing narrowband ultraviolet B phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=189544 14
PHOTOTHERAPY	Tanning beds as an alternative for psoriasis when office-based phototherapy is not accessible.	https://www.ncbi.nlm.nih.gov/pubmed/?term=190653 55
PHOTOTHERAPY	A comparative study on the efficacy of treatment with 585 nm pulsed dye laser and ultraviolet B-TL01 in plaque type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=190761 90

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19112758
PHOTOTHERAPY	A short cycle of narrow-band UVB phototherapy in the early phase of long-term efalizumab can provide a quicker remission of moderate and severe psoriasis: a pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19279381
PHOTOTHERAPY	Spectrophotometric intracutaneous analysis as an early non-invasive predictor of efficacy in the phototherapy of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19292783
PHOTOTHERAPY	Failure of short-term psoralen and ultraviolet A light maintenance treatment to prevent early relapse in patients with chronic recurring plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19292785
PHOTOTHERAPY	The effects of phototherapy on the numbers of circulating natural killer cells and T lymphocytes in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19292789
PHOTOTHERAPY	Continued use of home narrowband ultraviolet B light phototherapy for psoriasis after completion of a clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19389535
PHOTOTHERAPY	Home UVB phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19423624
PHOTOTHERAPY	Vitamin D production in psoriasis patients increases less with narrowband than with broadband ultraviolet B phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19438988
PHOTOTHERAPY	Narrowband ultraviolet B therapy in psoriasis: randomized double-blind comparison of high-dose and low-dose irradiation regimens.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19466961
PHOTOTHERAPY	Narrowband ultraviolet B phototherapy does not influence serum and red cell folate levels in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19493587
PHOTOTHERAPY	UVB phototherapy for psoriasis. Narrowband UVB phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19493945
PHOTOTHERAPY	Itch and scratching as predictors of time to clearance of psoriasis with narrow-band ultraviolet B therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19538185
PHOTOTHERAPY	Estimated ultraviolet doses to psoriasis patients during climate therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19614899
PHOTOTHERAPY	Retinoids and phototherapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19661548
PHOTOTHERAPY	What is the most common phototherapy prescription for psoriasis: NB-UVB or PUVA? Prescription behavior.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19668937
PHOTOTHERAPY	Practice of phototherapy in the treatment of moderate-to-severe psoriasis. [Review] [64 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=19710550

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Topical 8-methoxysoralen increases the efficacy of narrowband ultraviolet B in psoriasis.[Erratum appears in Photodermatol Photoimmunol Photomed. 2009 Dec;25(6):335]	https://www.ncbi.nlm.nih.gov/pubmed/?term=197472 41
PHOTOTHERAPY	Combination 830-nm and 633-nm light-emitting diode phototherapy shows promise in the treatment of recalcitrant psoriasis: preliminary findings.	https://www.ncbi.nlm.nih.gov/pubmed/?term=197648 93
PHOTOTHERAPY	Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks.	https://www.ncbi.nlm.nih.gov/pubmed/?term=197663 50
PHOTOTHERAPY	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. [Review] [170 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=198118 50
PHOTOTHERAPY	Recovery from tanning induced by narrow-band UVB phototherapy in brown-skinned individuals with psoriasis: twelve-month follow-up.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199140 43
PHOTOTHERAPY	Using 'number needed to treat' to express the magnitudes of benefit of ultraviolet B phototherapy and of antitumour necrosis factor-alpha therapies for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199196 32
PHOTOTHERAPY	Comparing narrowband ultraviolet B treatment regimens for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199414 85
PHOTOTHERAPY	A comparison of three times vs. five times weekly narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=200708 33
PHOTOTHERAPY	Tumor necrosis factor-alpha-converting enzyme as a potential mediator of the influence of smoking on the response to treatment with narrowband ultraviolet B in psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=200708 37
PHOTOTHERAPY	Phototherapy for psoriasis: what to choose and how to use: facts and controversies. [Review] [82 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=200829 55
PHOTOTHERAPY	Early administration of ultraviolet treatment is effective in pegylated interferon alpha-induced severe acute exacerbation of psoriasis: a case report and short review of the literature. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=200890 20
PHOTOTHERAPY	Expression of cyclin D1 and p16 in psoriasis before and after phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=200890 81

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Urinary mutagenicity and genotoxic risk in children with psoriasis after therapeutic exposure to polycyclic aromatic hydrocarbons and ultraviolet radiation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20096371
PHOTOTHERAPY	Efficacy of a far erythemogenic dose of narrow-band ultraviolet B phototherapy in chronic plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20175848
PHOTOTHERAPY	A review of home phototherapy for psoriasis. [Review] [59 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=20178697
PHOTOTHERAPY	Targeted phototherapy of plaque-type psoriasis using ultraviolet B-light-emitting diodes.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20302573
PHOTOTHERAPY	Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20331450
PHOTOTHERAPY	Cost effectiveness of home ultraviolet B phototherapy for psoriasis: economic evaluation of a randomised controlled trial (PLUTO study).	https://www.ncbi.nlm.nih.gov/pubmed/?term=20406865
PHOTOTHERAPY	8-methoxysoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20488788
PHOTOTHERAPY	Vitamin D status in psoriasis patients during different treatments with phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20579901
PHOTOTHERAPY	Effect of written emotional disclosure interventions in persons with psoriasis undergoing narrow band ultraviolet B phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20605769
PHOTOTHERAPY	Home phototherapy for psoriasis is cost-effective.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20687238
PHOTOTHERAPY	Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20716219
PHOTOTHERAPY	Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20716226
PHOTOTHERAPY	Comparative evaluation of NBUVB phototherapy and PUVA photochemotherapy in chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20826993
PHOTOTHERAPY	Bath psoralen+ultraviolet A photochemotherapy vs. narrow band-ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T-helper and T-suppressor/cytotoxic cells.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20831697
PHOTOTHERAPY	Effect of narrow-band UVB phototherapy on soluble cell adhesion molecules in patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20926025

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Narrowband ultraviolet B in the treatment of psoriasis: the journey so far!. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21079308
PHOTOTHERAPY	Comparative efficacy of narrow-band ultraviolet B phototherapy alone and its combination with topical 8-methoxysoralen in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21079310
PHOTOTHERAPY	Effect of narrowband ultraviolet B phototherapy on serum folic acid levels in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21344249
PHOTOTHERAPY	Duration of remission period of narrowband ultraviolet B therapy on psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21352300
PHOTOTHERAPY	Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21412260
PHOTOTHERAPY	A review of phototherapy protocols for psoriasis treatment. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21429620
PHOTOTHERAPY	Phototherapy reduces serum resistin levels in psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21535169
PHOTOTHERAPY	A single blind randomized clinical study: the efficacy of isotretinoin plus narrow band ultraviolet B in the treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21535171
PHOTOTHERAPY	Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21564068
PHOTOTHERAPY	Evaluation of a skin protection cream for dry skin in patients undergoing narrow band UVB phototherapy for psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21566547
PHOTOTHERAPY	Narrowband ultraviolet B phototherapy improves the quality of life in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21666943
PHOTOTHERAPY	Clastogenic plasma factors in psoriasis--comparison of phototherapy and anti-TNF-alpha treatments.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21824151
PHOTOTHERAPY	Comparison of psoralen plus ultraviolet A therapy and biologics in moderate to severe chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21884039
PHOTOTHERAPY	Disseminated superficial actinic porokeratosis in a patient undergoing treatment with long-term narrowband ultraviolet B for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21914157
PHOTOTHERAPY	Phototherapy of psoriasis in the era of biologics: still in. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21933648
PHOTOTHERAPY	Successful treatment of psoriasis vulgaris with targeted narrow-band ultraviolet B therapy using a new flat-type fluorescent lamp.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21950629

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	A review of targeted ultraviolet B phototherapy for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22000769
PHOTOTHERAPY	Comparison of topical 8-methoxysoralen and narrowband ultraviolet B with narrowband ultraviolet B alone in treatment-resistant sites in plaque-type psoriasis: a placebo-controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22092732
PHOTOTHERAPY	Targeted 307 nm UVB-phototherapy in psoriasis. A pilot study comparing a 307 nm excimer light with topical dithranol.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22092772
PHOTOTHERAPY	Narrowband ultraviolet B phototherapy decreased the serum IL-17E level in a patient with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22097932
PHOTOTHERAPY	Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22126311
PHOTOTHERAPY	Narrowband ultraviolet B and biologics in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22212055
PHOTOTHERAPY	Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22508874
PHOTOTHERAPY	Narrowband ultraviolet B treatment for psoriasis increases serum vitamin A levels.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22512237
PHOTOTHERAPY	Reflectance confocal microscopy: an effective tool for monitoring ultraviolet B phototherapy in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22512282
PHOTOTHERAPY	Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22512675
PHOTOTHERAPY	Topical treatment and phototherapy in psoriasis: systematic review and expert opinion of a panel of dermatologists.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22512683
PHOTOTHERAPY	Efficacy and safety of non-laser, targeted UVB phototherapy alone and in combination with psoralen gel or calcipotriol ointment in the treatment of localized, chronic, plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22515588
PHOTOTHERAPY	Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22724918
PHOTOTHERAPY	A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22859237

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Melanoma and other malignant skin cancers in psoriatic patients treated with phototherapy. Role of the p16 protein in psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=232642 <u>10</u>
PHOTOTHERAPY	Phototherapy in psoriasis: a review of mechanisms of action. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=233641 <u>44</u>
PHOTOTHERAPY	The efficacy of narrow-band ultraviolet B phototherapy in the treatment of patients with active chronic plaque psoriasis and its effect on peripheral blood levels of various T-lymphocyte subpopulations: a clinical and flow cytometric immunophenotypical study	https://www.ncbi.nlm.nih.gov/pubmed/?term=233994 <u>53</u>
PHOTOTHERAPY	Catechol-O-methyltransferase activity is higher in psoriasis patients and is down-regulated by narrowband ultraviolet B treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=233995 <u>36</u>
PHOTOTHERAPY	Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and na	https://www.ncbi.nlm.nih.gov/pubmed/?term=234142 <u>98</u>
PHOTOTHERAPY	Systemically elevated Th1-, Th2- and Th17-associated chemokines in psoriasis vulgaris before and after ultraviolet B treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=235718 <u>25</u>
PHOTOTHERAPY	Narrowband ultraviolet B interferes with gene expression in the peripheral blood T cells of patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=236354 <u>88</u>
PHOTOTHERAPY	Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=237729 <u>97</u>
PHOTOTHERAPY	Influence of phototherapy in psoriasis on Ki-67 antigen expression: a preliminary study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=239008 <u>66</u>
PHOTOTHERAPY	Narrow-band ultraviolet B treatment boosts serum 25-hydroxyvitamin D in patients with psoriasis on oral vitamin D supplementation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=239957 <u>95</u>
PHOTOTHERAPY	Catechol-O-methyltransferase activity in psoriasis patients treated with psoralen plus ultraviolet A therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=240013 <u>77</u>
PHOTOTHERAPY	Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=241510 <u>11</u>

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Psoriasis treatment: faster and long-standing results after bathing in geothermal seawater. A randomized trial of three UVB phototherapy regimens.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24255991
PHOTOTHERAPY	Efficacy of localized phototherapy and photodynamic therapy for psoriasis: a systematic review and meta-analysis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=24283358
PHOTOTHERAPY	Phototherapy, psoriasis, and the age of biologics. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=24313462
PHOTOTHERAPY	Effect of narrowband ultraviolet B therapy on serum vitamin D and cathelicidin (LL-37) in patients with chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24377473
PHOTOTHERAPY	Phototherapy-induced erythema in patients with psoriasis and obesity treated with narrowband UVB phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24602066
PHOTOTHERAPY	Body mass index, waist circumference and HOMA-IR correlate with the Psoriasis Area and Severity Index in patients with psoriasis receiving phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24641699
PHOTOTHERAPY	Effect of narrowband ultraviolet B treatment on endocannabinoid plasma levels in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24641781
PHOTOTHERAPY	Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24656729
PHOTOTHERAPY	Broadband ultraviolet A in the treatment of psoriasis vulgaris: a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24697586
PHOTOTHERAPY	Novel topical cream delivers safe and effective alternative to traditional psoriasis phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24773915
PHOTOTHERAPY	Oxidation reduction is a key process for successful treatment of psoriasis by narrow-band UVB phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24909845
PHOTOTHERAPY	Remission period in psoriasis after multiple cycles of narrowband ultraviolet B phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24942986
PHOTOTHERAPY	A randomized, prospective, sham-controlled study of localized narrow-band UVB phototherapy in the treatment of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25116969
PHOTOTHERAPY	Recovery of the response to biological treatments using narrow band ultraviolet-B in patients with moderate to severe psoriasis: a retrospective study of 17 patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25132192
PHOTOTHERAPY	Digital ultraviolet therapy: a novel therapeutic approach for the targeted treatment of psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25307476
PHOTOTHERAPY	Psoriasis and daily low-emission phototherapy: effects on disease and vitamin D level.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25377657

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Narrowband ultraviolet B phototherapy starting and incremental dose in patients with psoriasis: comparison of percentage dose and fixed dose protocols.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2537788
PHOTOTHERAPY	Phototherapy and photochemotherapy for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=25412785
PHOTOTHERAPY	An evaluation of the preferences of patients with psoriasis between systemic psoralen plus ultraviolet A and bath psoralen plus ultraviolet A.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25420468
PHOTOTHERAPY	Reduction in tissue plasmin: a new mechanism of action of narrowband ultraviolet B in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25557337
PHOTOTHERAPY	Toll-like receptor 9 promoter polymorphism as a predictive factor of narrow-band UVB phototherapy response in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25561051
PHOTOTHERAPY	A guide to prescribing home phototherapy for patients with psoriasis: the appropriate patient, the type of unit, the treatment regimen, and the potential obstacles. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=25748310
PHOTOTHERAPY	Home ultraviolet light therapy for psoriasis: why patients choose other options.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25756482
PHOTOTHERAPY	Understanding the role of haptoglobin in psoriasis: effects of ultraviolet B.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25958740
PHOTOTHERAPY	Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26130316
PHOTOTHERAPY	Effects of Narrow Band Ultraviolet B on Serum Levels of Vascular Endothelial Growth Factor and Interleukin-8 in Patients with Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26308328
PHOTOTHERAPY	Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26767505
PHOTOTHERAPY	Ultraviolet irradiation promotes FOXP3 transcription via p53 in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26781862
PHOTOTHERAPY	Ultraviolet B Phototherapy for Psoriasis: Review of Practical Guidelines. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26872953
PHOTOTHERAPY	Prospective Investigation of 25(OH)D3 Serum Concentration Following UVB Narrow Band Phototherapy in Patients with Psoriasis and Atopic Dermatitis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26977048

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Tacalcitol: A useful adjunct to narrow band ultraviolet B phototherapy in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27052200
PHOTOTHERAPY	Neutrophil/Lymphocyte Ratio, Serum Endocan, and Nesfatin-1 Levels in Patients with Psoriasis Vulgaris Undergoing Phototherapy Treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27070789
PHOTOTHERAPY	Effect of narrow band ultraviolet B phototherapy on T helper 17 cell specific cytokines (interleukins-17, 22 and 23) in psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27170430
PHOTOTHERAPY	The effect of phototherapy on systemic inflammatory process in patients with plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27314537
PHOTOTHERAPY	Correlation Between Severity Index and Quality of Life Index in Patients With Psoriasis Assessed Before and After Phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27319951
PHOTOTHERAPY	Desired response to phototherapy vs photoaggravation in psoriasis: what makes the difference?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27376966
PHOTOTHERAPY	Comparison of Phototherapy Guidelines for Psoriasis: A Critical Appraisal and Comprehensive Review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27538001
PHOTOTHERAPY	An investigation of cytochrome p450 (CYP) and glutathione S-transferase (GST) isoenzyme protein expression and related interactions with phototherapy in patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27613512
PHOTOTHERAPY	Ultraviolet B radiation therapy for psoriasis: Pursuing the optimal regime. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27638437
PHOTOTHERAPY	Assessing the validity and response distribution of the simplified psoriasis index in patients receiving phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27730628
PHOTOTHERAPY	C-reactive protein serum level in patients with psoriasis before and after treatment with narrow-band ultraviolet B.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27828628
PHOTOTHERAPY	Phototherapy with Narrow-Band UVB in Adult Guttate Psoriasis: Results and Patient Assessment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27883996
PHOTOTHERAPY	Challenge and perspective: the relevance of ultraviolet (UV) radiation and the vitamin D endocrine system (VDES) for psoriasis and other inflammatory skin diseases. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28054069
PHOTOTHERAPY	Phosphor for phototherapy: Review on psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28220603
PHOTOTHERAPY	Effectiveness and safety of traditional Chinese medical bath therapy combined with ultraviolet irradiation in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28323822

Medication Name	Title	Pubmed Link
PHOTOTHERAPY	Comparative evaluation of efficacy and safety of calcipotriol versus tacalcitol ointment, both in combination with NBUVB phototherapy in the treatment of stable plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=286020 <u>32</u>
PHOTOTHERAPY	A Systematic Review of Light Emitting Diode (LED) Phototherapy for Treatment of Psoriasis: An Emerging Therapeutic Modality. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=286286 <u>85</u>
PHOTOTHERAPY	Serum levels of tumor necrosis factor-alpha in patients with psoriasis before, during and after narrow-band UVB phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287049 <u>92</u>
PHOTOTHERAPY	Influence of narrowband ultraviolet B phototherapy on serum tumour necrosis factor-like weak inducer of apoptosis (TWEAK) in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287485 <u>92</u>
PHOTOTHERAPY	Effect of availability of at-home phototherapy on the use of systemic medications for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=288572 <u>59</u>
PHOTOTHERAPY	"Two-step phototherapy" for treatment-resistant psoriasis on the lower extremities.	https://www.ncbi.nlm.nih.gov/pubmed/?term=289174 <u>72</u>
PHOTOTHERAPY	Concentration of selenium, zinc, copper, Cu/Zn ratio, total antioxidant status and c-reactive protein in the serum of patients with psoriasis treated by narrow-band ultraviolet B phototherapy: A case-control study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=289655 <u>64</u>
PHOTOTHERAPY	A clinical review of phototherapy for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=290676 <u>16</u>
PHOTOTHERAPY	Phototherapy of Psoriasis, a Chronic Inflammatory Skin Disease. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=291247 <u>09</u>
PHOTOTHERAPY	Significant Changes in the Skin Microbiome in Patients with Chronic Plaque Psoriasis after Treatment with Narrowband Ultraviolet B.	https://www.ncbi.nlm.nih.gov/pubmed/?term=291993 <u>51</u>
PHOTOTHERAPY	Combining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy: A Review of the Literature. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=292408 <u>56</u>
PHOTOTHERAPY	Current developments in phototherapy for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=293693 <u>96</u>
PHOTOTHERAPY	Metabolic syndrome affects narrow-band UVB phototherapy response in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=293902 <u>61</u>
PHOTOTHERAPY	A non-inferiority randomized controlled clinical trial comparing Unani formulation & psoralen plus ultraviolet A sol in chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=297493 <u>63</u>

Medication Name	Title	Pubmed Link
PHOTOTHERAPY, METHOTREXATE	Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. [Review] [47 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=20082957
PHOTOTHERAPY, METHOTREXATE, PHOTOTHERAPY	Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16713455
PHOTOTHERAPY, METHOTREXATE, PHOTOTHERAPY	Methotrexate/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis--a randomized single-blinded placebo-controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=20015056
PHOTOTHERAPY, METHOTREXATE, PHOTOTHERAPY	Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24738793
PHOTOTHERAPY, METHOTREXATE, PHOTOTHERAPY	Combination therapy of methotrexate plus NBUVB phototherapy is more effective than methotrexate monotherapy in the treatment of chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25909368
PHOTOTHERAPY, PIMECROLIMUS, PHOTOTHERAPY	A case of infantile psoriasis with pseudoainhum successfully treated with topical pimecrolimus and low-dose narrowband UVB phototherapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062058
PHOTOTHERAPY, TAZAROTENE	Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10688723
PHOTOTHERAPY, TAZAROTENE, PHOTOTHERAPY	Tazarotene plus UVB phototherapy in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11050587
PHOTOTHERAPY, TAZAROTENE, PHOTOTHERAPY	Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29924221
PIMECROLIMUS	Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12406334
PIMECROLIMUS	An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion.	https://www.ncbi.nlm.nih.gov/pubmed/?term=14609102
PIMECROLIMUS	Current concepts and review of pimecrolimus in the treatment of psoriasis. [Review] [22 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=15450341
PIMECROLIMUS	Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15482317

Medication Name	Title	Pubmed Link
PIMECROLIMUS	Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15523351
PIMECROLIMUS	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15948985
PIMECROLIMUS	Pimecrolimus 1 percent cream in the treatment of psoriasis in a child.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16638400
PIMECROLIMUS	Pimecrolimus induced tinea incognito masquerading as intertriginous psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18076599
PIMECROLIMUS	Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18216475
PIMECROLIMUS	Pimecrolimus 1% cream is effective in the treatment of psoriasis in an infant.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19106045
PIMECROLIMUS	Pimecrolimus for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=23461536
PIMECROLIMUS, TACROLIMUS	The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. [Review] [22 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=15347485
PIMECROLIMUS, TAZAROTENE	Oral tazarotene and oral pimecrolimus: novel oral therapies in development for psoriasis. [Review] [15 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=15098968
SECUKINUMAB	Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23106107
SECUKINUMAB	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23362969
SECUKINUMAB	Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24330415
SECUKINUMAB	Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24393602
SECUKINUMAB	Secukinumab in plaque psoriasis--results of two phase 3 trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25007392
SECUKINUMAB	Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).	https://www.ncbi.nlm.nih.gov/pubmed/?term=25132411

Medication Name	Title	Pubmed Link
SECUKINUMAB	Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).	https://www.ncbi.nlm.nih.gov/pubmed/?term=252439 <u>10</u>
SECUKINUMAB	Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=253547 <u>38</u>
SECUKINUMAB	Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE).	https://www.ncbi.nlm.nih.gov/pubmed/?term=258239 <u>58</u>
SECUKINUMAB	Secukinumab (Cosentyx) for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=258535 <u>78</u>
SECUKINUMAB	Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).	https://www.ncbi.nlm.nih.gov/pubmed/?term=259825 <u>39</u>
SECUKINUMAB	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=260922 <u>91</u>
SECUKINUMAB	Secukinumab: a review in moderate to severe plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=262028 <u>71</u>
SECUKINUMAB	Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=262677 <u>26</u>
SECUKINUMAB	Secukinumab (AIN457) for the treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=264280 <u>36</u>
SECUKINUMAB	Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion.	https://www.ncbi.nlm.nih.gov/pubmed/?term=264397 <u>98</u>
SECUKINUMAB	Secukinumab for treating plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=265779 <u>56</u>
SECUKINUMAB	Secukinumab (AIN-457) for the treatment of Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=266473 <u>00</u>
SECUKINUMAB	Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=266500 <u>14</u>
SECUKINUMAB	Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=266601 <u>43</u>
SECUKINUMAB	Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=266815 <u>27</u>

Medication Name	Title	Pubmed Link
SECUKINUMAB	Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26720159
SECUKINUMAB	Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26783352
SECUKINUMAB	Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26866518
SECUKINUMAB	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27180926
SECUKINUMAB	Secukinumab in the Treatment of Generalized Pustular Psoriasis: A Case report.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27231055
SECUKINUMAB	The impact of long-term secukinumab treatment on Epstein-Barr virus and cytomegalovirus loads in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27261186
SECUKINUMAB	The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27317524
SECUKINUMAB	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27518376
SECUKINUMAB	Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27541729
SECUKINUMAB	Safety of secukinumab in the treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27545070
SECUKINUMAB	Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27646769
SECUKINUMAB	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27663079
SECUKINUMAB	Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27707593
SECUKINUMAB	Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27741340
SECUKINUMAB	Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27965188

Medication Name	Title	Pubmed Link
SECUKINUMAB	Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28111801
SECUKINUMAB	Secukinumab in the treatment of psoriasis: an update. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28162025
SECUKINUMAB	Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.[Erratum appears in J Dermatolog	https://www.ncbi.nlm.nih.gov/pubmed/?term=28266243
SECUKINUMAB	Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28273356
SECUKINUMAB	Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.[Erratum appears in Adv Ther. 2017 Jul;34(7):1772; PMID: 28589404]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28397079
SECUKINUMAB	Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28498514
SECUKINUMAB	Image Gallery: Resolution of lichen striatus in a patient with coexisting chronic plaque psoriasis and vitiligo during secukinumab treatment. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28504405
SECUKINUMAB	Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: Update and commentary.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28522069
SECUKINUMAB	Anti IL-17 flared psoriasis in a patient on secukinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28547879
SECUKINUMAB	Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28580579
SECUKINUMAB	Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.[Erratum appears in Br J Dermatol. 2017 Dec;177(6):1772;	https://www.ncbi.nlm.nih.gov/pubmed/?term=28580646

Medication Name	Title	Pubmed Link
SECUKINUMAB	Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=286020 <u>39</u>
SECUKINUMAB	Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=287321 <u>52</u>
SECUKINUMAB	Treatment of Moderate to Severe Psoriasis With High-Dose (450-mg) Secukinumab: Case Reports of Off-Label Use.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287355 <u>69</u>
SECUKINUMAB	Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287374 <u>40</u>
SECUKINUMAB	The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287803 <u>64</u>
SECUKINUMAB	Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=294049 <u>66</u>
SECUKINUMAB	Complete response of secukinumab in palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=294697 <u>99</u>
SECUKINUMAB	A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=295230 <u>55</u>
TACROLIMUS	Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=137610 <u>2</u>
TACROLIMUS	IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=753162 <u>7</u>
TACROLIMUS	Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study.[Erratum appears in Arch Dermatol 1998 Nov;134(11):1386]	https://www.ncbi.nlm.nih.gov/pubmed/?term=976202 <u>1</u>
TACROLIMUS	Tacrolimus ointment improves psoriasis in a microplaque assay.	https://www.ncbi.nlm.nih.gov/pubmed/?term=104175 <u>22</u>
TACROLIMUS	Topical tacrolimus is effective for facial lesions of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=112436 <u>45</u>
TACROLIMUS	Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.	https://www.ncbi.nlm.nih.gov/pubmed/?term=126640 <u>20</u>
TACROLIMUS	Deep dermatophytosis during topical tacrolimus therapy for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=129268 <u>03</u>
TACROLIMUS	Topical tacrolimus for facial psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=129322 <u>57</u>

Medication Name	Title	Pubmed Link
TACROLIMUS	A case of generalized pustular psoriasis treated with topical tacrolimus.[Erratum appears in Arch Dermatol. 2003 Nov;139(11):1406]	https://www.ncbi.nlm.nih.gov/pubmed/?term=12975175
TACROLIMUS	Topical tacrolimus: an effective therapy for facial psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=14693492
TACROLIMUS	Tacrolimus ointment is effective for facial and intertriginous psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15523350
TACROLIMUS	Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15655140
TACROLIMUS	Tacrolimus ointment for the treatment of severe facial plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15752305
TACROLIMUS	Generalized pustular psoriasis successfully treated with topical tacrolimus.	https://www.ncbi.nlm.nih.gov/pubmed/?term=15787845
TACROLIMUS	Proven efficacy of tacrolimus for facial and intertriginous psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16172314
TACROLIMUS	Topical tacrolimus in the treatment of inverse psoriasis in children.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16198804
TACROLIMUS	Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16223203
TACROLIMUS	0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16585986
TACROLIMUS	Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16673800
TACROLIMUS	Tacrolimus ointment 0.1% alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16774101
TACROLIMUS	Successful treatment with topical tacrolimus for oral psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16987275
TACROLIMUS	Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17300658
TACROLIMUS	Treatment of inverse psoriasis with excimer therapy and tacrolimus ointment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17338698
TACROLIMUS	Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17935517

Medication Name	Title	Pubmed Link
TACROLIMUS	Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18284400
TACROLIMUS	Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18845092
TACROLIMUS	Evaluation of methylprednisolone aceponate, tacrolimus and combination thereof in the psoriasis plaque test using sum score, 20-MHz-ultrasonography and optical coherence tomography.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21084037
TACROLIMUS	Palmoplantar pustular psoriasis: clinical and video thermographic evaluation before and after topical tacrolimus treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21690553
TACROLIMUS	Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22788697
TACROLIMUS	Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25057896
TACROLIMUS	Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25285355
TACROLIMUS	Sterile Corneal Infiltrates Secondary to Psoriasis Exacerbations: Topical Tacrolimus as an Alternative Treatment Option.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26222098
TACROLIMUS	Pilot Study to Evaluate the Efficacy and Safety of Oral Tacrolimus in Adult Patients With Refractory Severe Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26553734
TACROLIMUS	Topical tacrolimus 0.03% for the treatment of ocular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27130870
TACROLIMUS	Combination Therapy of Tacrolimus and Chinese Herb Medicated Bath in Children with Inverse Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28914435
TAZAROTENE	Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9035703
TAZAROTENE	Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9216528
TAZAROTENE	Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. [Review] [34 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=9270551
TAZAROTENE	Molecular mechanisms of tazarotene action in psoriasis. [Review] [33 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=9270552
TAZAROTENE	Clinical safety of tazarotene in the treatment of plaque psoriasis. [Review] [50 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=9270553

Medication Name	Title	Pubmed Link
TAZAROTENE	Tazarotene gel: efficacy and safety in plaque psoriasis. [Review] [19 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=927054
TAZAROTENE	The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9449910
TAZAROTENE	Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9591815
TAZAROTENE	Genital ulcers in a psoriasis patient using topical tazarotene.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9640392
TAZAROTENE	Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9777766
TAZAROTENE	The pathogenesis of psoriasis and the mechanism of action of tazarotene. [Review] [27 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=9777790
TAZAROTENE	The management of psoriasis-tazarotene: the bottom line. [Review] [0 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=9787992
TAZAROTENE	Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=9951595
TAZAROTENE	Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10417841
TAZAROTENE	Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. [Review] [65 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=10554045
TAZAROTENE	Tazarotene--a topical retinoid for psoriasis. [Review] [10 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=10692712
TAZAROTENE	Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10731130
TAZAROTENE	The role of tazarotene in the treatment of psoriasis. [Review] [20 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=10731131
TAZAROTENE	Tazarotene combination treatments in psoriasis. [Review] [31 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=10898828
TAZAROTENE	Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. [Review] [10 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=10898829
TAZAROTENE	Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer.	https://www.ncbi.nlm.nih.gov/pubmed/?term=10955811
TAZAROTENE	An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11147088

Medication Name	Title	Pubmed Link
TAZAROTENE	Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11277960
TAZAROTENE	Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11422529
TAZAROTENE	Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11766122
TAZAROTENE	A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11992180
TAZAROTENE	Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging. [Review] [21 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=12007011
TAZAROTENE	Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12734506
TAZAROTENE	Short-contact therapy with tazarotene in psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12771482
TAZAROTENE	Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12890227
TAZAROTENE	The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis. [Review] [45 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640932
TAZAROTENE	Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging. [Review] [65 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=15087589
TAZAROTENE	Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16040409
TAZAROTENE	Topical tazarotene: a review of its use in the treatment of plaque psoriasis. [Review] [57 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=16060713
TAZAROTENE	Short contact therapy with tazarotene in psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=16549919
TAZAROTENE	Receptor-selective retinoids for psoriasis: focus on tazarotene. [Review] [67 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=16605289
TAZAROTENE	Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17319037

Medication Name	Title	Pubmed Link
TAZAROTENE	Childhood nail psoriasis: a useful treatment with tazarotene 0.05%.	https://www.ncbi.nlm.nih.gov/pubmed/?term=17542899
TAZAROTENE	Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19052406
TAZAROTENE	Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22818395
TAZAROTENE	A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24286371
TAZAROTENE	Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24819765
TAZAROTENE	A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28301614
TAZAROTENE, PHOTOTHERAPY	Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=11122033
TAZAROTENEPHOT OTHERAPY	A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=12366423
TILDRAKIZUMAB	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.[Erratum appears in Br J Dermatol. 2016 Jun;174(6):1426; PMID: 27317290]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26042589
TILDRAKIZUMAB	The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. [Review][Erratum appears in Expert Opin Investig Drugs. 2017 Feb;26(2):263; PMID: 28114863]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28042732
TILDRAKIZUMAB	Tildrakizumab for treating psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28271735
TOFACITINIB	Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22924949

Medication Name	Title	Pubmed Link
TOFACITINIB	Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23294276
TOFACITINIB	A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23387374
TOFACITINIB	Tofacitinib and other kinase inhibitors in the treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23583515
TOFACITINIB	Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23855761
TOFACITINIB	The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24289224
TOFACITINIB	Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24595567
TOFACITINIB	Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24940651
TOFACITINIB	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25418186
TOFACITINIB	Tofacitinib for the treatment of moderate-to-severe psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=25666451
TOFACITINIB	Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25951857
TOFACITINIB	Oral tofacitinib for psoriasis: what happens with interrupted treatment?.	https://www.ncbi.nlm.nih.gov/pubmed/?term=25963217
TOFACITINIB	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26149717
TOFACITINIB	Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26267721
TOFACITINIB	Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26267737
TOFACITINIB	XELJANZ (Tofacitinib) for Chronic Plaque Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26380510
TOFACITINIB	Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=26889081

Medication Name	Title	Pubmed Link
TOFACITINIB	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=26899199
TOFACITINIB	Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27059729
TOFACITINIB	Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27168266
TOFACITINIB	Tofacitinib for the treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27267933
TOFACITINIB	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27282428
TOFACITINIB	Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27349217
TOFACITINIB	Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27498960
TOFACITINIB	Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.[Erratum appears in J Dermatolog Treat. 2017 Feb;28(1):x; PMID: 28201942]	https://www.ncbi.nlm.nih.gov/pubmed/?term=27538247
TOFACITINIB	Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27600367
TOFACITINIB	Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27692733
TOFACITINIB	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=27716172
TOFACITINIB	Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28133877
TOFACITINIB	Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28317328

Medication Name	Title	Pubmed Link
TOFACITINIB	Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=28329404
TOFACITINIB	Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28396102
TOFACITINIB	Herpes zoster in psoriasis patients treated with tofacitinib.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28711084
TOFACITINIB	Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28714180
TOFACITINIB	Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=28751001
TOFACITINIB	Tofacitinib: A New Oral Therapy for Psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=29094282
TOFACITINIB	Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.	https://www.ncbi.nlm.nih.gov/pubmed/?term=29182790
USTEKINUMAB	Ustekinumab for chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=18486724
USTEKINUMAB	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).[Erratum appears in Lancet. 2008 May 31;371(9627):1838]	https://www.ncbi.nlm.nih.gov/pubmed/?term=18486739
USTEKINUMAB	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).	https://www.ncbi.nlm.nih.gov/pubmed/?term=18486740
USTEKINUMAB	Ustekinumab poised to enter the psoriasis market.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19060851
USTEKINUMAB	Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=19179295
USTEKINUMAB	Ustekinumab: a new option in psoriasis therapy. [Review] [115 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=19537833
USTEKINUMAB	Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. [Review] [37 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=19671802

Medication Name	Title	Pubmed Link
USTEKINUMAB	Ustekinumab for the treatment of moderate to severe psoriasis. [Review] [4 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=198460 31
USTEKINUMAB	Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199031 83
USTEKINUMAB	Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=199340 30
USTEKINUMAB	Ustekinumab (Stelara) for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=202084 73
USTEKINUMAB	Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=202229 26
USTEKINUMAB	Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. [Review] [20 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=204303 07
USTEKINUMAB	Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=204563 44
USTEKINUMAB	Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.	https://www.ncbi.nlm.nih.gov/pubmed/?term=204626 64
USTEKINUMAB	Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=205027 23
USTEKINUMAB	Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters.	https://www.ncbi.nlm.nih.gov/pubmed/?term=205366 46
USTEKINUMAB	Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.	https://www.ncbi.nlm.nih.gov/pubmed/?term=205992 93
USTEKINUMAB	Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. [Review] [55 refs]	https://www.ncbi.nlm.nih.gov/pubmed/?term=206358 31
USTEKINUMAB	Ustekinumab in the treatment of severe rupiod psoriasis: A case report.	https://www.ncbi.nlm.nih.gov/pubmed/?term=206649 17
USTEKINUMAB	Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=207162 16
USTEKINUMAB	Efficacy of ustekinumab in palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=209807 24

Medication Name	Title	Pubmed Link
USTEKINUMAB	Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21034290
USTEKINUMAB	Ustekinumab for rapid treatment of nail psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21079083
USTEKINUMAB	Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21108668
USTEKINUMAB	Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21233062
USTEKINUMAB	Ustekinumab for the treatment of an adolescent patient with recalcitrant plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21233068
USTEKINUMAB	Flare of pustular psoriasis after initiating ustekinumab therapy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21254881
USTEKINUMAB	Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21267358
USTEKINUMAB	Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21327538
USTEKINUMAB	Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21332467
USTEKINUMAB	Ustekinumab for the treatment of psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21426253
USTEKINUMAB	Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21434940
USTEKINUMAB	Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21521375
USTEKINUMAB	Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21549089
USTEKINUMAB	Exacerbation and change of psoriasis morphology in a patient treated with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21561590
USTEKINUMAB	Bounded outcome score modeling: application to treating psoriasis with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21688068
USTEKINUMAB	Ustekinumab for the treatment of HIV psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21787206

Medication Name	Title	Pubmed Link
USTEKINUMAB	Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21797806
USTEKINUMAB	Rapid response of scalp psoriasis to ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21856561
USTEKINUMAB	Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=21902296
USTEKINUMAB	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21929536
USTEKINUMAB	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21930328
USTEKINUMAB	Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/?term=21978572
USTEKINUMAB	Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22134046
USTEKINUMAB	Differential response of chronic plaque psoriasis to briakinumab vs. ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22169986
USTEKINUMAB	Spotlight on ustekinumab in moderate to severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22201419
USTEKINUMAB	Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22270196
USTEKINUMAB	The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22309334
USTEKINUMAB	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22356258
USTEKINUMAB	Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22364316
USTEKINUMAB	Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22390688

Medication Name	Title	Pubmed Link
USTEKINUMAB	An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.	https://www.ncbi.nlm.nih.gov/pubmed/?term=2239580
USTEKINUMAB	Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22438028
USTEKINUMAB	Ustekinumab biotherapy and real-time psoriasis capacitance mapping: a pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22536025
USTEKINUMAB	Ustekinumab for psoriasis and psoriatic arthritis. [Review][Erratum appears in J Rheumatol Suppl. 2012 Sep 1;39(9):1908]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22751602
USTEKINUMAB	Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22754278
USTEKINUMAB	Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis Duhring.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22784106
USTEKINUMAB	The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22803615
USTEKINUMAB	Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22823582
USTEKINUMAB	The safety of ustekinumab in psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22859234
USTEKINUMAB	Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22859249
USTEKINUMAB	Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22890275
USTEKINUMAB	Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22913449
USTEKINUMAB	Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=22927720
USTEKINUMAB	Development of linear IgA bullous dermatosis in a patient with psoriasis taking ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22980274
USTEKINUMAB	Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.	https://www.ncbi.nlm.nih.gov/pubmed/?term=22985451
USTEKINUMAB	Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23121260

Medication Name	Title	Pubmed Link
USTEKINUMAB	Treatment of severe psoriasis with ustekinumab during pregnancy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23134993
USTEKINUMAB	Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23148307
USTEKINUMAB	Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23210683
USTEKINUMAB	Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23251632
USTEKINUMAB	A successful treatment with ustekinumab in a case of antilaminin-gamma1 pemphigoid associated with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23252972
USTEKINUMAB	Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23278559
USTEKINUMAB	Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23278632
USTEKINUMAB	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23279003
USTEKINUMAB	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23301632
USTEKINUMAB	Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23320916
USTEKINUMAB	Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23330782
USTEKINUMAB	Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23377523
USTEKINUMAB	Psoriasis treated with ustekinumab in a patient with hepatitis C.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23414168
USTEKINUMAB	Concurrent treatment of chronic psoriasis and asthma with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23469809
USTEKINUMAB	Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.[Erratum appears in Br J Dermatol. 2016 Jul;175(1):228-9; PMID: 27484281]	https://www.ncbi.nlm.nih.gov/pubmed/?term=23521149
USTEKINUMAB	The efficacy of ustekinumab in psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=23545915

Medication Name	Title	Pubmed Link
USTEKINUMAB	Ustekinumab in the treatment of severe paediatric psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23581999
USTEKINUMAB	Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23728153
USTEKINUMAB	Long-term safety of ustekinumab for psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=23745965
USTEKINUMAB	The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23746170
USTEKINUMAB	Resident Rounds. Part III A. Serendipitous improvement in moderate to severe acne in psoriasis patients treated with ustekinumab: a two-case series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=23839194
USTEKINUMAB	Adherence to ustekinumab in psoriasis patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24085042
USTEKINUMAB	Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24085047
USTEKINUMAB	Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24117389
USTEKINUMAB	Successful management of ustekinumab-induced pustular psoriasis without therapy discontinuation.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24183227
USTEKINUMAB	Ustekinumab: moving the target from psoriasis to Crohn's disease. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=24410468
USTEKINUMAB	Recalcitrant psoriasis responding to new biologic drug: ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24413873
USTEKINUMAB	Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24552612
USTEKINUMAB	Monoclonal gammopathy of undetermined significance (MGUS) in patients with psoriasis may be associated with long-term treatment with efalizumab, but not with anti-TNF-alpha treatments or ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24593678
USTEKINUMAB	Treatment of recalcitrant erythrodermic psoriasis with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24721883
USTEKINUMAB	Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24754476
USTEKINUMAB	Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.	https://www.ncbi.nlm.nih.gov/pubmed/?term=24813816

Medication Name	Title	Pubmed Link
USTEKINUMAB	Immunoglobulin G4-related disease in a psoriasis vulgaris patient treated with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=249309 15
USTEKINUMAB	Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=249628 08
USTEKINUMAB	Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=250395 93
USTEKINUMAB	Some clinical factors affecting quality of the response to ustekinumab for psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=250401 59
USTEKINUMAB	The use of ustekinumab in a patient with severe psoriasis and positive HBV serology.	https://www.ncbi.nlm.nih.gov/pubmed/?term=250547 56
USTEKINUMAB	Ustekinumab treatment for psoriasis in 119 patients maintained on therapy for a minimum of one year: a review. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=251169 66
USTEKINUMAB	Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: a prospective study in a clinical setting.	https://www.ncbi.nlm.nih.gov/pubmed/?term=251169 77
USTEKINUMAB	Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=251202 33
USTEKINUMAB	Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=251417 74
USTEKINUMAB	Therapeutic effect and safety of ustekinumab for plaque psoriasis: a meta-analysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=252648 79
USTEKINUMAB	Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.	https://www.ncbi.nlm.nih.gov/pubmed/?term=253079 31
USTEKINUMAB	Ustekinumab improves psoriasis without suppressing tumor antigen-specific cytotoxic T lymphocytes.	https://www.ncbi.nlm.nih.gov/pubmed/?term=253424 44
USTEKINUMAB	Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=253463 01
USTEKINUMAB	Ustekinumab treatment in a patient with psoriasis and systemic lupus erythematosus.	https://www.ncbi.nlm.nih.gov/pubmed/?term=254133 58
USTEKINUMAB	Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=254138 95
USTEKINUMAB	Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=254450 92
USTEKINUMAB	Observational cases report of a group of severe plaque type psoriasis patients treated with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=255097 10

Medication Name	Title	Pubmed Link
USTEKINUMAB	Gastric mucosa-associated lymphoid tissue lymphoma in a patient with severe psoriasis receiving ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=255294 64
USTEKINUMAB	Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=255570 81
USTEKINUMAB	Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis: comment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=257039 44
USTEKINUMAB	Successful treatment of severe psoriasis in an adolescent with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=257278 45
USTEKINUMAB	Pregnancy during Ustekinumab Treatment for Severe Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=257909 47
USTEKINUMAB	The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting.	https://www.ncbi.nlm.nih.gov/pubmed/?term=258651 53
USTEKINUMAB	Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=259596 02
USTEKINUMAB	Successful treatment with ustekinumab of psoriasis vulgaris in a patient undergoing hemodialysis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=261037 88
USTEKINUMAB	Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=261346 67
USTEKINUMAB	Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).	https://www.ncbi.nlm.nih.gov/pubmed/?term=261517 87
USTEKINUMAB	Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=262428 57
USTEKINUMAB	Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.	https://www.ncbi.nlm.nih.gov/pubmed/?term=262599 89
USTEKINUMAB	Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=262677 36
USTEKINUMAB	Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.	https://www.ncbi.nlm.nih.gov/pubmed/?term=263677 99
USTEKINUMAB	Ustekinumab as therapy for psoriasis in a 2-year-old girl.	https://www.ncbi.nlm.nih.gov/pubmed/?term=263772 48
USTEKINUMAB	Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=264369 67

Medication Name	Title	Pubmed Link
USTEKINUMAB	The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=264881 86
USTEKINUMAB	Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=265593 93
USTEKINUMAB	Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.	https://www.ncbi.nlm.nih.gov/pubmed/?term=266432 60
USTEKINUMAB	IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=266780 60
USTEKINUMAB	Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=267037 91
USTEKINUMAB	Different Responses to Ustekinumab of Two HLA-Cw6-positive Homozygous Twins with Psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=267146 60
USTEKINUMAB	HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.	https://www.ncbi.nlm.nih.gov/pubmed/?term=267757 78
USTEKINUMAB	Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.	https://www.ncbi.nlm.nih.gov/pubmed/?term=270285 05
USTEKINUMAB	Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre.	https://www.ncbi.nlm.nih.gov/pubmed/?term=270383 63
USTEKINUMAB	A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment.	https://www.ncbi.nlm.nih.gov/pubmed/?term=270523 87
USTEKINUMAB	Safety of ustekinumab in severe psoriasis with chronic hepatitis B. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=270889 44
USTEKINUMAB	Inverse psoriasis treated with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=272222 77
USTEKINUMAB	Generalized pustular psoriasis treated with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=273339 48
USTEKINUMAB	HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.	https://www.ncbi.nlm.nih.gov/pubmed/?term=274767 22
USTEKINUMAB	Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=278648 41
USTEKINUMAB	Ustekinumab in the treatment of palmoplantar pustular psoriasis - a case series of nine patients.	https://www.ncbi.nlm.nih.gov/pubmed/?term=278790 67
USTEKINUMAB	Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=279773 34

Medication Name	Title	Pubmed Link
USTEKINUMAB	Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.	https://www.ncbi.nlm.nih.gov/pubmed/?term=280718 37
USTEKINUMAB	Morphea in a Patient With Psoriasis on Treatment With Ustekinumab: Comorbidity or Adverse Effect?. [Review]	https://www.ncbi.nlm.nih.gov/pubmed/?term=281108 25
USTEKINUMAB	Varicella zoster virus meningitis under ustekinumab because of plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=281503 33
USTEKINUMAB	Clearance of annular pustular psoriasis with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=282024 22
USTEKINUMAB	Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=283008 62
USTEKINUMAB	Cutaneous mucinosis in a patient taking ustekinumab for palmoplantar psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=283295 15
USTEKINUMAB	Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=284220 02
USTEKINUMAB	Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=284233 01
USTEKINUMAB	No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=285083 87
USTEKINUMAB	Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=285085 36
USTEKINUMAB	Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma.	https://www.ncbi.nlm.nih.gov/pubmed/?term=287306 74
USTEKINUMAB	Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=288339 73
USTEKINUMAB	Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=288860 99
USTEKINUMAB	Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.	https://www.ncbi.nlm.nih.gov/pubmed/?term=290846 39
USTEKINUMAB	Excellent response to ustekinumab in a 9-year-old girl with severe psoriasis.	https://www.ncbi.nlm.nih.gov/pubmed/?term=292054 79